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"There appears to be no reason why cancer attacks one individual 
and spares others exposed to the same external conditions. It is 
this failure to account for the apparently artaritary selection 
of its victims which gives to the disease the air of a grim 
mystery.
The explanation of this failure is to be found in the fact that 
up to ncm such comparisons have been made by taking into account 
only the extrinsic factor as the determining condition and 
neglecting altogether the complicating influence of the 
intrinsic factor of susceptibility."
Cramer. W. (1934).
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SUMMARY
Interindividual differences in the biotransformation of 
drugs and other xenobiotics, whether caused by genetic or 
environmental factors or their interaction, may have important 
clinical consequences in drug therapy and chemical toxicity.
The use of caffeine as an in vivo probe for the assessment 
of variability in hepatic drug metabolising enzymes in human 
populations was investigated. Population studies revealed a 
considerable degree of variation in the pattern of urinary 
metabolites excreted, following consumption of caffeine
containing beverages. Caffeine metabolite ratios were found to 
be reproducible and unaffected by either the time of urine 
collection or the amount of caffeine consumed. A simple caffeine 
test was thus developed, involving collection of a spot urine 
sample 2-6 h after caffeine consumption, for widespread use and 
measurement of P450IA, NAT and xanthine oxidase activities.
The metabolite ratio of (AAMU + 1-MU + 1-MX) /1,7-DMX was 
used to determine P450IA activity. The frequency distribution 
for P450IA activity appeared to be bimodal with 9% of the 
control population exhibiting high activity. The degree of 
enzyme activity was significantly altered by cigarette smoking 
and a greater proportion of smokers had high P450IA activity 
than nonsmokers. The proportion of patients with carcinoma of 
the lung, head and neck with high P450IA activity was 
signif icantly greater than that of controls. The proportion of 
leukaemia, colorectal cancer and FAP patients with high P450IA 
activity was not significantly different from controls.
The metabolite ratio used to determine P450IA2 activity was
(AAMU + 1-MU + 1-MX + 1,7-DMX) /Caffeine. The frequency
distribution for this enzyme activity also appeared to be 
bimodal. 16.5% of the control population exhibited high P450IA2 
activity and significantly more smokers had high activity 
compared to nonsmokers. The proportion of FAP patients with high 
P450IA2 activity was significantly greater than that of 
controls. The proportion of patients with colorectal cancer, 
lung, head and neck cancer and leukaemia who had high P450IA2 
activity however, was not different to that of controls.
The metabolite ratio of (AAMU + 1-MU + 1-MX)/AAMU was used 
to determine NAT activity. The frequency distribution was 
bimodal and 59% of control volunteers were slew acetylators. NAT 
activity was significantly altered by age. A greater proportion 
of subjects over 60 y of age were slow acety lators, as others 
have found. There was a significantly greater percentage of slow 
acety lators in patients with FAP and their first degree 
relatives, compared to age-matched controls. The proportion of 
slew acety lators in patients with neoplastic disorders however, 
was not altered compared to control volunteers.
Preliminary studies using cDNA expressed cytochrome P450IA1 
suggested that this isozyme of the P450IA family was capable of 
metabolising both caffeine and 1,7-EMX. Should P450IA1 be
induced in human liver, it may be involved in caffeine




Most of the xenobiotics to which the human body is exposed are 
lipid soluble, weak electrolytes which are readily absorbed 
across membranes and distributed throughout the body. After 
filtration by the glomerulus, these compounds are likely to be 
reabsorbed by the renal tubules unless they become chemically 
modified to form more polar derivatives. Metabolism of drugs 
results in the production of molecules which are usually less 
lipid soluble, more strongly ionised than those from which they 
are derived and therefore excreted more quickly. Consequently, 
excretion of xenobiotics is often preceded by their
biotransformation into more polar metabolites.
The enzyme systems responsible for such metabolism are
traditionally divided into two groups; Phase I and II. During 
Phase I metabolism, one or more water soluble groups are 
attached to the lipid soluble parent molecule, such that a 
position is formed for Phase II or "conjugating" enzymes to 
attack. Many Phase I, and especially the Phase II metabolites 
are sufficiently water soluble to be excreted from the body 
(Curry, 1977).
1.2 CYTOCHROMES P450
The cytochrome P450 monooxygenase system is a family of enzymes 
(Conney, 1980; Nebert & Negishi, 1982; Nebert et al, 1989; Puga 
& Nebert, 1990) which have different, but overlapping substrate 
specificities for a diverse group of substrates, in a wide
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variety of tissues (Yang & Lu, 1987).
"Cytochrome", derived from the Greek means "coloured substance 
in the cell" and "P450" denotes the reddish pigment of
00-binding haemoprotein that has its major optical absorption 
peak at 450nm. The ubiquitous cytochromes P450 catalyse the 
majority of Phase I oxidations and metabolise a vast array of 
chemicals and endogenous substances (Nebert, 1979).
In order to oxidise such chemicals, the P450 haemqproteins 
receive electrons from the cofactors NADPH and/or NADH. These 
electrons are received one at a time, usually via reductases, 
which are flavqproteins. The reduced drug-P450 complex then 
combines with oxygen to form an active complex, from which 
oxidised drug and water are released. This electron chain is 
located principally in the ER, to same degree in the inner 
mitochondrial membrane and perhaps the nuclear envelope (Nebert 
et al, 1980a,b).
The cytochrcme P450 system is primarily concerned with 
xenobiotic detoxification but can activate several different 
classes of chemicals into reactive metabolites, which may be 
involved in the pathogenesis of cytotoxicity (Gillette, 1980; 
Nelson & Harvison, 1987; Nebert et al. 1987; Guengerich, 1988). 
The enzymes involved in detoxification and toxication coexist in 
the same cells, are likely to differ among various tissues and 
are controlled by many host factors, such that a delicate 
balance exists between these two processes (Nebert, 1979).
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1.3 CYTOCHROME P450IA
The P450IA family has two genes, CYPIA1 and CYPIA2 on chromosome 
15 (Wolf et al, 1990) which encode P450IA1 and P450IA2 
(Hildebrand et al, 1985; Jaiswal et al, 1987). The IA1 and IA2 
genes are ubiquitous in mammals and for the most part, have 
similar catalytic activity in several species. Cytochromes 
P450IA appear to be involved in the conversion of relatively 
inocuous chemicals to reactive electrqphilic metabolites which 
may react covalently with cellular macramolecules (Miller & 
Miller, 1981), rather than detoxification. Other P450
cytochromes tend to direct metabolism towards the formation of 
inactive metabolites and detoxification (Creaven & Parke, 1966; 
Ioannides & Parke, 1987). Although P450IA1 and IA2 shew 
overlapping substrate specificity, P450IA1 tends actively to 
metabolise PAH, which are ubiquitous products of combustion, 
into carcinogenic metabolites (Nebert, 1981b; Kadlubar & 
Hammons, 1987). P450IA2 exhibits a high level of catalytic
activity towards arylamine compounds, in addition to 
metabolising pjotent promutagens derived from pyrolysates of 
proteins (Thorgeirsson & Nebert, 1977; Kamataki et al, 1983; 
Hammons et al, 1985; Shimada & Okuda, 1988; Aoyama et al, 1989;
Butler et al, 1989a; Shimada et al 1989; Batula et al, 1990;
Gonzalez et al. 1990) (Fig.1.1).
Most chemical carcinogens, except direct alkylating agents, 
require metabolic activation in vivo to electrcphiles, before 
they become ultimate carcinogens. Such chemicals seek to react 
with nucleophilic sites, which are abundant in DNA, ENA and 
other proteins. As some chemicals are activated to several 
carcinogenic products, and there are several nucleophilic sites
3
Figure 1.1 - Hydroxylation of BP by P450IA1 and arylamines by 
P450IA2 (Nebert, 1991).
in each mcromolecule, multiple adducts are possible and 
frequently observed (Miller, 1978; Miller & Miller, 1981). 
Chemical carcinogenesis has long been associated with the 
induction of P450IA (Creaven & Parke, 1966) and it has been 
suggested that this family of enzymes is specifically concerned 
with the activation of chemicals to reactive intermediates and 
the formation of mutagens and carcinogens (Phillipson et al, 
1982; Ioannides et al, 1984; Lewis et al, 1986; Ioannides & 
Parke, 1987).
Both P450IA enzymes could therefore play potentially important 
roles in chemically induced human cancer (Gonzalez, 1989). 
Individual variation in cytochrome P450IA activity would give 
rise to differences in drug metabolism and pharmacological 
response (Wolf et al, 1990). The extent to which variability in
CYPIA expression can be attributed to genetic factors in man is 
unknown but environmental factors are important, as genes within 
the CYPIA family are inducible with drugs and environmental 
agents (Conney, 1967).
Recent studies have shewn that the degree of induction of
P450IA1 correlates well with the carcinogenicity of PAH
chemicals (Ayrton et al, 1990a) and that P450IA2 induction by
arylamines also correlates with the carcinogenicity or 
mutagenicity of these chemicals (Ayrton et al, 1990b). Thus
chemical carcinogens not only induce the P450IA enzymes but are 
preferentially metabolised by these enzymes (Ioannides & Parke, 
1990).
Location
P450IA1 is found in many tissues following inducer treatment 
(Gonzalez, 1989), while P450IA2 is only measured in the liver. 
In general, the form of P450 analogous to P450IA2 predominates 
over that of P450IA1 in rat (Goldstein & Linko, 1983) and mouse 
liver (Negishi & Nebert, 1979) and a similar situation appears 
to occur in man (Wrighton et al, 1986; Jaiswal et al, 1987; 
Sesardic et al, 1988). While some studies have failed to measure 
P450IA1 in human liver (Sesardic et al, 1988), several others 
have found it to be present in small quantities, particularly in 
heavy smokers (Quattrochi et al, 1985; Wrighton et al, 1986; 
Jaiswal et al, 1987; Cresteil & Eisen, 1988; Ikeya et al, 1989). 
P450IA1 is present in the placenta of smokers (Fujino et al, 
1982; Wong et al, 1986; Pasanen et al, 1989; Vahakangas et al,
1989), in human lymphocytes (Fujino et al, 1982), breast tissue
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(Vickers et al, 1989), skin (Ichikawa et al, 1989) and bone
marrow (Schnier et al, 1989).
1.4 FACTORS AFFECTING DRUG METABOLISM
Hie process of drug biotransformation in man may be influenced 
by a multitude of environmental factors, such as cigarette smoke 
(Vahakangas et al, 1983), air pollution (Pike et al, 1975), and 
diet (Reddy et al, 1980; Miller, 1982), as well as host factors 
(Cole, 1982), including age (Greenblatt et al, 1980), race
(Kalow, 1985; Miller, 1986), sex (Kato, 1974), pregnancy
(Lambert et al, 1987), infectious disease (Renton & Knickle,
1990) and genetic constitution (Ihorgeirsson & Nebert, 1977; 
Nebert, 1980a; Nebert, 1981a) that are intimately interrelated 
(Vesell, 1977; 1982; 1984) (Fig.1.2). Thus, attempts to separate 
environmental from genetic contributions as though they were 
discrete, unrelated entities is often invalid as many 
environmental factors that alter rates of drug disposition do so 
by affecting genetic mechanisms.
Environmental
Environmental factors play an important part in the variability 
of drug disposition, especially when the cytochrome P450 enzymes 
are involved, as their activity is markedly affected by 
environmental exposure to inducing and inhibiting agents 
(Conney, 1967; Nebert, 1980c; Conney, 1982).
Cigarette smoke contains numerous compounds which are capable of 
inducing certain P450 enzymes and in this way, the metabolism of 
phenacetin (Sesardic et al, 1988), caffeine (Campbell et al, 
1987) and antipyrine (Vahakangas et al, 1983) is increased in
6
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Figure 1.2 - The multiplicity of factors influencing drug 
response in man. The concentric outer circles 
emphasise the multiple possibilities that exist for 
interaction among host factors and suggest that the 
magnitude of the inpact of host factors on drug 
response may be modulated be genetic constitution 
(Vesell, 1982).
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smokers compared to nonsmokers.
Diet is also an important source of variation of xenobiotic 
metabolism (Conney, 1980). The metabolism of BP by human liver 
is stimulated by PAH in charcoal-broiled beef (Conney, 1980) and 
sensitive to changes in the content of cruciferous vegetables, 
such as indoles and flavones present in sprouts and cabbage 
(Wattenberg, 1978; Wattenberg & Loub, 1978).
Pharmacogenetics
Studies of variation in drug response due to genetic factors are 
the foundation of the discipline termed pharmacogenetics, which 
aims to assess the genetic contribution to individual
differences in sensitivity to drugs and xenobiotics.
A polymorphism was described by Harris (1976) as "a type of 
variation in which individuals with sharply distinct qualities 
co-exist as normal members of a population". The molecular basis 
for such variation lies in the occurrence of mutant alleles at a 
given gene locus (or loci) encoding for an enzyme, resulting in
differences in activity due to varying amounts or structures of
that enzyme.
Same genetic variants are rare, occurring only in family groups 
while others are polymorphic, that is, the frequency of the 
least common allele exceeds 1% (Harris, 1976; Jackson et al,
1991). Genetic polymorphism as a phenomenen is extremely common 
and Harris (1976) has suggested that at least a third of human
gene loci are multiallelic.
There may be monogenic or polygenic inheritance of a particular 
trait, for example a metabolic drug reaction, and in order to
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distinguish between the frequency distributions of the 
investigated parameter, population studies are usually employed 
(Vesell, 1977; Breimer, 1983). If the frequency distribution 
displays bi- or trimodal characteristics, with each mode 
corresponding to a different genetically determined phenotype, 
then inheritance is monogenic and there is simple Mendelian 
segregation of two alleles at a single locus. Hcwever, if the 
frequency distribution is unimodal, inheritance is polygenic and 
at least two genes at different loci control the metabolic 
reaction (Eichelbaum, 1982).
With polygenic inheritance it is more difficult to distinguish 
between the genetic and environmental factors contributing to 
the observed variability and in order to do so family pedigree 
analyses and studies in mono- and dizygotic twins need to be 
employed (Vesell & Penno, 1983).
1.5 PHAFMAOOGENEITC DEFECTS IN DRUG BIOTRANSPORMATION 
Among the first polymorphisms to be discovered was that 
controlling the disposition of the tuberculostatic drug, 
isoniazid (Evans et al (1960). The observed variation was found 
to be related to differences in the rate of acetyl coenzyme 
A-dependent acetylation, which is catalysed by liver cytosolic 
arylamine N-acetyltransferase (NAT) (Grant et al, 1990). Three 
human NAT genes have been assigned to chromosome 8; gene 1 
encodes polymorphic NAT; gene 2 has multiple mutations and does 
not encode a functional NAT protein, while gene 3 encodes 
monomorphic NAT (Blum et al, 1990).
The first clear indication of polymorphism involving cytochrome 
P450 enzymes was demonstrated by Mahgoub et al (1977). CYPIID6,
the gene controlling debrisoquine hydroxylation in man is
multiallelic. Three different forms of incorrectly spliced 
P450IID6 pre-mRNAs have been identified in the livers of the 
poor metabolizer phenotypes (Gonzalez, 1989) such that 
functionally active proteins are not expressed.
There are several other forms of polymorphism in drug oxidation 
which do not cosegregate with that for debrisoquine. Metabolism 
of the anticonvulsant, S-mephenytoin by P450IIC9 is subject to 
genetic polymorphism (Kupfer et al, 1984; Wedlund et al, 1984; 
Inaba et al, 1985; Kalcw, 1986) and particularly affects
Oriental subjects. The same enzyme also contributes to the 
metabolism of diazepam (Bertillson et al, 1989) and possibly
seme anticancer drugs (Felling et al, 1989). Genetic
polymorphism has also been reported for the metabolism of 
phenacetin (Distlerath et al, 1985), the mucolytic agent 
S-carboxymethylcysteine (Waring, 1980; Waring et al, 1982), 
amobarbital (Kalow et al, 1977), theophylline (Dahlqvist et al, 
1984; Miller et al, 1985; Vesell, 1986) and antipyrene (Vesell & 
Page, 1968; Penno & Vesell, 1983; Vesell, 1986). Metabolism of 
the anticonvulsant phenytoin (Vermeij, 1988) and the oral 
hypoglycaemic agent, tolbutamide (Scott & Poffenbarger, 1979) is 
also subject to genetic polymorphism, although the latter two 
reactions may be catalysed by the same P450 isozyme (Doecke et 
al, 1991).
Polymorphism of Cytochrome P450IA
In mice, the Ah locus, which controls the induction of P450IA 
enzymes is inherited in a Mendelian dominant fashion, such that
10
Ah-responsive (Ah^ Ah^ ) and Ah-nonrespons ive (Ah^ Ah^ )
mice exist (Nebert et al, 1975; Thorgeirsson & Nebert, 1977; 
Nebert & Felton, 1975). Due to the fact that P450IA1 can convert 
procarcinogens to ultimate carcinogens and reactive 
intermediates, differences in cancer risk have been demonstrated 
in mice treated with PAH (Kouri, 1976; Kouri et al, 1980; 
Nebert, 1981b). When carcinogens such as PAH are placed in 
direct contact (via subcutaneous, topical or intratracheal 
routes) with the tissue being studied, the genetically
responsive mouse is at increased risk for developing a tumour in 
that tissue, compared to the nonresponsive mouse that receives 
the same dose of chemical. This is due to increased induction of 
P450IA and therefore increased carcinogen activation in tissues 
close to the site of chemical application in the responsive 
mouse (Nebert, 1982).
On the other hand, PAH given orally or subcutaneously cause 
malignancy and toxicity in tissues distant from the site of 
chemical administration in the nonresponsive mouse. Following 
oral administration of BP, Nebert et al (1980) showed that a 
20-fold higher uptake of the drug occurred in the marrcw and 
spleen of nonresponsive, compared to responsive mice. The 
concentration of nonmetabolised parent drug that reaches distal 
tissues is much greater in the nonresponsive animals and is 
responsible for the increased toxicity and tumorigenesis 
observed in such tissues (Fig. 1.3).
The responsive mouse is more prone to chemically induced 
pulmonary tumours, fibrocarcomas, epidermal carcinoma, fetal 
toxicity and cleft palate in the fetus, whereas the 
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Figure 1 . 3  - Illustrated scheme indicating the differential 
susceptibility for tumours in genetically 
responsive and nonresponsive mice (Nebert, 1981b).
lymphoma, leukaemia and bone marrow toxicity (Nebert et al, 
1977; Duran-Reynals et al, 1978; Shum et al, 1979; Nebert & 
Jensen, 1979; Nebert, 1980b: Nebert, 1980c; Nebert, 1981b; 
Nebert, 1982).
Relative lack of Ah responsiveness has been attributed to a 
mutation in the Ah regulatory locus, resulting in the formation 
of a defective receptor with decreased affinity for the binding 
of P450IA inducers (Greenlee & Poland, 1979; Nebert et al, 1975; 
Okey et al, 1979; Negishi & Nebert, 1979).
The human P450IA1 gene has been isolated and sequenced (Jaiswal 
et al, 1985) and assigned to chromosome 15 (Hildebrand et al,
1985). There is good evidence that polymorphism in P450IA1 
activity exists in man (Kellermann et al, 1973b) and that around 
10% of the Caucasian population exhibit high P450IA1
inducibility (Kouri et al, 1982). In addition, polymorphism of
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the CYPIA1 gene itself has been identified (Kawajiri et al. 
1990; Nakachi et al, 1991).
The human P450IA2 gene has also been sequenced (Quattrochi et 
al, 1986; Jaiswal et al, 1986) and there is seme evidence to 
suggest that certain individuals have higher levels of this 
enzyme than others (Butler et al, 1989a,b; Bartsch et al, 1990).
1.6 GENETIC POLYMORPHISM AND HUMAN CANCER
The importance of chemical carcinogenesis is demonstrated by the 
association between human exposure to certain chemicals and the 
likelihood to develop certain cancers. In this light, the 
incidence of cancer of the lung (Hammond, 1975) and oral cavity 
(Muir & Kirk 1960) that has paralleled the increase in cigarette 
smoking in both sexes is particularly important. In addition, 
aflatoxin, a mycotoxin common in the African food chain is 
associated with liver cancer (Peers et al, 1976; Shimada & 
Guengerich, 1989), asbestos with malignant mesothelioma (Muscat 
& Wynder, 1991), dye chemicals with bladder cancer (Cartwright 
et al. 1982) and hair dyes with cancer of the breast (Nasca et 
al. 1980). Environmental carcinogenesis however, does appear to 
be modified by the genetic constitution of the host (Bottcmley & 
Conditt, 1968; Anderson, 1975; Mulvihill, 1975; Knudson, 1977; 
Sdhimke, 1978; Schull & Weiss, 1982; Blattner et al, 1983). This 
would explain why upto 20% of lung cancers are not related to 
smoking habits, in populations where cigarette smoking is 
widespread; why seme nonsmokers may develop lung cancer, while 
smokers might not and why lung cancer patients frequently have a 
higher than expected number of relatives with cancer. Heritable 
risk factors are implicated in cancer aetiology (Yokota et al,
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1987; Weston et al, 1989; Caporaso et al, 1990) and first degree 
relatives of patients with cancer of the lung, colon, stomach 
and breast have around three times the risk for developing the 
same cancer than the general population (Anderson, 1975; Burt et 
al, 1985).
Polymorphic expression of xenobiotic-metabolising enzymes may 
form the basis for individual susceptibility to chemically 
induced human cancers (Wolf, 1986; Idle, 1991; Nebert, 1991) in 
that one phenotype may be more prone than another to develop 
certain types of cancer.
Subjects with slow NAT activity may be more susceptible to 
bladder cancer (Cartwright et al, 1982; Evans et al, 1983; 
Hanssen et al, 1985; Ladero et al, 1985; Vineis et al, 1990) and 
carcinoma of the larynx (Drozdz et al, 1987). On the other hand, 
rapid acetylation has been associated with cancer of the breast 
(Bulovskaya et al, 1978) and with development of colorectal 
carcinoma (Ilett et al, 1987; Lang et al, 1986), although the 
latter association has been disputed (Kirlin et al, 1991; Ladero 
et al. 1991). It may therefore be of value to determine the 
acetylator phenotype of an individual.
The human debrisoquine polymorphism has also been suggested to 
be associated with cancer risk. A significantly greater
proportion of extensive metabolisers of debrisoquine was found 
in groups of patients with abdominal cancers associated with 
aflatoxin in Nigeria (Idle et al, 1981; Ritchie & Idle, 1982), 
with Balkan endemic nephropathy and renal tumours in Bulgaria 
(Ritchie et al, 1983) and in patients with carcinoma of the
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bronchus (Ayesh et al, 1984; Caporaso & Idle, 1990). Several 
workers however, have not substantiated the latter finding 
(Roots et al, 1988; Boobis & Davies, 1990; Speirs et al, 1990; 
Duche et al, 1991). The poor metaboliser phenotype has been 
associated with Parkinson's disease (Barbeau et al, 1985).
Increased risk of bronchogenic car cinema, induced by cigarette 
smoke, appears to be associated with the high P450IA1 
inducibility phenotype in man (Kellermann et al, 1973b) such 
that the Ah-responsive smoker is 20-30 times more prone to lung 
cancer than the Ah-nonresponsive smoker (Kouri et al, 1982). 
Although polymorphism of the CYPIA1 gene has been detected 
(Jaiswal & Nebert, 1986), most investigators have not linked a 
particular genotype with increased lung cancer risk (Jaiswal et 
al. 1985, 1986). However, a recent study has found that more 
patients with cigarette smoke-induced lung cancer have the rare 
CYPIA1 genotype corresponding to high P450IA1 activity (Kawajiri 
et al. 1991).
Cancer of the breast (Pyykko et al, 1991) and tropical chronic 
pancreatitis (Chaloner et al, 1990) have also been associated 
with high P450IA1 inducibility in man, while an increased risk 
of acute leukaemia of childhood may be associated with the low 
P450IA1 phenotype (Blumer et al, 1979).
As P450IA2 activity is highly correlated with cancer induced by 
aromatic amines in animals (Kamataki et al, 1983), the human 
orthologue is of great interest.
Cigarette smoke and especially its particulate matter (tar) 
contain carcinogens and cocarcinogens (Wynder & Hoffmann, 1979)
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and tobacco is generally recognised as being responsible for 
80-90% of cancers of the lung and oral cavity (Hammond, 1975). 
Early diagnosis of bronchogenic, head and neck cancers is
unusual (Sanderson & Jett, 1989). As P450IA may activate 
carcinogens in cigarette smoke, the screening of populations for 
subjects with high P450IA activity may be useful in determining 
those who are at high risk for cancer of the lung, head and 
neck.
The incidence of colorectal cancer is second only to malignant 
lung tumours and increasing. This disease shews considerable 
variation in incidence worldwide and like lung cancer,
environmental factors are thought to be important in its
aetiology (Reddy et al, 1980). Conversely, familial adenomatous
polyposis (FAP) is a hereditary disorder, transmitted as an
autosomal dominant trait involving chromosome 5 and is
determined by a single gene (Harris et al, 1980). It is a
clearly defined premalignant lesion of the colon and rectum, 
with carcinoma developing in 100% of patients if they are 
followed up for sufficient length of time. Currently,
prophylactic colectomy by the age of 20 y offers the only hope 
of cancer prevention (Barton, 1992).
Although the most potent cause of FAP is the mutant gene, 
environmental factors may alter the disease process (Utsuncmiya 
et al. 1974). Dietary chemicals may be important in FAP onset, 
as the pattern of polyps throughout the bowel, parallels mucosal 
exposure to bile. As dietary arylamines may be activated by 
P450IA2 and possibly inactivated by NAT, the screening of 
populations for subjects with low and high P450IA2 and NAT 
activities, may be useful in determining those who are risk for
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certain premalignant disease and cancer.
1.7 IN VIVO ASSESSMENT OF DRUG METABOLISM
The most widely used technique for assessing the activity of the 
hepatic drug-metabolising enzymes is to study the kinetics of 
model drug substrates in vivo (Park, 1982). An ideal probe drug 
for assessing hepatic enzyme activities should have the
following properties: (1) single compartment pharmacokinetics;
(2) elimination entirely dependent on hepatic metabolism; (3) 
metabolism independent of liver blood flow and protein binding. 
In addition, drugs administered orally should be rapidly and 
completely absorbed (Park, 1982).
For measurements involving urinary metabolites as indicators of 
enzyme activity, (1) the fraction of the dose of drug absorbed 
should be known; (2) elimination should be first order; (3) the 
excretion rate should be rapid compared to the rate of 
metabolism, so that metabolism is the rate limiting step in the 
appearance of the metabolite in urine; (4) the metabolite should 
be excreted entirely by the kidneys and (6) the metabolite 
should be produced exclusively by the enzyme (s) of interest 
(Park, 1982; Bartsch et al, 1982).
Caffeine as a probe drug
Coffee, the principal source of caffeine, is said to be the 
world's most widely traded commodity after oil and the near 
universal use of caffeine-containing beverages and foods exceeds 
the popularity of alcoholic beverages (Dews, 1984). Caffeine is 
present in coffee, tea, cocoa and chocolate and the cola nut 




Figure 1.4 - The structure of caffeine and its 
dimethylxanthine metabolites, 
is related to its stimulant properties (Dews, 1984; Gong et al,
1986). The structures of caffeine (1,3,7-trimethylxanthine) and 
its dimethylxanthine metabolites: paraxanthine
(1,7-dimethylxanthine), theophylline (1,3-dimethylxanthine) and 
theobromine (3,7-dimethylxanthine) are shown in Fig. 1.4.
Absorption and distribution.
Following oral ingestion, caffeine is rapidly and essentially 
completely absorbed form the gastrointestinal tract into the 
bloodstream (Blanchard & Sawers, 1983). Bonati et al (1982) 
studied the plasma concentrations of caffeine in healthy
subjects and found that following an oral dose of 5 mg/kg, peak 
levels were achieved in 47 + 5 min. They reported that 99% of
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the administered dose of caffeine was absorbed in approximately 
45 min.
Once ingested, caffeine is readily distributed throughout the 
whole body (Bonati et al, 1982). It is detected in breast milk, 
placenta and semen and crosses the blood:brain barrier but does 
not appear to sequester in particular body organs (Yesair et al. 
1984).
Elimination
The disappearance of caffeine from plasma in adults and infants 
is first order and excretion is faster than metabolite formation 
(Aldridge et al, 1979). In humans, the elimination half-life of 
caffeine varies between 1.5 and 9.5 h (Bonati et al, 1982) but 
this may be influenced by a variety of factors. Age (Yesair et 
al. 1984), use of oral contraception (Patwardhan et al. 1980; 
Callahan et al, 1983), pregnancy (Aldridge et al, 1979), 
cigarette smoking (Hart et al, 1976; Parsons & Neims, 1978; 
Kotake et al, 1982) and hepatic disease (Scott et al, 1989) may 
alter the elimination of caffeine by affecting its metabolism.
Metabolism
Caffeine is extensively metabolised and only around 1% of the 
caffeine dose is excreted unchanged in urine (Newton et al, 
1981; Tang-Liu et al, 1983). Whereas 85% of the caffeine dose 
was recovered in urine by Bonati et al (1982) within 24 h, 
others have recovered only 70% (Amaud & Welsch, 1981; Tang-Liu 
et al. 1983). The markedly prolonged caffeine half-life in 
patients with liver disease (Scott et al, 1989) is evidence that
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the biotransformtion of caffeine is performed primarily by the 
liver (Muir et al, 1980).
A number of reports have verified that caffeine undergoes 
oxidative N-demethylation via the P450IA enzymes and ring
hydroxylation by other P450 enzymes, to produce a variety of 
methylated xanthines and uric acid derivatives (Cornish & 
Christman, 1957; Wietholtz et al, 1981; Amaud & Welsch, 1981; 
Callahan et al, 1982; Tang et al, 1983; Amaud, 1984). The 
multiple pathways by which caffeine is known to be metabolised 
have been established from metabolites identified in urine
(Amaud & Welsch, 1981). Caffeine is metabolised through a
series of sequential and competing steps and is virtually
completely transformed (Burg, 1975) (Fig. 1.5).
Some 70-80% of caffeine is metabolised to paraxanthine (1,7-DMX) 
in man (Amaud & Welsch, 1981; Callahan et al, 1982) and 1,7-DMX 
and its metabolite 1,7-EMU account for 12% of the caffeine dose 
excreted in urine; theophylline (1,3-CMX) accounts for 3% and 
theobromine (3,7-EMX) for 2% (Cornish & Christman, 1957; Bonati 
et al. 1982). 1,7-DMX is formed at about seven times the rate of 
the other two dimethylxanthines and appreciable quantities of
1.7-DMX (up to 2ug/ml) are detected in the plasma of coffee and 
tea drinkers (Lelo et al, 1986a). It is surprising therefore 
that although caffeine consumers are continuously exposed to
1.7-DMX, there is very little information relating to its 
effects in humans, even though available evidence suggests that
1.7-DMX is more toxic than caffeine in the rat (Bortolotti et 
al, 1985).
Of the moronethylxanthine and uric acid metabolites, 1-MU and 
1-MX are the major compounds assayed in urine and up to 30% of
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AFMU
Figure 1.5 - The major metabolic pathway of caffeine in man
21
the caffeine dose may be recovered as 1-MU (Bonati et al. 1982). 
1-MX and 1-MU were found to account for around 50% of 1,7-DMX 
clearance in a study by Lelo et al (1989); AFMU for 17% and 
renal excretion of unchanged 1,7-DMX comprised 9% of its 
clearance. Hcwever, Callahan et al (1982) found that AAMU and 
AFMU accounted for up to 40% of the caffeine dose.
Caffeine Metabolite Ratios
The profile of urinary metabolites of caffeine in man has been 
found to vary significantly between individuals (Parsons & 
Neims, 1978; Aldridge et al, 1979; May et al, 1982; Grant et al, 
1983a, Lelo, 1986a,b,c; Campbell et al, 1987; Birkett & Miners, 
1991). In order to use caffeine as a probe drug to measure such 
variation, metabolite ratios (MRs) may be used. The MR is 
extensively used and is usually expressed as D/M, where D and M 
are the concentrations of drug and metabolite, respectively in 
urine. Urinary ratio frequency plots appear to be more 
discriminatory than those for urinary recovery of a metabolite 
and differences in metabolic ability are often best determined 
by MRs as indirect measures of enzyme activity (Jackson et al, 
1986). An implicit assumption in the use of the MR is that renal 
clearance remains constant across populations and that renal 
clearance is less variable than metabolic clearance (Birkett et 
al. 1981). As 1-MX, 1-MU and AAMU are very polar compounds, they
are likely to be excreted by the kidney without reabsorption.
Hence the MR should be relatively insensitive to variation in 
urine flew or kidney function (Grant et al, 1984).
The advantage of using MRs is that they are essentially
independent of the total recovery of the metabolites with time,
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bat relate the amounts of metabolites measured to each other. 
Therefore, any variability in a ratio implies variation in an 
enzyme pathway (Grant et al, 1983b).
There are limitations in the methods for establishing the 
presumed existence of, or identifying high risk groups of 
individuals in the population. Firstly, the P450IA enzymes 
involved in the metabolism of caffeine are inducible by many 
commonly encountered chemicals, such that intra- and inter­
laboratory reproducibility may prove difficult to demonstrate. 
Secondly, for studies involving patients with lung cancer, it is 
not known whether hepatic P450IA activity truly reflects P450IA1 
activity in the lung - the preferential target organ for 
tobacco-smoke carcinogens. Lastly, it is conceivable that 
cigarette smoking and/or malignant states perturb the normally 
prevailing relationship between enzyme activities in liver and 





2.1.1 Drugs and Reagents
Drugs and reagents used in the present investigation were 
purchased from Sigma (Poole, UK) and are listed in Table 2.1. 
Chemicals were of analytical grade purity and were used as 
rececived without further purification.
5-Acetylamino-6-fornylamino-3-methyluracil was kindly gifted by 
Dr MJ Amaud (Nestle, La Tour-de-Peilz, Switzerland).
2.1.2 Acids and Salts
Hydrochloric acid; glacial acetic acid and perchloric acid were 
purchased from Rathbums (Scotland, UK). Sodium hydroxide and 
ammonium sulphate were of Analar grade and purchased from Sigma 
(Poole, UK).
2.1.3 Solvents
Acetonitrile and acetic acid used for high performance liquid 
chromatography were of HPLC grade. Isopropyl alcohol, chloroform 
and methanol used for these studies were of analytical grade 
purity. All solvents were obtained from BDH (Bristol, UK). Water 
used for this study was double-distilled by a 'Fi-Streem' water 
purification system (Fisons, UK) and subsequently de-ionised 
(Bibby Products Ltd., UK).
2.1.4 Enzymes
Functionally active human cDNA-expressed cytochrome P450IA1 
expressed in yeast cells was a gift from Dr. M.S. Ching
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(University of Sheffield). The microsomal pellet was resuspended 
in 0.1M potassium phosphate buffer (pH 7.4) containing IrrM EDTA 
and 0.65M sorbitol at a protein concentration of 15 mg/ml. 
Cytochrome P450IA1 had a specific activity of 43.6 pmol/mg of 
microsomal protein.
Control yeast cells containing undetectable levels of cytochrome 
P450 were also prepared in the Department of Pharmacology and 
Therapetics, University of Sheffield.
2.2 INSTRUMENTATION
2.2.1 High Performance Liquid Chromatography System (HPLC)
HPLC assays were performed using IDC (Laboratory Data Control) 
components (Staffordshire, UK). The mobile phase was pumped to 
the column at constant flew by means of a Constametric CM4000 
tertiary pump and programmable multiple solvent delivery system. 
Samples were automatically injected onto the column through a 
lOOul loop from a rotating Prcmis I autosampler and the eluted 
products were detected using a Spectrcmonitor 3100 variable 
wavelength U.V. spectrophotometer (UV range 190-350 nm). 
Chromatograms were produced on a chart recorder and peak heights 
and areas determined by a CI-10B integrator.
Both the 5 cm long precolumn and the 25 cm long analytical 
column consisted of stainless steel tubes with a 4.6 mm internal 
diameter, packed with reversed-phase microparticle silica, 5 urn 
(Spherisorb COS, Phase Separations Ltd., UK). The equipment was 
operated at room temperature throughout. Mobile phase was 
filtered through a 0.45uM membrane filter (Millipore 
Corporation, UK) before use and subsequently maintained degassed 
Jay constant purging with helium (BOC, Bristol).
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Table 2.1 - Caffeine, xanthine and uric acid metabolite 
standards used in the study




Paraxanthine 98% Pure 180.2
(1,7-dimethylxanthine) 1,7-DMX RT
Theophylline 180.2
(1,3 -dimethylxanthine) 1,3-EMX RT
Theobromine 180.2
(3,7-dimethylxanthine) 3,7-CMX RT
1,7-dimethyluric acid 1,7-DMU RT 196.2
1,3-dimethyluric acid 1,3-DMU 0-5°C 196.2
3,7-dimethyluric acid 3,7-EMU RT 196.2
1-methylxanthine 1-MX RT 166.1
3-methylxanthine 3-MX 0-5°C 166.1
7-methylxanthine 7-MX RT 166.1
1-methyluric acid 1-MU RT 182.1
3-methyluric acid 95% pure 3-MU RT 182.1
7-methyluric acid 7-MX 0-5°C 182.1
8 -chlorotheophy 11 ine RT 214.6
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2.3 HUMAN STUDIES
All human studies received prior approval from the Bath Health 
District Research Ethics Committee. A study involving a group of 
patients with familial adenomatous polyposis (FAP) attending St. 
Mark's Hospital, London was carried out following approval from 
the Regional City & Hackney Health Authority.
All control volunteers and patients participating in the 
caffeine test were of Caucasian origin.
2.3.1 Control Volunteers
Personnel from the Ministry of Defence (MOD), Foxhill, Bath and 
the Royal United Hospital (RUH), Bath, participated in this
study. All were judged healthy following an interview with a 
Nursing Sister and results of liver and kidney function tests. 
For these tests, the following measurements were made by the
Department of Biochemistry, RUH: plasma sodium, calcium,
potassium, bicarbonate, phosphate, urea, total protein, albumin, 
globulin, bilirubin, alkaline phosphatase and aspartate
transaminase. For all studies subject age, body mass index
(BMI), current medication and smoking status were recorded 
(Appendix 1-4). Studies involving control volunteers were 
classified in three parts.
a) Effect of caffeine consumption on urinary metabolite profiles 
Twenty-three members of staff (9 male and 14 female) from the 
Wolf son Centre, RUH were studied. Their ages ranged between 22 
and 56 y (31.07 + 1.85; mean age + standard error of mean
(SEM)). Six volunteers smoked cigarettes; 7 took oral 
contraceptive steroids (OCS) and none was taking prescribed or
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over-the-counter medication. Volunteers participated in several 
caffeine tests following different protocols:
(i) Seventeen subjects consumed a caffeine containing 
beverage (CCB) i.e. tea, coffee or cola in the morning, 
after emptying their bladder. No further CCBs were 
consumed during the test and all urine passed in the 
subsequent 8 h was collected for analysis of caffeine 
metabolites (Appendix la).
(ii) The above protocol was repeated two to three months 
later in ten of the volunteers to assess the 
reproducibility of the test (Appendix lb).
(iii) Nineteen subjects consumed a CCB in the morning, after 
emptying their bladder (time 0). CCBs were also consumed 
at mid-morning, lunch and tea time until four cups in 
total had been drunk. 0-8 h urine was collected and 
assayed (Appendix lc).
(iv) A spot urine sample was collected 2-6 h after a single 
CCB in seventeen subjects and caffeine metabolites 
assayed (Appendix Id).
b) Effect of timing of urine collection on metabolite profiles 
Seven subjects (2 male and 5 female) who participated in 
protocol (a) were studied in detail for changes in caffeine 
metabolite profiles over 2 h periods, following different 
caffeine doses.
(i) The first urine passed in the morning was collected and 
labelled as specimen t o .  A  CCB was immediately consumed 
but all subjects abstained from further beverages 
containing caffeine during the 8 h test. Urine was
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passed every two hours and the samples labelled t2, t4, 
t6 and t8 h (Appendix 2a).
(ii) The above test was repeated but in addition subjects 
consumed CCBs at mid-morning, lunch and tea time such 
that t2, t4, t6 and t8 h urine samples were collected, 
following multiple caffeine dosing (Appendix 2b).
c) 0-8 hour urinary metabolite profiles: a population study
One hundred and twenty-seven subjects (86 male and 41 female) 
were studied, consisting mainly of MOD staff. Their ages ranged 
between 21 and 63 y (37.0 + 1.07; mean + SEM). Twenty-five 
volunteers smoked cigarettes; 14 took OCS or hormone replacement 
therapy (HRT); 5 were using salbutamol pressurised aerosol
inhalers; 2 were prescribed aspirin; 5 were taking atenolol; 2 
were taking non-steroidal anti-inflammatory preparations for 
arthritis and 2 were taking diuretics. No other volunteer smoked 
or took regular medication.
Each subject emptied their bladder on rising and immediately 
consumed a CCB. No restrictions were placed on caffeine dosing 
but all volunteers recorded the number of chocolate bars and 
CCBs consumed during the study. All urine passed over the next 8 
h period was collected and pooled (Appendix 3).
d) 2-6 hour urinary metabolite profiles; a population study
One hundred and fifty subjects (59 male and 91 female) were 
studied, consisting mainly of hospital staff. Their ages ranged 
between 17 and 91 y (39.4 + 1.5; mean + SEM). Forty-five
volunteers smoked cigarettes; 28 took OCS or HRT; 3 were using 
salbutamol pressurised aerosol inhalers; 1 taking sodium
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valproate; 1 taking ranitidine; 2 taking penicillin; 1 talcing a 
diuretic; 1 taking atenolol; 1 taking lorazepam and 2 taking 
non-steroidal preparations for arthritis. No other volunteer 
smoked or took regular medication.
Each subject collected a spot urine sample 2-6 h after a CCB. No 
restrictions were placed on the total number of CCBs consumed on 
the day of the test nor on the time of day that the urine 
specimen was collected (Appendix 4).
2.3.2 Patients
Three groups of cancer patients admitted to the RUH, Bath or 
attending its Outpatient Clinics were studied. A group of 
patients with familial adenomatous polyposis (FAP) and their 
first degree relatives attending St. Mark's Hospital, London 
were also studied. Patients recruited had liver and kidney 
function values within normal limits and none were knewn to have 
metastases or evidence of other neoplasia at the time of 
diagnoses. Several patients had received chemotherapy, months or 
years before participating in the caffeine test; several were on 
courses of medication but patients taking drugs kncwn to 
interfere with caffeine metabolism or cytochrome P450 enzymes, 
were excluded from the study.
For all studies a record of subject age, EMI, smoking status, 
current medication and cancer cell type was made (Appendix 5-8).
a) Caffeine metaolism in patients with carcinoma of the lung, 
head or neck
Fifty-one patients with carcinoma of the lung, head or neck were 
studied. Forty-five patients were diagnosed by histology and 6
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radiographically. Forty were male, 11 were female and their ages 
ranged between 47 and 83 y (67.92 + 1.41; mean + SEM). Sixteen 
smoked cigarettes at the time of the test; 4 had never smoked 
and 31 had smoked previously but had given up the habit for at 
least 2 months and were therefore classified as nonsmokers for 
the purpose of this study. Forty-one patients had bronchial 
carcinoma and 10 had cancer in tissue of the head or neck. 
Thirty had tumours of squamous cell origin; 10 had tumours of 
oat cell origin; 1 was of Swan cell type; 2 had adenocarcinoma 
and 8 tumours could not be cell-typed.
Each patient provided a spot urine sample 2-6 h after a single 
CCB (Appendix 5).
b) Caffeine metabolism in patients with leukaemia
Fifty-four patients with leukaemia were studied. All patients 
were diagnosed by blood or bone marrcw examination. Twenty-two 
were male, 32 were female and their ages ranged between 24 and 
86 y (61.85 + 2.13; mean ± SEM). Seven smoked cigarettes at the 
time of the test; 23 had never smoked and 24 had given up 
smoking for at least 2 months and were classified as nonsmokers. 
Twenty-nine patients had chronic leukaemia (23 lymphocytic; 3 
granulocytic; 3 myeloid); 8 patients had acute leukaemia (2
lymphocytic; 6 myeloid); 10 patients had lymphcma (4 Hodgkin's; 
4 Non-Hodgkin's); 4 had myeloma and 3 had hairy cell leukaemia. 
Each patient provided a spot urine sample 2-6 h after a single 
CCB (Appendix 6).
c) Caffeine metabolism in patients with colorectal cancer 
TWelve patients with carcinoma of the colon, rectum or anus were
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studied. All patients were diagnosed histologically. Five were 
male, 7 were female and their ages ranged between 54 and 86 y
(69.4 + 2.8; mean + SEM). Eight were nonsmokers and 4 had given
up smoking for at least 2 months and were classified as 
nonsmokers. Four had cancer of the colon; 6 had cancer of the 
rectum; 1 of the anus and 1 of the caecum. One patient had a 
tumour of squamous cell origin and 11 had adenocarcinoma.
Each patient provided a spot urine sample 2-6 h after a single 
CCB (Appendix 7).
d) Caffeine metabolism in patients with familial adenomatous 
polyposis
Thirty-seven patients with endoscopically and histologically 
confirmed FAP attending St. Mark's Hospital, London were
studied. All patients had undergone colectomy, prior to the 
caffeine test. Twenty-one were male, 16 were female and their
age ranged between 19 and 70 y (36.38 ± 2.44; mean + SEM). Five
smoked cigarettes; 27 were nonsmokers and the smoking status of
5 patients was unknown. Each patient took caffeine citrate
(300mg) by mouth and all urine passed during the following 8 h
was collected and pooled (Apendix 8a).
Sixteen first degree relatives of the patients with FAP were 
studied. These persons were considered to be at risk for FAP, as 
they may have inherited the mutant gene frcm affected parents 
but none had clinical symptoms of FAP at the time of study. Nine 
were male, 7 were female and their ages ranged between 15 and 65 
y (31.25 + 4.06; mean ± SEM). Six were cigarette smokers and 10 
were nonsmokers. Each patient took caffeine citrate (300mg) by 
mouth and all urine passed in the following 8h was collected and
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pooled (Appendix 8b).
2.4 nr>T.T.FICTION OF BIOLOGICAT. SAMPT.FS
10 ml blood samples were collected in unheparinised glass tubes 
for estimation of various enzyme, protein and ion concentrations 
outlined previously, to determine liver and kidney function. 
Individual blood samples were allowed to clot at room 
temperature for 30 min. before being centrifuged at 1500g for 15 
min to obtain serum.
Following urine collection, the total volume was recorded and 
approximately 20ml aliquots were stored.
2.5 STORAGE OF BJOTfXTTCAT. SAMPLES
All samples were stored at -20°C between collection and
analysis and were subsequently unfrozen at room temperature. 
Most samples were analysed within a month of collection.
2.6 ANALYSIS OF CAFFEINE AND METABOLITES IN URINE
Due to the wide range in polarity of the caffeine metabolites, 
the large variation in the levels of their excretion and the 
instability of one of the metabolites, four separate protocols 
were employed to analyse caffeine, its polar metabolites, its 
nonpolar metabolites and AAMU.
2.6.1 Analysis of caffeine and its nonpolar metabolites in urine
1,7-DMX, 1,7-DMU, and caffeine were assayed in urine samples by
high performance liquid chromatography (HPLC). Ihe method was a 
modification of that reported by Grant et al (1983a), using 
8-chlorotheophylline as the internal standard.
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a) Extraction of caffeine and its nonpolar metabolites
Urine samples were extracted with 10 ml chloroform: isopropanol 
(95:5 % v/v) as follows.
1 ml of saturated ammonium sulphate solution was added to 1 ml 
of urine sample in screw top glass tubes and vortex-mixed 
briefly. Two hundred microlitres of 8-chlorotheophylline (100 
ug/ml) were added and the resultant mixture was extracted in 10 
ml chloroform: isopropanol (95:5% v/v), shaken for 10 min on a
rotating mixer and centrifuged at 2000g for 10 min. Hie organic 
layer was transferred into a Z10 glass tube (LIP Ltd.,Yorks.) 
and evaporated to dryness by centrifugal evaporation under a 
vacuum at 30°C (Gyrovap, V.A. Howe Comp., London). The residue 
was reconstituted in 1 ml of acetic acid (0.5%) by vortexing for 
15 sec. The solution was pipetted into a vial, injected 
automatically (100 ul volumes) onto the HPLC column.
Calibration.
Blank urine (i.e. with no detectable concentrations of any 
caffeine metabolites) was achieved cifter a single volunteer 
abstained from caffeine for 120 hr s.
Blank urine was spiked with standard solutions of 1,7-EMU (0-5 
ug/ml) and 1,7-DMX (0-40 ug/ml) dissolved in water and processed 
in the same way as the experimental samples. Standard curves 
were prepared as described in Section 2.8.
b) HPLC conditions for nonpolar metabolites
Column: separations were carried out using a 5 um
Spherisorb CDS, 25 cm * 4.6 mm ID reversed phase 
column






Detection of each injected sample was achieved by 
means of a gradient elution program. % ACN in 
mobile phase was 0% for 10 min, 0-36% in 20 min, 
36-0% in 0.5 min and 0% for 4.5 min.




All separations were performed at room temperature and the 
metabolites were identified on the basis of their retention 
times. Under the above conditions, retention times for 1,7-EMU,
1,7-DMX and internal standard in urine extracts were 
approximately 24.40, 24.80 and 26.80 min respectively.
A typical chromatogram of 1,7-EMU (3 ug/ml), 1,7-EMX (15 ug/ml) 
and internal standard (20 ug/ml) extracted in blank urine is 
depicted in Figure 2.1A. A sample of extracted urine from a 
healthy volunteer, analysed under these HPLC conditions,
produced the chromatogram depicted in Figure 2.IB.
c) HPLC conditions for caffeine
A reversed phase HPLC method for analysing caffeine with a short 
run time was developed.
Column: separations were carried out using a 5 urn
Spherisorb ODS, 25 cm * 4.6 mm ID reversed phase
column
Mobile Phase: 0.5% acetic acid /acetonitrile (ACN) (75:25% v/v)
Flow Rate: 1 ml/min generated a back pressure of 1800 psi
Detection: 280 nm
Range: 0.02 AUF
Chart Speed: 4 mm/min
The retention times for caffeine and IS under these conditions 
were approximately 5.30 and 4.50 min, respectively. A typical 
chromatogram of caffeine (2.5 ug/ml) and internal standard (20 
ug/ml) extracted in blank urine is depicted in Figure 2.2A. A 
sample of extracted urine from a healthy volunteer, analysed by 
this HPLC method produced the chromatogram depicted in Figure 
2.2B.
2.6.2 Analysis of the polar metabolites of caffeine in urine 
1-MU and 1-MX were assayed in human urine by HPLC. The method 
used was a modification of that reported by Grant et al (1983a), 
using 8-chlorotheophy 11 ine as the internal standard.
a) Extraction of the polar metabolites of caffeine
Urine samples were extracted with 10 ml chloroform: isoprcpanol
(50:50% v/v) as follows.
Saturated ammonium sulphate solution (0.25 ml) was added to 0.25 
ml of urine sample in screw top glass tubes and vortex-mixed 
briefly. Two-hundred microlitres of 8-chlorotheqphylline (100 
ug/ml) was added as internal standard and the resultant mixture 
was extracted in 10 ml chloroform: isopropanol (50:50% v/v), 
shaken for 10 min on a rotating mixer and centrifged at 2000g 
for 10 min. The organic layer was transferred into a glass Z10 
tube and evaporated to dryness by centrifugal evaporation under 
a vacuum at 30°C. The residue was reconstituted in 1 ml of 
acetic acid (0.5%) by vortexing for 15 sec. The solution was
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Figure 2.1 - Chromatograms of A) standard 1,7-EMU (3 ug/ml) 
and 1,7-DMX (15 ug/ml) in blank urine and B) 
nonpolar metabolites extracted from urine of a 
healthy subject, with IS (20 ug/ml).
(1) 1,7-DMU, (2) 1,7-DMX, (3) IS. 
Values given are the retention times (mins).
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Figure 2.1 - Chromatograms of A) standard 1,7-DMU (3 ug/ml) 
and 1,7-DMX (15 ug/ml) in blank urine and B) 
nonpolar metabolites extracted from urine of a 
healthy subject, with IS (20 ug/ml).
(1) 1,7-DMU, (2) 1,7-DMX, (3) IS.
Values given are the retention times (mins).
in
ID
Figure 2.2 - Chromatograins of A) standard caffeine (2.5ug/ml) 
in blank urine and B) caffeine extracted from 
urine of a healthy subject, with IS (20 ug/ml).
(1) IS, (2) Caffeine.
Values given are the retention times (mins).
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pipetted into a vial, injected automatically (100 ul volumes) 
onto the column and assayed.
Calibration
Blank urine spiked with standard solutions of 1-MJ and 1-MX 
(0-30 ug/ml) dissolved in 0.00IM NaOH solution (pH 9) were 
processed in the same way as the experimental samples. Standard 
curves were prepared as described in Section 2.8.
b) HFLC conditions for polar metabolites
Column: separations were carried out using a 5 um
Spherisorb COS, 25 can * 4.6 mm ID reversed phase 
column
Mobile Phase: 0.5% acetic acid/ acetonitrile (ACN)
Detection of each injected sample was achieved by 
means of a gradient elution program. % ACN in 
mobile phase was 6% for 0-11 min, 6-50% in 6 min, 
50-6% in 0.5 min and 6% for 7.5 min.








All separations were carried out at room temperature and the 
metabolites were identified on the basis of their retention 
times. Under the above conditions, retention times for 1-MU, 
1-MX and internal standard in urine extracts were approximately 
5.80, 7.70 and 20.40 min respectively.
A typical chromatogram of 1-MU and 1-MX (10 ug/ml) and internal 
standard (20 ug/ml) extracted in blank urine is depicted in
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Figure 2.3A. A sample of extracted urine from a healthy
volunteer, analysed under these HPLC conditions, produced the 
chromatogram depicted in Figure 2.3B.
2.6.3 Analysis of AAMCJ in urine
a) Assay procedure
Due to the instability of 5-acetylamino-6-formylamino-3-methyl 
-uracil (AFMJ) in urine, this caffeine metabolite was
deliberately deformylated into its stable product 5-acetylamino-
6-amino-3-methyluracil (AAMCJ) as follows.
1M NaOH solution (200 ul) was added to 100 ul aliquots of urine 
and vortex-mixed briefly. The solution was left at room 
temperature for 10 min and then neutralised with 200 ul 1M HC1. 
The solution was vortexed again and the resulting 500 ul samples 
injected directly (100 ul volumes) onto the column. Standard 
AFMJ, kindly donated by Dr MJ Amaud (Nestle, Switzerland) was 
dissolved in acetonitrile (100 ug/ml) and aliquots were taken 
such that a standard curve in the range of 0-40 ug/ml could be 
produced. Each aliquot was evaporated to dryness and
reconstituted in 100 ul blank urine. These standards were then
deformylated in the same way as experimental samples.
b) HPLC conditions
A reversed phase HPLC method was developed for analysis of AAMU 
in urine.
Column: separations were carried out using a 5 urn
Sperisorb ODS, 25 cm * 4.6 mm ID reverse phase 
column

















Figure 2.3 - Chromatogram of A) standard 1-MU and 1-MX (10 
ug/ml) in blank urine and B) polar metabolites 
extracted from urine of a healthy subject, with 
IS (20 ug/ml).
(1) 1-MU, (2) 1-MX, (3) IS.






0.5 ml/min for 0-5 min
1.0 ml/min for 5-8 min
2.0 ml/min for 8-13 min 




AAMCJ was identified on the basis of its retention time. Under 
the above conditions AAMLJ eluted at approximately 7.70 min. 
Typical chromatograms of standard AAMCJ (10 ug/ml) in blank urine 
and AAMU in urine of a healthy volunteer are depicted in Figures 
2.4A and 2.4B, respectively.
2.7 IN VITRO METABOLISM OF PARAXANTHINE AND CAFFEINE BY 
CYTOCHROME P450IA1
2.7.1 Cofactor Solution
For a total incubation volume of 500 ul, the following amounts 
of cofactors were prepared in order to provide an NADPH 
regenerating system:
2 umol glucose 6-phosphate 
0.2 umol NADP
0.2 units glucose 6-phosphate dehydrogenase 
1 umol magnesium chloride.
Cofactors were dissolved in 0.2M potassium phosphate buffer (pH 
7.4) to give a total volume of 100 ul.
2.7.2 Standard Incubation Mixtures
For microsomal incubation studies, 50 ug/ml caffeine and 1,7-DMX
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Figure 2.4 - Chromatogram of A) standard AAMU (10 ug/ml) in 
blank urine and B) AAMU from urine of a healthy 
subject.
(1) AAMU.
Values given are the retention times (mins).
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stock solutions were prepared. Standard mixtures (500 ul) 
contained 100 ul of the appropriate substrate at a final 
concentration of 10 ug/ml; 100 ul of cofactor solution and 300 
ul of yeast microsomal suspension (15 mgs protein/ml) expressing 
cytochrome P450IA1, at a concentration of 43.6 pmol/mg protein. 
Metabolism was initiated by addition of the substrate and the 
complete mixture was incubated at 37°C for 60 min in a shaking 
water bath. The reaction was terminated by adding 420 ul of the
incubation mixture to 50 ul of perchloric acid (6%), resulting
in deproteinization and the protein was sedimented by 
microfugation at 10,000g for 3 min.
Each incubation was performed in triplicate. Results were 
compared to control incubations where microsomes expressing 
P450IA1 were replaced with 300 ul yeast microsomes not 
expressing P450IA1.
2.7.3 Analysis of caffeine and paraxanthine metabolites 
Following protein precipitation and microfugation of each
incubation mixture, the supernatant was removed and 50 ul of
8-chlorothecphylline (internal standard; 1 ug/ml) and saturated 
ammonium sulphate solution (470 ul) was added. The mixture was 
vortexed briefly.
Incubations with caffeine as substrate were extracted in 6 ml 
chloroform: isopropanol (95:5% v/v) for analysis of any 1,7-DMX
that may have formed. Incubations with 1,7-DMX as substrate were 
extracted in 6 ml chloroform: isopropanol (50:50% v/v) for
analysis of any 1-MX that may have formed. Each mix was shaken, 
centrifuged and evaporated to dryness as previously described. 
The residue was reconstituted in 0.5% acetic acid (500 ul) by
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vortex-mixing for 15 sec. The sample was pipetted into a vial 
and injected automatically (100 ul volumes) onto the column. 
Standard solutions of 1,7-DMX (0-5 ng on column) and 1-MX (0-20 
ng on column) with 50 ul internal standard (1 ug/ml; 5 ng on 
column) were prepared in 300 ul control rat microsomes, made up 
to 420 ul with water and processed in the same way as the 
experimental samples.
2.7.4 HPLC conditions
Column: separations were carried out using a 5 urn
Sperisorb CDS, 25 cm * 4.6 mm ID reversed phase 
column
Mobile Phase: Acetic acid (0.5%)/ acetonitrile (ACN)
Analysis of each injected sample was achieved by 
means of a gradient elution program. % ACN in 
mobile phase was 0% for 0-10 mins, 0-15% in 10
mins, 15% for 5 mins, 15-0% in 0.5 mins and 0%
for 9.5 min.
Flow Rate: 1 ml/min for 0-10 min
2 ml/min for 10-25 min 
1 ml/min for 25-35 min 
Detection: 280 nm
Range: 0.002 AUF
Chart Soeed: 4 mm/min
Metabolites were identified on the basis of their retention
times. Under the above conditions, retention times for 1-MX,
1,7-DMX, IS and caffeine were approximately 17, 20, 22.50 and 23 
mins, respectively. Typical chromatograms of 1-MX (20 ng) and IS
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2.5 - Chromatograins of standard A) 1-MX (20ng) and B)
1,7-DMX (5ng) extracted in control microsomes 
with IS (5ng).
(1) 1-MX, (2) IS, (3) 1,7-DMX.
Values given are the retention times (mins).
(5 ng) and 1,7-DMX (5ng) and IS (5 ng) in control rat microsomes 
are depicted in Figs.2.5A and B.
2.8 QUANTITATION OF CAFFEINE METABOLITES IN URINE
a) Preparation of standard curves
Eight to ten blank urine samples were spiked with a range of 
solute concentrations and a constant concentration of internal 
standard and assayed by HPLC. Calibration curves for 1-MU and 
1-MX, 1,7-EMU and 1,7-EMX and caffeine itself were constructed
by determining the peak height ratios (i.e. peak height of 
metabolite/ peak height of internal standard) of each metabolite 
concentration in urine. A calibration curve for AAMU was 
constructed by determining the absolute peak height of varying 
concentrations in urine.
Any urine samples with a concentration greater than the highest 
standard (s) were diluted, so as to fall in the linear portion of 
the calibration curves. Standard curves were prepared for each 
new batch of urine samples to be extracted/ deformylated. There 
were no significant changes in gradient with time.
For standard curves of metabolites in microsomal suspensions, 
lower concentrations were prepared to match those expected to 
result from incubations. In this way, peak height ratios of 
absolute ng of each metabolite and internal standard on column 
were determined.
The data was fitted to the following equation using linear 
least-squares regression: 
y = mx + c
where y is the peak height ratio or absolute peak height
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x is the concentration of solute
m is the gradient and c is the constant (point of crossing 
the y axis).
b) t .i neari tv of calibration curves
For each standard curve, the correlation coefficient r, the 
slope m and the intercept c were determined by linear 
least-squares regression. Typical data for each metabolite 
calibration curve is shown.
r m c Range (ug/ml)
Caffeine 0.998 0.0318 -0.0064 0.25 - 20
1,7-EMU 0.998 0.0205 0.0032 0.25 - 5
1,7-DMX 0.999 0.0173 -0.0034 1 - 40
1-MU 0.999 0.0312 0.0097 1 - 30
1-MX 0.999 0.0103 0.0009 1 - 30
AAMU 0.999 3576.6 214.3 0.50 - 40
c) Concentration determination
Peak height ratios for 1-MJ, 1-MX, 1,7-DMU, 1,7-EMX and caffeine 
itself; and absolute peak heights for AAMU were determined in 
urine. Concentrations were calculated using the equation
xi = * i - ^  
m
where x^ is the unknown concentration to be determined,
is the observed peak height ratio or absolute peak
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height,
c and m are regression coefficients calculated from the 
calibration curves.
2.9 STATISTICAL ANALYSIS AND TREATMENT OF THE DATA.
Statistical analyses of data were carried out using the computer 
statistical package, Statgraphics (Statistical Graphics 
Corporation). Results are expressed as mean + (SEM). Significant 
differences between means of different populations were 
determined by the Student t-test (two-tailed, unpaired) or by 
non-parametric methods, such as the Mann-Whitney and Wilcoxon 
tests. Spearman Rank correlations were used to test for goodness 
of fit of data to a straight line. A probability of p <0.05 was 
taken to denote a significant difference.
For this study, most of the data are presented in the form of 
frequency histograms. Skewness of distribution was measured by 
the Kolmogorov-Smimov (K-S) test, the Chi-square test and the 
degree of kurtosis. Statistically significant results for these 
tests indicated deviation from a normal distribution. In 
addition to studying cumulative frequency distributions, the 
Lilly-Fors test was used to determine whether a highly skewed 
distribution was likely to be bimodal.
A variation of Chi-square was used to test whether the observed 
frequencies of enzyme activity in a given population were 
different from the expected frequencies in a control papulation, 
based on the following equation:
X2 = N (ad - bc)-
(a + b) (a + c) (b + d) (c + d)
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Genetic Trait 
rr RR Rr Total
Population l a  b a + b
Population 2 c d c + d
N
Where a, b, c and d are numbers of individuals expressing a 
particular genetic trait and N is the grand total of (a + b) and 
(c + d). A probability of p <0.05 was taken to denote 
significant difference between observed and expected results.
The absolute quantities of each caffeine metabolite excreted in 
the urine of different subjects was highly variable. Therefore, 
all data for comparing individual metabolite profiles were 
expressed as the percentage of the total metabolites excreted in 
urine. Total amount (mg) of each metabolite were used to 




THE USE OF CAFFEINE AS AN INDICATOR OF ENZYME ACTIVITY:
METHOD DEVFT OPMKNT
3.1 ANALYTICAL DEVELOPMENT 
Introduction
Due to the ubiquitous use of caffeine, its relative safety and 
its degradation by several enzymes, use of this compound as a 
probe drug of hepatic enzyme activities warrants investigation. 
Caffeine is a substance which is metabolised to a large number 
of different products in man (Amaud, 1984) and analysis of its 
metabolites in man is complex. A number of HPLC methods have 
been developed for the analysis of caffeine and its metabolites 
in biological samples (Aldridge et al, 1979; Monks et al, 1979; 
Grygiel & Birkett, 1980; Muir et al, 1980; Callahan et al, 1982; 
Bonati et al, 1982; Tang-Liu & Riegelman, 1982; Grant et al, 
1983b). However, most published methods were inadequate for 
practical use as they either lacked selectivity or sensitivity; 
or were unreproducible; or they were elaborate and lengthy. In 
light of this, the author has developed extraction and HPLC 
procedures based on modifications of several existing methods.
3.1.1 Extraction procedures
Direct injection of urine samples onto the column was attempted, 
in order to minimise sample work-up. Unlike other workers 
(Desiraju & Sugita, 1977), this approach was found to be 
unsuccessful as endogenous, interfering peaks in urine did not 
allow adequate resolution of the caffeine metabolites of 
interest. It was therefore necessary improve test selectivity by
51
extraction of urine samples with various organic solvents. 
Attempts were made to reproduce the extraction procedure 
described by Aldridge et al (1979) which has been modified by 
several other groups (Bonati et al, 1982; Grant et al, 1983b; 
Campbell et al, 1987; Berthou et al, 1989; Kilbane et al, 1990). 
These workers reported efficient extraction of caffeine
metabolites, in a single step using chloroform: iscprcpanol 
(85:15% v/v). It was found however, that due to the differences 
in physical and chemical properties of the mono- and 
dimethylated xanthines and uric acids, it was not possible to 
obtain a high extraction efficiency for both groups of 
metabolites by using a single, extraction step. Therefore two 
procedures were employed.
The less polar metabolites, 1,7-EMX, 1,7-EMU, 1.3-EMX, 3,7-EMX 
and caffeine were extracted in chloroform: isopropanol (95:5% 
v/v). Recovery (%) for the extraction procedure, for each 
metabolite ranged between 82 and 99.8% and the coefficient of 
variation between 2.2 and 9.1% (Appendix 9).
Even at lew urinary pH, however, when the monomethylated 
xanthines and uric acids are predominantly in the unionised 
form, their extraction from aqueous phase into this organic 
solvent was very inefficient, ranging from 2.8 to 33% fcy virtue 
of their high polarity. This seemed to be the case particularly 
for 1-MU and is in agreement with Muir et al (1980). Methods 
used by Aldridge et al (1979), Berthou et al (1989) and Grant 
and coworkers (1983b) extracted 1-MU with % recoveries of 36, 50 
and 75%, respectively, which were not deemed satisfactory for 
this study.
Therefore, 1-MU, 1-MX, 3-MU, 3-MX, 7-MU, 7-MX, 1,3-EMU and
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3,7-EMU were extracted in chloroform: isopropanol (50:50% v/v) 
and by thus increasing the polarity of the organic solvent, the 
extraction efficiency was increased, ranging from 68.7 to 100% 
(Appendix 3). In this way 1-MU in particular could be accurately 
measured from 0-40 ug/ml. The coefficient of variation for these 
extraction procedures ranged between 4.2 and 7.5% and it was not 
necessary to resort to ion-pair extraction techniques as 
previously reported (Muir et al, 1980; Tang-Liu & Riegelman, 
1982; Scott et al, 1989).
Additional modifications of the extraction method described by 
Grant et al (1983b) used in this study were:
a) Substrate volume; for analysis of the less polar metabolites,
1 ml of urine was extracted and for the polar metabolites,
0.25 ml of urine was extracted, in contrast to 0.3 ml.
b) Solvent volume; 10 ml of total extraction solvent were used 
as opposed to 6 ml to ensure that this was not a limiting 
factor.
c) Internal standard; 8-Oilorotheophy 11 ine was used as internal 
standard as N-acetyl-para-ammqphenol co-eluted with an 
endogenous peak in urine (Carbo et al. 1989; Bonati et al, 
1982; Berthou et al,1989).
d) Use of saturated ammonium sulphate to precipitate proteins in 
urine. Extraction of caffeine metabolites was enhanced by 
adding saturated ammonium sulphate solution to the system, in 
volumes equal to the volume of urine being extracted.
3.1.2 Chromatography
In contrast to several other workers (Aldridge et al, 1979; 
Berthou et al, 1989; Callahan et al, 1982, 1983; Grant et al,
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1983b; Campbell et al, 1987; Carbo et al, 1989) attempts to 
elute all 14 xanthines and uric acids in one chromatograph were 
unsuccessful, as peak broadening for compounds eluting late in 
the run did not allow their accurate quantitation. Grant and 
ccworkers (1983b) could not quantify unchanged caffeine for the 
same reason. Peak merging also occurred and separation of
1.7-EMX and 1,3-DMX using a single chromatographic procedure was 
not possible. Furthermore, carry-over peaks from previous 
injections, representing compounds with long retention times 
were frequently seen. Therefore gradient elution programs using 
acetonitrile (Aldridge et al, 1979; Bonati et al, 1982) and 
acetic acid (0.5%) as mobile phase were developed. Methanol was 
excluded from mobile phase in the present study, unlike others 
(Grant et al, 1983b; Grygiel & Birkett, 1980) which allowed 
better resolution of several peaks.
The gradient system for the nonpolar metabolites (Section 2.6.1) 
allowed selective measurements of 1,7-EMX, EMMIOD, 1,3-EMX,
3.7-DMX and caffeine whereas previous methods fail to resolve
1.7-EMX and 1,3-EMX (Grygiel et al, 1984; Aldridge et al, 1979; 
Callahan et al, 1982, 1983) and 1,3-DMU and 3,7-EMX (Tang-Liu & 
Riegelman, 1982). Although this system allowed quantitative 
estimation of caffeine itself, this compound was estimated 
separately and more accurately isocratically, using 25% 
acetonitrile in the mobile phase so that it eluted at 
approximately 5.40 min, instead of 30-60 min seen in other 
methods.
The gradient elution program for the polar metabolites (Section 
2.6.2) allowed good resolution of the moncmethylated xanthines 
and uric acids. In the past, this has proved difficult,
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particularly for separation of 7-MX and 3-MU (Tang-Liu & 
Riegelman, 1982), 1-MU and 7-MX (Callahan et al, 1982; Kilbane 
et al, 1990), 3-MU and 7-MU (Bonati et al, 1982) and 1-MX and
3,7-EMU (Aldridge et al, 1979; Callahan et al, 1982).
Resolution of the rapidly eluting peaks was also achieved when 
this system was run isocraticaliy with 0.5% acetic acid: 
acetonitrile (6:94%). In order to maximise quantitative 
estimation of the peaks however, and to elute endogenous 
compounds with long retention times, the gradient elution system 
was used for routine assays. The choice of 280 nm as the 
detection wavelength optimised the absorbance of both the methyl 
xanthines (ABS.MAX 270 nm) and uric acids (ABS.MAX 290 nm). 
Although both groups of compounds have significant absorbance at 
254 nm, more interfering and spurious peaks were evident at this 
wavelength.
It has been established that the portion of AFMU excreted in 
urine by different subjects is dependent on their arylamine 
N-acetylation phenotype and simple methods for AFMU analysis 
were therefore developed (Grant et al, 1983a, 1984). AFMU
hcwever, is an unstable caffeine metabolite that is 
spontaneously deformylated to the stable AAMU (Tang et al, 1983) 
at ambient temperature at a pH greater than 3.5 (Grant et al,
1984). Most workers have therefore acidified urine samples 
following their collection in order to stabilise any AFMU 
present (Hardy et al, 1988; Evans et al, 1989). Due to the fact 
that AFMU may be retained in the bladder for several hours at a 
pH and temperature far from ideal for maintaining stability of 
this metabolite, it would be expected that AFMU recovery may be
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lew. In fact after 4 h at 37°C, AFMU levels fell by 29% at pH 
5; 35% at pH 6; 39% at pH 7 and 45% at pH 8 (Lorenzo & 
Reidenberg, 1989). Also, Branfman et al (1983) noted that 23% of 
AFMJ degraded in urine frozen for 6 months. AFMJ appears to be 
so labile under physiological conditions that even if urine 
specimens were adjusted immediately to pH<3 and frozen, there 
would still be considerable loss of AFMJ in more basic urines 
prior to voiding. This problem was potentiated further by the 
fact that 1-MX is unstable in aqueous solution if the pH is 
adjusted to pH<3, in which case it precipitates out of solution 
(Lorenzo & Reidenberg, 1989). Redissolution of 1-MX in the urine 
by raising the temperature or pH would accelerate AFMU 
degradation if both metabolites were measured from the same 
sample.
It was shown by Tang et al, (1983) that AFMU could be readily 
and irreversibly changed into AAMU within 10 mins at RT by 
adding NaOH solution (1M) to the samples and adjusting the pH to 
10. As AFMU deformylates quantitatively to stable AAMU, we 
deliberately deformylated AFMU in urine to its stable product, 
AAMU. In this way, urine did not need to be acidified; 1-MX 
recovery remained unaffected; the level of AAMU which 
represented total acetyluracil formed from paraxanthine may have 
improved estimation of acetylation capacity.
Initially in the 1960s, the concentration of AAMU in urine was 
measured by high-performance anion-exchange chromatography but 
the required time of 40 h per sample was too long for routine 
usage. It had been reported that AFMU was well extracted in 100% 
chloroform (Grant et al, 1983b) but we failed to extract AAMU in
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this solvent, in agreement with Tang et al (1983) who found that 
AAMU could not be extracted by chloroform or chloroform/ 
iscpropanol mixtures. In contrast to other workers however (Tang 
et al. 1986; Kilbane et al, 1990), AAMU was retained by 
reversed-phase HPLC when mobile phase with pH2 was used and this 
metabolite could be selectively quantitated in urine as it did 
not co-elute with any other compounds, even without prior 
extraction. Exclusion chromatography was thus not used. This 
method has the advantage of a short run-time (15 min) in 
comparison with others (Tang et al, 1986).
The detection wavelength was set at 263.5 nm (ABS.MAX for AAMU).
3.1.3 Stability Studies
As each urine sample was stored at -20°C prior to analysis and 
subsequently unfrozen at room temperature, it was necessary to 
establish the stability of caffeine metabolites at -20°C over 
a period of months and at 24°C over a period of hours.
Preliminary results showed that if caffeine metabolites are 
frozen, they remain stable for at least three months. They also 
remain stable for over 12 h at room temperature (Appendix 10).
As urine samples were collected for up to 8 h in some caffeine 
tests, it was also necessary to establish the stability of 
caffeine and its metabolites at 37°C, as urine may be retained 
in the bladder at this temperature for several hours.
Results indicated that caffeine metabolites are stable at 37°C 
for over 10 h (Appendix 10).
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3.2 METABOLISM OF CAFFEINE AND PARAXANTHINE BY CYIOCHRCME
P450IA1
3.2.1 Introduction
It has recently been shewn in man that caffeine 3 -demethylation 
to paraxanthine is catalysed exclusively by the P450IA2 enzyme 
(Butler et al, 198Sa; Sesardic et al, 1990). This is the only 
pathway of caffeine metabolism for which the exact P450 isozyme 
involved, has been elucidated. One of the major pathways of 
caffeine metabolism determined during these studies was the 
7-demethylation of paraxanthine. A joint study with the 
Department of Pharmacology & Therapeutics, University of 
Sheffield (Royal Hallamshire Hospital) was undertaken using 
human cDNA-expressed cytochrome P450IA1 to determine whether 
this enzyme was capable of metabolising caffeine and its major 
metabolite paraxanthine. This approach has been used in the past 
to determine the substrate specificity of P450IA2 (Aoyama et al. 
1989; Gonzalez et al, 1990).
3.2.2 Results
Following incubation of caffeine (10 ug/ml) and 1,7-EMX (10 
ug/ml) with yeast microsames expressing P450IA1, the resultant 
mixtures were extracted and analysed by HPLC for the presence of
1,7-EMX and 1-MX, as outlined in Section 2.7. These preliminary 
tests suggested that P450IA1 was capable of metabolising 
caffeine to 1,7-EMX and that the 1,7-EMX formed during this 
reaction was itself metabolised further to 1-MX (Fig.3.2.1A). 
The total conversion of caffeine to these demethylated products 
was 18.5%, as 5% was metabolised to 1,7-EMX and 13.5% to 1-MX. 








Figure 3.2.1 - Chromatograins of extracted incubates of A)
caffeine and microsomes containing P450IA1 and B) 
caffeine and control microsomes.
(1) 1-MX, (2) 1,7-DMX, (3) IS, (4) Caffeine. 





Figure 3.2.2 - Chromatograins of extracted incubates of A)
1.7-EMX and microsomes containing P450IA1 and B)
1.7-EMX and control microsomes.
(1) 1-MX, (2) 1,7-DMX, (3) IS.
Values used are the retention times (mins).
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the P450IA1 enzyme, did not metabolise caffeine (Figs.3.2.IB). 
Microsames containing P450IA1 also metabolised 1,7-DMX into 
1-MX, as shewn in Fig.3.2.2A. The total conversion of 1,7-DMX to 
1-MX was 49%. Control incubations utilising microsomes which did 
not express cytochrome P450 enzyme, were unable to metabolise
1,7-DMX (Fig.3.2.2B).
3.2.3 Discussion
Several lines of evidence indicate that N-demethylation pathways 
involved in the metabolism of caffeine are catalysed by the 
P450IA family of enzymes, in both animals (Aldridge et al, 1977; 
Welch et al, 1977; Bonati et al, 1980; Wietholtz et al, 1981) 
and man (Jenne et al, 1975; Hunt et al, 1976; Parsons & Neims, 
1978; Grygiel & Birkett, 1980; Kotake et al, 1982; May et al. 
1982; Grygiel et al, 1984; Cusack et al, 1985; Miners et al,
1985). More recently, studies using human liver microsames in 
vitro have shewn that the N-demethylations of caffeine (Grant et 
al. 1987) and its primary metabolites (Campbell et al, 1987) are 
catalysed by the P450IA family of enzymes. They went as far as 
suggesting that the same P450IA isozyme mediated all methyl- 
xanthine demethylations as pairs of metabolites competitively 
inhibited the demethylation of each other and biotransformation 
rates for multiple demethylation pathways were strongly 
correlated. These workers hypothesised that P450IA1 was 
responsible for the biotransformation of caffeine (Kalcw & 
Campbell 1988). However, a recent study of caffeine metabolism 
by Sesardic et al (1990) showed that furafylline, a selective 
inhibitor of P450IA2, inhibited caffeine N3-demethylation. As a 
previous study by Sesardic et al (1988) shewed that P450IA1 was
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below the level of detection in 45 human liver samples, even in 
smokers, they concluded that P450IA1 was absent from normal 
human liver and that caffeine metabolism to 1,7-EMX was
catalysed almost exclusively by P450IA2 in man. Wrighton et al
(1986) however, found that of 14 human liver samples tested, one
specimen did contain P450IA1 and interestingly, this patient had
had a clinical history of heavy cigarette smoking. Furthermore, 
studies by Cresteil & Eisen (1988), Robson et al (1988) and 
Ikeya et al (1989) show that human liver microsames contain 
P450IA1.
In addition, evidence is emerging that metabolism of all the 
methylxanthines is not the same and that more than one 
PAH-inducible isozyme is responsible for caffeine metabolism 
(Bonati et al, 1980; Birkett et al, 1981; Miners et al, 1985; 
Lelo et al, 1986a; Slusher et al, 1987; Robson et al, 1988; 
Berthou et al, 1989; Ratanasavarih et al, 1990).
Should P450IA1 be induced in human liver, the preliminary
results from this study, suggest that it is capable of 
metabolising both caffeine and 1,7-DMX to moncmethylxanthines. 
This might be expected to occur because both isozymes of the 
P450IA family are subject to similar regulatory control and shew 
overlapping substrate specificity. Also, nine demethylation 
reactions occur during caffeine metabolism and all proceed at 
different rates, so it seems unlikely that a single enzyme 
catalyses all these reactions alone.
In the past, liver microsomal preparations were found to 
metabolise caffeine to its primary metabolites only (Grant et 
al, 1987; Campbell et al, 1987; Berthou et al, 1988; Berthou et
al. 1989; Sesardic et al, 1990). Elucidation of further pathways
in caffeine biotransformation therefore required separate
incubations with each dimethylxanthine as the substrate. The 
present study has shewn that incubation of caffeine with human 
cytochrome P450IA1 enzyme results in the formation of 1,7-EMX 
and its metabolite 1-MX. Unfortunately, the inhibitor of 
P450IA2, furafylline was not available, to test whether the 
purified form of P450IA1 used in these experiments could be 
inhibited by this compound.
It has also been a common finding that the total percent 
conversion of caffeine to its metabolites is very lew (Lehmann & 
Miech, 1976; Bonati et al 1980; Campbell et al, 1987; Robson et 
al, 1988; Berthou et al, 1988; Berthou et al, 1989; Sesardic et
al. 1990). For example Grant et al (1987) found that caffeine
metabolism never exceeded 1% at a substrate concentration of ImM 
for any of the livers that they tested, due to a markedly lew 
turnover rate of the enzyme. The substrate concentrations 
required in these in vitro studies were therefore considerably 
higher (0.5-5.0 mM) than those which would be expected in vivo, 
in order that detectable levels of metabolites could be 
produced. Lew caffeine metabolism in vitro has been explained by 
incubation conditions being less than optimal. The present 
results would agree with this in part, as a particularly high 
degree of caffeine metabolism by the P450IA1 enzyme was not 
found, tut compared to liver microsomal preparations the degree 
of metabolism was considerably higher. This might suggest that 
steps involved in actual microsomal preparation are less than 
optimal. It is known that cDNA expression of P450 enzymes offers 
numerous advantages over standard approaches in which the P450s
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are purified and reconstituted (Gonzalez et al, 1990).
Due to the abnormally lew rate of caffeine biotransformation by 
microsomal preparations, the studies using large substrate 
concentrations described, have had to assume that their results 
could be extrapolated to the lower concentrations that would be 
found in man and interpretations must therefore be approached 
with caution. This would appear to apply particularly for
studies using specific inhibitors of enzyme activities during
incubations, as the metabolism of caffeine by control microsomes 
alone is low enough to make detection of its metabolites a 
problem. Nonetheless, qualitatively, the metabolites formed in 
vitro in most studies corresponded well to those detected in the 
body fluids of man after caffeine intake. Quantitatively
speaking, one series of incubation studies with human liver 
microsomes produced less caffeine metabolites than the others 
(Sesardic et al, 1990) even though they used 1 nM caffeine as 
substrate and carried out the incubations for at least 15 mins, 
like other workers.
In addition to the greater degree of metabolism obtained with 
yeast microsomes expressing human P450IA1, the present HPLC 
methods for detecting the metabolites of interest were more 
sensitive than those used by other workers. The limits of 
detection for 1,7-DMX and 1-MX were 5ng and 25ng on column, 
respectively, in comparison to the method used by Ratanasavanh 
et al (1990) which had a detection limit of 25ng of each
metabolite on column. This enabled smaller substrate
concentrations (10 ug/ml) to be incubated, which are closer to 
those amounts found in human tissues following caffeine 
consumption (Lelo et al, 1986a).
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Results from these preliminary studies indicate that should 
P450IA1 be induced in human liver, it may be able to metabolise 
both caffeine and 1,7-DMX into their demethylated products.
3.3_____ CAFFEINE METABOLITE RATIOS AS INDICATORS OF ENZYME
ACTIVITIES
3.3.1 P450IA2 Activity
It has recently been demonstrated that the major route of 
caffeine metabolism via the 3 -demethylation pathway to form 
paraxanthine is catalysed by P450IA2 (Sesardic et al, 1990; 
Butler et al, 1989a). Of the nine possible demethylation 
pathways involved in caffeine metabolism, this is the only route 
for which the exact P450IA isozyme has been elucidated.
The amount of caffeine excreted compared to its metabolites is 
low - generally about 1% of the dose (Cornish & Christman, 1957; 
Burg, 1975; Aldridge et al, 1979; Callahan et al, 1982; Tang-Liu 
et al. 1983) due to its extensive metabolism in the liver 
(Bonati et al, 1982). The discriminating pcwer of metabolite 
ratios is therefore high, as slight differences in caffeine 
metabolism between subjects might be expected to produce large 
differences in MR values in the population.
Products of the 3 -demethylation of caffeine were therefore 
measured and compared to concentrations of caffeine itself in 
urine samples. In this way, the following metabolite ratio was 
determined as an in vivo indicator of P450IA2 activity 
(Fig. 1.5):
(1,7-DMX + 1-MX + 1-MU + AAMU) /Caffeine
A similar MR has been used by other workers to determine P450IA2
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activity (Bartsch et al, 1990). Any 1,7-DMX which has been 
subsequently metabolised is accounted for by measuring its major 
products 1-MX, 1-MCJ and AAMU. Demethylation of caffeine and the 
dimethylxanthines is not thought to go beyond the formation of 
moncmethylxanthines because xanthine and uric acid themselves do 
not accumulate in urine (Cornish & Christman, 1957).
3.3.2 P450IA Activity
In man, paraxanthine formation has been found to account for 70% 
(Bonati et al, 1982) and 80% (Lelo et al, 1986b) of caffeine 
metabolic clearance via 3-demethylation. N7 -Demethylation of
1.7-DMX to 1-MX is catalysed by the P450IA family of enzymes and 
has been reported to be the major biotransformation pathway of
1.7-DMX (Lelo et al, 1989). Whether the isozyme involved is 
P450IA1 or IA2 remains to be determined but this demethylation 
pathway exhibits the largest response to enzyme inducers and 
inhibitors and should provide the best measure of induction by 
cigarette smoke (Grant et al, 1984). 1-MX, 1-MU and AFMU have 
been found to account for 67% of 1,7-DMX clearance and renal 
excretion of unchanged 1,7-DMX comprises 9% of its clearance 
(Lelo et al, 1989). Approximately 50% of the 1,7-DMX dose was 
excreted as 1-MU and 1-MX and approximately 17% excreted as AFMU 
in their study, whereas Callahan et al (1982) found that AFMU 
and AAMU accounted for up to 40% of the caffeine dose.
1.7-Diaminouracil formation has been reported (Amaud & Welsch, 
1981) to comprise around 4% of urinary 1,7-DMX metabolites; this 
compound was not measured in the present study as an authentic 
standard was not available. Major products of the
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7-demethylation of 1,7-DMX were measured and compared to 
concentrations of 1,7-DMX itself in urine samples (Fig.1.5). In 
this way the following metabolite ratio was determined as an in 
vivo index of P450IA activity, based on that from the study by
Grant et al (1984):
(1-MX + 1-MU + AAMU) /1,7-DMX
7-MU and 7-MX metabolites are not included in the MRs as their
lew levels of urinary excretion do not allcw their accurate
quantitation (Grant et al, 1984). The validity of this urinary 
ratio rests on two assumptions. First, although 1-MX formation 
from caffeine is the sum of 1-MX formed via 1,3-DMX 
3-demethylation and 1,7-DMX 7-demethylation, it is assumed that 
1-MX formed via 1,3-DMX is negligible, given that <5% of 
caffeine is metabolised to 1,3-DMX (Cornish & Christman, 1957; 
Lelo et al, 1986b) and that only about 15% of 1,3-DMX is 
metabolised to 1-MX. Second, it is assumed that the urinary
ratio is unaffected by variations in urine flew. The polar 
nature of 1-MX, 1-MU and AAMU mean that these compounds are 
likely to be rapidly excreted without reabsorption by the kidney 
(Tang-Liu et al, 1983). Formation of all four metabolites 
included in the above ratio shewed no dependence on total urine 
volume and consequently a ratio based on these metabolites 
should show no dependence on urine volume (Section 4.1).
Any 1-MX which has in turn been metabolised, is accounted for by 
measuring its product 1-MU. Also, the unknown, unstable 
ring-opened metabolite of 1,7-DMX can be metabolised to form 
1-MX or AAMU depending on the acetylation status of an 
individual (Grant et al, 1984; Lelo et al, 1989). For this
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reason, AAMU is also included in the MR to give as good an 
estimate as possible for P450IA activity.
As appreciably larger quantities of 1,7-DMX than caffeine are 
recovered in urine, one may expect an Improvement in the 
reproducibility of measurements using this ratio at the cost of 
a slight reduction in discriminating pcwer. Furthermore, because 
the substrate for this ratio is 1,7-DMX and not caffeine itself, 
results should not be affected by differences in absorption of 
the test drug.
It should be acknowledged at this stage that 1,7-DMU is a 
metabolite of 1,7-DMX - albeit a minor one, accounting for 
around 8% of 1,7-DMX clearance (Lelo et al, 1989) . It was 
discovered late in these studies that the 1,7-DMU standard 
purchased from Sigma was not authentic. A compound with a very 
similar structure, called 1,3-dihydro-l-methy 1-1-5- (methylamino) 
-8-imidazo [4,5-d] [1,3] oxazine-2,7-dione (DMMIOD) had been
measured (Fig.3.3.1).




Figure 3.3.1 - Chemical structures of (A) 1,7-dimethyluric acid 
(1,7-DMU) and (B) 1,3-dihydro-l-methy 1-1-5- 
(methylamino)-8-imidazo [4,5-d] [1,3] oxazine-2,7 
-dione (DMMIOD).
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Other workers have suggested measuring the ratio:
AFMU + 1-MU + 1-MX/ 1,7-DMU as a measure of P450IA1, following 
the observation that it corelated well with caffeine clearance 
(Campbell et al, 1987). However, it is unlikely that this ratio 
reflects P450IA1 activity alone, as P450IA2 is known to be 
involved in caffeine 3-demethylation in human livers (Sesardic 
et al. 1990). Furthermore, 8-hydroxylation pathways are not 
inducible (Brown et al, 1988) and are thought to be catalysed by 
P450 enzymes other than the IA family, that is, by enzymes that 
probably do not activate compounds into ultimate carcinogens. 
Whereas the degree of caffeine and 1,7-DMX demethylation are 
thought to parallel activation of certain environmental 
pollutants, it has never been shown that the degree 
8 -hydroxy lat ion of caffeine is related to some major 
inactivation pathway of importance in protecting against 
environmental carcinogens. In the absence of such evidence
1,7-DMX demethylation alone was assayed as a measure of absolute 
P450IA activity. The lack of 1,7-DMU in the calculation is not 
therefore believed to undermine the results.
3.3.3 Xanthine Oxidase
Xanthine oxidase is a cytosolic enzyme, responsible for 
metabolising 1-MX to 1-MU whether its source is paraxanthine 
(Grant et al, 1983a, 1984, 1986; Lelo et al, 1989) or
theophylline (Lehmann & Miech, 1976). Allopurinol pretreatment 
markedly decreases 1-MU excretion and enhances 1-MX excretion 
without changing the combined recovery of these metabolites 
(Grant et al, 1984; Lelo et al, 1989). 7-MX can also be
metabolised by this enzyme to form 7-MU (Miners et al, 1982). In
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contrast, 3-MX and the dimethylxanthines are not substrates for 
this enzyme. It is presumed therefore that the following MR can 
be used as an in vivo index of xanthine oxidase activity 
(Fig.1.5):
1-MU /1-MX
Brown et al (1988) also used this ratio as an index of xanthine 
oxidase activity.
3.3.4 N-Acetvltransferase Activity
Following the isolation (Fink et al, 1964) and identification by 
HPLC (Callahan et al, 1982) of a urinary caffeine metabolite, 
AAMU, it was subsequently shown that AAMU and the major uracilic 
metabolite, AFMU (Tang et al, 1983; Branfman et al, 1983) were 
excreted in urine in varying concentrations, depending on 
acetylator phenotype (Callahan et al, 1983). It has been 
proposed that an unstable ring-opened intermediate which arises 
from 1,7-EMX can either be acetylated by the cytosolic NAT 
enzyme to form AFMU or reclose to form 1-MX (Grant et al, 1984; 
Lelo et al, 1989). AFMU and 1-MX are therefore apparently 
derived from a common intermediate, the formation of which is 
mediated by P450IA. Urinary concentration of AFMU was found to 
directly relate to N-acetyltransferase (NAT) activity (Grant et 
al. 1983a) and led to the determination of acetylation phenotype 
by lose of the urinary ratio of AFMU/ 1-MX (Grant et al, 1984; 
Gascon et al, 1987; Hardy et al, 1988; Evans et al, 1989). As 
discussed in Section 3.1 however, this method is subject to at 
least two sources of error: the instability of AFMU and
assumptions about the mode
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and constancy of formation of 1-MX (Tang et al, 1986).
AFMJ was deliberately deformylated in urine samples to stable 
AAMU, overccming stability problems (Section 2.6.3). 
Furthermore, 1-MU was measured so that any fluctuations in 
xanthine oxidase activity were accounted for. The following 
metabolite ratio was therefore determined (Fig. 1.5), as an in 
vivo indicator of NAT activity, in agreement with Tang et al
(1987) and Lelo et al (1989):
AAMU/ (AAMU + 1-MX + 1-MU)
Use of the metabolite/(metabolite + drug) ratio was suggested by 
Inaba et al (1980) in order to normalise for variability in 
recovery of unchanged drug. This ratio has several advantages: 
it is not influenced by the amount of methylxanthine intake in 
that it does not change following single dose or multidoses of 
caffeine (Tang et al, 1987); it is independent of xanthine 
oxidase activity because the sum of 1-MU and 1-MX is included in 
the denominator; use of this ratio would make sense even if 1-MX 
is formed directly from paraxanthine without going through a 
ring-opened intermediate as currently proposed; pH of urine is 
unimportant because AAMU as the deformylated product of AFMU 
represents total acetyluracil, formed from paraxanthine.
The validity of this ratio as an index of acetylation phenotype 
has been demonstrated by the complete accordance with the plasma 
index for sulphamethazine (SMZ) acetylation (Tang et al, 1987) 
and dapsone acetylation (Kilbane et al, 1990) in contrast to the 
AFMU/1-MX ratio previously used (Grant et al, 1983a).
The main disadvantage of the ratio AAMU / (AAMU + 1-MX + 1-MU) 
compared with AFMU /1-MX is the reduced numeric difference
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between values characterising rapid and slew acetylators. The 
new ratio therefore seems to bring about improvement in 




THE USE OF CArrnLLNE AS AN INDICATOR OF ENZYME ACTIVITY: 
ROBUSTNESS OF THE TEST
Introduction
Initial caffeine tests were performed involving pooled urine 
collections as reported by other workers (Cornish & Christman, 
1957; Tang-Liu & Riegelman, 1982; Grant et al, 1983a; Campbell 
et al, 1987; Carbo et al, 1989; Jorikman et al, 1991). Unlike 
other test drugs, it proved difficult to restrict participants 
from consuming caffeine over an eight hour period. It was 
desirable in this study therefore, to measure caffeine and its 
metabolites in healthy volunteers without restricting caffeine 
consumption. To this end, 0-8 h urinary metabolite profiles 
resulting from a single CCB or several CCBs were compared. 
Collection of urine samples at outpatient clinics, would 
necessitate spot urine collection, if there was to be 
opportunistic enrollment of suitable patients. Spot urinary 
metabolite profiles were therefore compared in 2 hourly samples 
and results correlated with 0-8 hour results to see whether a 
reduction in collection period could be achieved without 
sacrificing the result.
Procedure
23 subjects, comprising nine males and fourteen females were 
studied for caffeine metabolism (Section 2.3.1). Caffeine,
1,7-DMX, 1-MX, 1-MU and AAMU were assayed in urine by HPLC as
previously described (Sections 2.6). The caffeine metabolite
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DMMIOD, originally thought to be 1,7-DMU was also assayed. 
Details of volunteers and measurements of individual metabolites 
in urine are given in Appendices 1-2.
4. 1____ EFFECT OF CAFFEINE CONSUMPTION ON URINARY METABOLITE
PROFIT ES
4.1.1 Metabolite profile in 8 h urine, following consumption of 
a sincrle CCB (Test 1).
Seventeen healthy subjects (volunteers #1-17) with a mean age of 
31.12 + 2.12 y consumed a single CCB on rising, after an 
overnight fast. The major metabolites assayed in 0-8 h urine 
samples were AAMU, 1-MU and 1-MX. 1,7-DMX, DMMIOD and caffeine 
were also measured (Table 4.1.1) (Appendix la).
Table 4.1.1 - Total mgs of caffeine metabolites in 0-8 h urine 




(mean + SEM) Range
AAMU 38.37 ± 9.72 17.3 - 190.0
1-MU 19.58 ± 2.94 8.6 - 59.2
1-MX 11.79 ± 1.58 5.9 - 26.4
1,7-DMX 3.64 ± 0.39 1.5 - 7.0
*DMMIQD 0.89 ± 0.19 0.2 - 3.6
Caffeine 0.62 ± 0.21 0.1 - 3.0
* Originally thought to be the caffeine metabolite 1,7-DMU.
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In order to make direct correlations between the metabolites 
measured in different caffeine tests, recovery (%) of each
metabolite was also determined. Ihe metabolites listed in Table
4.1.1 were presumed to account for 100% of the total caffeine 
metabolites in urine as other measurable metabolites, such as
7-MX, were present in smaller quantities. Recoveries (%) for
each caffeine test are compared in Fig. 4.1.1. When the 
metabolites of caffeine were compared, AAMU correlated
negatively with 1-MX (r=-0.177, p<0.005) and with 1-MU
(r -^0.652, p<0.01). There was also a tendency for DMMIOD and 
1-MX to correlate negatively (r=-0.434, p=0.08). None of the 
metabolites was shewn to correlate with total 0-8 h urine
volume.
4.1.2 Intra-subiect Reproducibility (Test 2).
The test involving consumption of a single CCB and collection of
0-8 h urine was repeated two to three months later in ten 
subjects (#2,3,6,7,8,9,12,13,16,17). Total mgs of each 
metabolite measured are shewn in Table 4.1.2 (Appendix lb). The 
major metabolites recovered in urine were similar to that of the 
first test as shewn in Fig.4.1.1.
The % recoveries of AAMU and 1-MX (r=-0.9273, p<0.01) and AAMU 
and 1-MU (r=-0.6364, p=0.0563) were found to correlate in a
similar way as they did for the first test. In this repeat test, 
% recoveries of 1,7-DMX and DMMIOD (r=0.7212, p<0.05) and
caffeine and 1,7-DMX (r=0.8667, p<0.01) were also found to 
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Table 4.1.2 - Total mgs of caffeine metabolites in 0-8 h urine 
samples following consumption of a single CCB 
(itfIO)
Total mg % Change in mean
Metabolite (mean + SEM) Range compared to first test
AAMU 33.71 + 9.21 13.9 - 99.7 13.8
1-MU 16.67 + 2.99 9.0 - 38.4 17.5
1-MX 10.66 + 1.92 3.9 - 23.6 10.6
1,7-DMX 3.15 + 0.43 1.4 - 5.8 15.6
*DMMIOD 0.70 + 0.10 0.3 - 1.3 27.1
Caffeine 0.36 + 0.09 0.1 - 1.05 72.2
* Originally thought to be the caffeine metabolite 1,7-DMU.
Reproducibilty of this caffeine test for each of the 10 
volunteers was determined by comparing the metabolite ratios 
(MR) used to measure P450IA, NAT and XO activities, on study 
days 2-3 months apart. P450IA activity (r=0.7333, p<0.05)
(Fig.4.1.2A) and NAT activity (r=0.7173, p<0.05) (Fig.4.1.2B) 
were not significantly different when measured on study days 2-3 
months apart, while XO activity (r=0.6485, pMD.0517)
(Fig.4.1.2C) tended to correlate on different test days.
4.1.3 Metabolite profile in 8 h urine, following consumption of 
several CCBs (Test 3).
Nineteen of the 23 healthy subjects who participated in previous 
protocols were studied. They had a mean age of 32.95 ± 2.15 y
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Figure 4.1.2 - Reproducibility of A) P450IA, B) NAT and C) 
Xanthine oxidase activity in 10 volunteers. 
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and consumed CCBs at breakfast, coffee, lunch and tea time 
throughout the working day until four CCBs in total had been 
consumed. Total amount (mg) of each metabolite measured is shown 
in Table 4.1.3 (Appendix lc).
Table 4.1.3 - Recovery of caffeine metabolites in 0-8 h urine 
samples following consumption of four CCBs each 
(nFl9)
Total mg
Metabolite (mean + SIM) Range
AAMU 43.69 + 6.59 13.1 - 107.0
1-MU 20.74 + 2.58 6.2 - 37.8
1-MX 15.58 + 2.29 5.2 - 40.0
1,7-DMX 6.29 + 0.82 2.2 - 15.1
*DMMIOD 1.06 + 0.14 0.4 - 2.61
Caffeine 0.64 + 0.18 0.05 - 2.82
* Originally thought to be the caffeine metabolite 1,7-EMU.
The major metabolites recovered were similar to other tests 
(Fig.4.1.1). As in the first test, correlations were found for 
the % recoveries of 1,7-DMX and DMMIOD (r=0.5116, p<0.05); AAMU 
and 1-MX (r=-0.6789, p<0.005) and AAMU and 1-MU (r=-0.7491,
p<0.005). None of the other metabolites correlated either with 
each other or with total urine volume.
There were significant correlations between P450IA (n=13, 
rM).6575, p<0.05), NAT (n=13, r=0.5502, p=0.0567) and XO (nF=13,
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r=0.8736, p<0.05) activities in this caffeine test involving
several CCBs and the first test involving consumption of a 
single CCB. Enzyme activities from the caffeine test involving 
several CCBs were also compared to the repeat test involving 
consumption of a single CCB. P450IA (n=9, r=0.7667, p<0.05), NAT 
(n=9, 1^ =0.8034, p<0.05) and XO (np=9, r^ =0.8, p<0.05) activities
were again found to correlate significantly.
4.2 EFFECT OF URINE COT.T.ECTION TIME ON METABOLITE FROFTT.ES
4.2.1 Urinary metabolite profile in 2 hourly samples for 8 h. 
following consumption of a sincrle CCB.
In seven of the subjects who had participated in the previous 
tests, urine samples were collected immediately following 
consumption of a single CCB, and every 2 h over an 8 h period.
The major metabolites assayed in urine were similar to previous 
results. Total amount (mg) of metabolites measured for each 
subject were compared (Table 4.2.1) (Appendix 2a).
Metabolite profiles for subjects #2, #9 and #16 are shown in
Figs 4.2.1A, B and C. P450IA, NAT and XO activities were also 
determined over 2 h periods. Results for subjects #2, #9 and #16 
are shewn in Figs.4.2.2A, B and C, respectively.
4.2.2 Urinary metabolite profile in 2 hourly samples for 8 h. 
following consumption of several CCBs
In the same seven subjects, urine samples were collected 
immediately following consumption of CCB at breakfast and every 
2 h over an 8 h period. During this test, CCBs were also 
consumed at coffee, lunch and tea time throughout the working 
day; thus 4 CCBs were consumed in total by each subject. Total
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Figure 4.2.1 -Urinary excretion of individual caffeine
metabolites in volunteers A) #2, B) #9 and C) #16, 
following consumption of a single CCB.
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Figure 4.2.2 - A) P450IA, B) NAT and C) Xanthine oxidase
activity in 7 volunteers, following consumption 
of a single CCB.
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Table 4.2.1 - Total rags of caffeine metabolites in urine sampled
2 hourly for 8 h, following consumption of a
single CCB (n=7)
Total mg (mean + SEM)
Vol # AAMU 1-MU 1-MX 1,7-EMX *EMMIOB
2 SF 15.4 ±6.8 6.2 ±3.7 3.3 ±1.7 1.4 ±0.5 0.21 ±0.1
9 SO 12.6 ±4.9 5.5 ±3.0 3.6 ±1.5 0.9 ±0.4 0.23 ±0.1
12 JK 15.3 ±5.0 6.4 ±2.9 2.6 ±1.3 0.7 ±0.3 0.12 ±0.1
14 MB 12.1 ±7.8 13.1 ±11 10.0 ±7.5 1.9 ±1.5 0.17 ±0.1
16 HH 7.2 ±2.9 4.8 ±2.4 3.9 ±2.0 2.3 ±1.0 0.50 ±0.3
18 SA 24.2 ±15.2 8.9 ±5.0 6.0 ±3.6 3.8 ±1.4 0.40 ±0.2
19 SH 14.4 ±4.2 6.5 ±1.7 4.8 ±0.9 2.5 ±1.0 0.18 ±0.1
* Originally thought to be the caffeine metabolite 1,7-EMU.
amount (mg) of metabolites measured for each subject are shewn 
in Table 4.2.2 (Appendix 2b). P450IA, NAT and XO activities for 
each subject were also determined over 2 h periods and the 
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Table 4.2.2 - Total mgs of caffeine metabolites in urine sampled
2 hourly for 8 h, following consumption of four
CCBs (n=7)
Total mg (mean ± SEM)
Vol # AAMU 1-MU 1-MX 1,7-DMX *DMMIOD
2 SF 15.7 ±8.2 7.5 ±4.5 3.9 ±2.6 2.9 ±0.7 0.47 ±0.1
9 SO 17.8 ±11.7 6.1 ±4.9 3.8 ±2.4 0.9 ±0.6 0.19 ±0.2
12 JK 26.0 ±9.3 8.2 ±3.4 3.4 ±1.8 1.2 ±0.8 0.26 ±0.1
14 MB 10.3 ±5.0 16.4 ±11 13.6 ±9.3 2.4 ±2.0 0.49 ±0.2
16 HH 4.9 ±1.3 3.5 ±1.3 2.9 ±0.9 1.6 ±0.6 0.45 ±0.2
18 SA 15.5 ±2.8 6.8 ±1.4 4.3 ±1.1 3.6 ±0.6 0.27 ±0.03
19 SH 19.7 ±5.1 8.1 ±1.5 6.2 ±1.0 4.1 ±1.6 0.45 ±0.1
* Originally thought to be the caffeine metabolite 1,7-DMU.
4.2.3 Metabolite profile in spot urine samples collected 2-6 h 
afer CCB consumption (Test 4).
Seventeen healthy subjects who participated in previous 
protocols were studied. They had a mean age of 32.24 ± 1.84 y. 
Spot urine samples were collected 2-6 h after CCB consumption. 
Total amount (mg) of each metabolite measured is shewn in Table
4.2.3 (Appendix Id).
The major metabolites recovered are compared in Fig.4.1.1. As 
for previous caffeine test, correlations were found for the % 
recoveries of AAMU and 1-MX (r=-0.7431, p<0.005) and AAMU and
1-MU (r^ =-0.7713, p<0.005). In this test, % recoveries of 1,7-DMX 
and DMMIOD were also related (r=0.5101, p<0.05).
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Table 4.2.3 - Total mgs of caffeine metabolites in spot urine
samples collected 2-6 h after consumption of a
CCB (nFl7).
Total mg
Metabolite (mean + SM) Range
AAMU 13.79 + 3.29 2.4 - 55.6
1-MU 6.29 + 1.00 1.9 - 16.4
1-MX 4.18 + 0.70 1.4 - 12.7
1,7-DMX 1.81 + 0.24 0.4 - 4.00
*DMMI0D 0.23 + 0.05 0.05 - 0.76
TMX 0.35 + 0.07 0.03 - 1.03
* Originally thought to be the caffeine metabolite 1,7-EMU.
There were significant correlations between P450IA (r=0.7868, 
p<0.005), NAT (r=0.7448, p<0.005) and XO (r=0.6687, p<0.01)
activities in this caffeine test involving spot urine sample 
collection 2-6 h after a CCB, and the test involving 0-8 h urine 
collection after four CCBs.
4.3 Discussion
While caffeine is considered to be a good probe drug for 
estimating the activities of several enzymes, there are as yet 
no prototype methods in the literature which are routinely 
followed. Some groups have collected pooled urine samples 
following caffeine consumption (Grant et al, 1983a; Campbell et 
al. 1987; Carbo et al, 1989; Jonkman et al, 1991) while others
86
have collected spot samples (Grant et al, 1984; Hardy et al. 
1988; Kilbane et al, 1990; Vineis et al, 1990; Bartsch et al, 
1990) or first-void (overnight) urine samples (Tang et al, 
1987). Rather than follow one of the published methods, several 
studies were undertaken to investigate the effects of varying 
effective caffeine dose and urine collection times on caffeine 
metabolism, to determine as simple a test as possible.
Initially, pooled 0-8 h urine samples were collected following 
consumption of a single CCB in 17 volunteers. Analysis of urine 
revealed AAMU, 1-MU, 1-MX and 1,7-DMX as the principal 
metabolites of caffeine, in agreement with previous studies 
(Cornish & Christman, 1957; Aldridge et al, 1979; Wietholtz et 
al. 1981; Kotake et al, 1982; Bonati et al, 1982; Callahan et 
al. 1982; Grant et al, 1983b; Campbell et al, 1987) indicating 
that the initial 3 -demethylation of caffeine to paraxanthine is 
the predominant pathway in man. This pattern was followed for 
all other caffeine tests performed.
Before AAMU and AFMU were found to be major metabolites of 
caffeine by Callahan et al in 1982, earlier studies did not 
assay acetyluracil metabolites and therefore found 1-MU to be 
the major metabolite excreted in urine. In addition, Grant et al 
(1983b) and Campbell et al (1987) did not measure total 
acetyluracil but AFMU alone and found that AFMU was excreted in 
lower amounts than 1-MU, 1-MX, 1,7-DMU and 1,7-DMX. This may
explain why percentage recoveries of caffeine metabolites were 
so lew in these studies. Callahan et al (1982, 1983) have shewn 
that formation of polar ring-opened uracil metabolites of 
paraxanthine may account for up to 40% of caffeine metabolism in
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man, which is more consistent with the present data; these may 
also be explained by the fact that a sensitive assay for AAMQ 
was developed. APMJ in urine was deliberately deformylated to 
stable AAMU so that total acetyluracil formed from paraxanthine 
could be assayed. Differences in measurements are almost 
undoubtedly due to the differences in methodology used.
In the present study, although the quantities of each metabolite 
were found to vary markedly between subjects, the total amount 
(mg) excreted by each individual was not significantly different 
when the 0-8 h caffeine test was repeated 2 - 3  months later. 
When the amounts of each metabolite were expressed as a 
percentage of the total metabolites measured (designated
recovery %) (Fig.4.1.1), the variation between subjects was less 
and not significantly different over a 2-3 month period. The 0-8 
h test following consumption of a single CCB was therefore 
reproducible and P450IA, NAT and XO activities were not
significantly different on different study days.
During the first tests it proved difficult to restrict
volunteers from consuming further CCBs over an 8 h period - a 
problem not encountered with most test drugs. It was therefore 
desirable to measure caffeine and its metabolites without
restricting caffeine consumption. To test the effect of
increasing the caffeine dose on metabolite profiles, 19 healthy
volunteers participated in a different caffeine test and
consumed CCBs at breakfast, coffee, lunch and tea time
throughout the working day, until four CCBs in total, had been 
consumed. 0-8 h urine samples were again collected and pooled. 
Total amounts (mg) of each metabolite excreted during this study
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were higher than in either test involving collection of 8 h 
urine after a single CCB; but not significantly so. This may be 
explained by the fact that although the number of drinks of 
coffee and tea consumed has often been used as an index of 
caffeine intake (Curatolo & Robertson, 1983; Barone & Roberts, 
1984) this number is in fact a poor index of actual caffeine 
intake, due to very large differences in caffeine content and 
volume per drink (Lelo et al, 1986c). Furthermore, caffeine 
intake itself correlates poorly with 24 h average caffeine 
concentration in vivo (Lelo et al, 1986c). Percentage recoveries 
of each metabolite were not significantly different between the 
single- and multi- dose caffeine tests in the present studies. 
In addition, P450IA, NAT and XO activities were not
significantly altered by the amount of caffeine consumption. 
These results suggest that caffeine MRs were unaffected by 
increasing the amounts of caffeine consumed throughout the test 
and indicated that restrictions on caffeine consumption were not 
necessary.
Campbell et al (1987) found that their caffeine metabolite
ratios, determined under a regimen of multiple caffeine 
administrations were similar to the ratios obtained using a 
pooled 24 hour urine sample after ingestion of a single caffeine 
dose. Similar results have been found in other studies (Grant et 
al, 1984; Tang et al, 1987) comparing single and multi- caffeine 
doses. It might have been expected that increasing the caffeine 
dose would not alter its metabolite profiles as Bonati et al
(1982) reported that caffeine was eliminated by first-order
kinetics and that its metabolism was dose independent at the 
doses of caffeine to which man is normally exposed, in agreement
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with Parsons & Neims (1978). Further studies supported this and 
reported that caffeine followed linear kinetics up to 10 mg/kg 
in man (Blanchard & Sawers, 1983; Newton et al, 1981). Also, 
theobromine disposition was found to be unaffected when subjects 
consumed theobromine (6 mg/kg/day) for 7 days in the form of 
dark chocolate (Shively et al, 1985).
Initial caffeine tests performed on the general population 
therefore involved collection of 0-8 h urine samples following 
consumption of a CCB, without restriction on further CCB 
consumption.
For widepread use of the caffeine test, it was desirable that 
spot urine samples could be collected. It was also important to 
try and shorten the urine collection period for the patient 
studies, most of whom were attending outpatient clinics. In 
order to investigate the effects of varying urine collection 
times, 7 subjects who had participated in all of the caffeine 
tests provided 2 hourly urine samples over an 8 h period 
follcwing consumption of either a single or several CCBs.
Although the total amount (mg) of each metabolite excreted for 
each volunteer were higher in the urine samples after 4 CCBs 
than those follcwing a single CCB, the results were not 
significantly different between the two tests, which is in 
agreement with our results from tests involving 0-8 h urine 
samples, after either single or multi- caffeine doses.
When the metabolite profiles for three of the subjects were 
studied cifter a single CCB and compared with those sifter several 
CCBs, it could be seen that for all the metabolites, very large 
quantities were excreted in the first-void urine samples before
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caffeine had been consumed. The amounts excreted in this "blank” 
urine were not comparable with total amount (mg) excreted in the
2-8 h spot samples. This appeared to the case particularly for 
AAMU. In fact, the enzyme activities of interest, such as 
P450IA, NAT and XO when measured in first-void samples were not 
as consistent as in 2-6 h spot samples, whether single or 
multiple CCBs were consumed. Overall, the mean amount of 
metabolites excreted and the enzyme activities for each 
volunteer were not significantly different between the two 
tests.
These results suggested that total amount of caffeine 
metabolites excreted and P450IA, NAT and XO activities for an 
individual were most consistent in the spot urine samples 
collected 2-6 hours after a CCB, which has been found by other 
workers (Grant et al, 1984) who required a simplified caffeine 
test for routine use. Indeed, MRs for the test involving 
collection of a spot urine sample 2-6 h after a single CCB 
correlated well with those determined in the tests involving 
collection of 0-8 h urine. In addition, Campbell et al (1987) 
shewed that randomly collected urine samples after chronic 
dietary caffeine intake were adequate for the assessment of 
their caffeine MRs in population studies, particularly when 
routine dietary intake patterns approached steady-state 
conditions. The present study did not support the idea that 
first-void urine samples provide the best method for determining 
caffeine MRs because even if the MRs were highly reproducible in 
these urine samples, as reported by Tang and coworkers (1987), 
they did not give a good representation of MRs determined at 
other times throughout the day. It has been suggested that
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trough plasma caffeine concentrations measured in the morning 
might give an estimate of caffeine clearance and thus liver 
function (Renner et al, 1984) - however, Lelo and workers
(1986c) also found that the morning concentration of caffeine 
correlated very poorly with mean 24 h caffeine concentration, 
whereas plasma concentrations measured later in the day 
correlated well.
When metabolite profiles were studied for each caffeine test, 
recovery (%) of AAMU was found to correlate negatively with 1-MX 
(r=-0.777, p<0.005) and 1-MU (r=-0.652, p<0.01). This would be
expected as the formation of these metabolites from some 
unkncwn, unstable ring-opened intermediate depends on the 
acetylation status of an individual. In a rapid acetylator, more 
of this intermediate will be acetylated to form AAMU, whereas in 
a slew acetylator, more of the intermediate will reclose to form
1-MX and therefore in turn, 1-MU. The negative correlations 
found in this study lend further support for this theory.
Recovery (%) of 1,7-DMX was found to correlate positively with 
amounts of DMMIOD excreted in urine (r=0.7212, p<0.05).
Unextracted authentic 1,7-EMU standard had a very similar 
retention time to DMMIOD. Subsequent studies found that 
authentic 1,7-DMU could not be extracted in chloroform and 
isopropanol mixes, unlike other dimethylxanthine and uric acid 
products of caffeine. This is very unusual in light of other 
groups that have supposedly extracted 1,7-EMU (Adams Chamicals, 
USA) in these organic solvents (Grant et al, 1983a). It is of 
interest however that the DMMIOD chemical originally measured in 
urine could be extracted with other caffeine metabolites, eluted 
very closely to 1,7-DMX and was present in every urine sample
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analysed. It was almost certainly a caffeine related compound, 
as it was absent from the one subject who abstained form CCBs 
for 72 hours in order to obtain a blank urine sample. Amounts of 
DMMIOD excreted in urine seemed to parallel amounts of 1,7-DMX 
but were not present when 1,7-DMX standard was extracted alone. 
It was unlikely therefore to be a contaminant or by-product of 
another standard. Present knowledge of this compound is that it 
has never been described as a caffeine metabolite. These results 
indicate that this may be the case and warrant further 
investigation.
In summary, the method involving collection of spot urine 
samples is suitable for use in outpatient clinics, requiring 
only that patients consume a CCB 2-6 h prior to urine 
collection. The urinary test is suitable for large-scale 
population studies because it requires only dietary intake of 
caffeine - a popular and relatively safe substance - and because 
it relies on simple urine collection rather than on multiple 
blood sampling. In addition, this urine test is inexpensive 
compared to the caffeine breath test, involving use of
isotopically labelled caffeine (Wietholtz et al, 1981; Kotake et 
al, 1982) and also has an advantage in that several enzyme 
activities, including P450IA, XO and NAT can be measured from 
the same urine sample.
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CHAPTER FIVE
CYTOCHROME P450IA AND P450IA2 ACTIVITIES IN HUMAN VOLUNTEERS
5.1 P450IA AND P450IA2 AdTVTnES IN HEALTHY INDIVIDUALS
5.1.1 Introduction
Variation in P450IA1 (Pelkonen et al, 1979) and P450IA2
(Wrighton et al, 1986) activities have been reported in man. The 
cause of such variation may be attributed to several factors. 
Firstly, the P450IA isozymes are inducible, such that
individuals exposed to certain environmental chemicals, such as 
components of cigarette smoke, may have a higher enzyme activity 
than their basal levels. Also, P450 enzyme activities can be 
inhibited by several drugs, including oral contraceptive
steroids (OCS). In addition, several P450 enzymes, including 
possibly the P450IA isozymes, are subject to genetic
polymorphism. Such inherited variation in enzyme activity may 
result in large differences in drug biotransformation.
By giving caffeine to a large number of control volunteers and 
measuring caffeine metabolite ratios, the effects of both 
environmental and genetic factors on caffeine N-demethylation 
were examined.
5.1.2 Results
The 127 subjects who participated in the caffeine test involving 
collection of 0-8 h urine (Appendix 3) had a mean P450IA 
activity (MR) of 13.86 + 1.44. 105 of these subjects were also
studied for P450IA2 activity. Metabolite ratios were not
measured in 22 volunteers as the amount of caffeine was not
analysed. The mean P450IA2 activity was 96.64 + 8.73.
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For the 150 volunteers who participated in the caffeine test 
involving collection of a spot urine sample 2-6 h after a CCB 
(Appendix 4), the mean P450IA activity was 15.07 ± 1.04. 149 of 
these subjects were also studied for P450IA2 activity. The 
metabolite ratio was not measured in one of these subjects as 
the amount of caffeine was not analysed. Mean P450IA2 activity 
was 97.70 + 6.99. P450IA and P450IA2 activities in the 2-6 h
caffeine test were not significantly different from those in the 
0-8 h test (p>0.05), in agreement with previous results (Section 
4.2).
In light of the fact that neither the amount of caffeine 
consumption (Section 4.1) or the time of urine collection 
(Section 4.2) altered caffeine metabolite ratios, the results 
from the 0-8 h and the 2-6 h tests were combined.
Table 5.1.1 - P450IA and P450IA2 activities determined in 
the caffeine tests
Enzyme n Median Mean activity 
+SEM
Range
P450IA 277 11.64 14.52 ± 0.87 1.15 - 130.33
P450IA2 254 74.68 97.29 ± 5.45 7.92 - 607.62
Mean P450IA and P450IA2 activities determined for all subjects
are shewn in Table 5.1.1. For the each volunteer who had both
P450IA and P450IA2 activities determined, correlations between
the two enzymes were examined. The enzyme activities were highly
significantly correlated (n=254; r=0.4228; p<0.00001).
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5.1.3 Effect of Age
277 subjects with recorded dates of birth were studied. Their 
age ranged between 17 and 91 y (40.42 + 0.96 y; mean + SEM). 
There was no significant difference in the age of the subjects 
participating in the 0-8 h or the 2-6 h caffeine tests (40.67 + 
1.19 y vs 42.83 + 1.49 y; p>0.1). In addition, there was no
significant difference between the age of the males (n=145) and 
females (n=132) participating in the caffeine tests (40.06 + 
1.27 y vs 40.74 ± 1.46 y; p>0.5). No correlation was found
between subject age and the degree of either P450IA (r=-0.0846, 
p>0.5) or P450IA2 activity (r=-0.1234; p>0.05).
5.1.4 Effect of Body Mass Index
The effect of body mass index (EMI) was studied in 254 subjects. 
Twenty-three without recorded heights (m) and weights (kg) were 
excluded from this study.
BMC = body weight (kg) / height in metres squared.
129 females had EMI values ranging between 17.40 - 52.14 (23.72 
+ 0.37; mean ± SEM). 20 of these subjects had values outside the
normal range (>26.7). 125 males had EMI values ranging between
17.04 - 34.33 (24.45 + 0.26) and 22 of these subjects had values 
>26.7. EMI was not significantly different between males and 
females (p>0.1). No correlation was found between EMI values and 
the activity of P450IA (r=-0.0732; p>0.5) or P450IA2 (r^ =0.0053; 
p>0.5).
5.1.5 Effect of Subject Gender
In order to compare the sexes, values for P450IA and P450IA2 
activities were logged and results compared by Student's t-test.
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P450IA activity was determined in 145 males and 132 females. Of 
the females, 90 were non-OCS users, while 42 had been prescribed 
OCS or hormone replacement therapy (HRT).
P450IA activity was not significantly different between males 
and females (Table 5.1.2). This relationship was obtained 
whether males were compared with non-OCS user females (n=90; 
p>0.1) or the whole female population, including OCS and non-OCS 
users ( itf= 1 3 2 ;  p>0.1).
Table 5.1.2 - P450IA and P450IA2 activities in male and female 
populations





145 11.76 15.82 ± 1.37 3.06 -130.33
(All) 132 11.33 13.11 ± 1.02 1.15 -118.46
(Non-OCS) 90 11.47 13.26 ± 1.38 2.95 -118.46
P450IA2 Males
Females
125 74.67 94.15 ± 6.23 8.56 -395.22
(All) 129 74.69 100.34 ± 8.89 7.92 -607.62
(Non-OCS) 87 78.04 109.58 ±12.02 11.58 -607.62
P450IA2 activity was determined in 125 males and 129 females. Of 
the females, 87 were non-OCS/HRT users and 42 were taking OCS or 
HRT. P450IA2 activity was also found to be not significantly 
different between the male and female populations (Table 5.1.2).
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This was the case whether males were compared to non-OCS user 
females (np=87; p>0.5) or the whole female population (n=129;
p>0.1).
5.1.6 Effect of Oral Contraceptive Steroids
P45CIA activities (Table 5.1.3) in women using OCS/HRT were not 
significantly different from those measured in women not taking 
steroids (p>0.5). P450IA2 activities (Table 5.1.3) were also not 
significantly altered by OCS/HRT use (p>0.1).
Table 5.1.3 - P450IA and P450IA2 activities in OCS and non-OCS 
using females
Enzyme Group n Median Mean activity 
± SIM
Range
P450IA OCS 42 10.67 12.80 ±1.25 1.15 -40.35
Non-OCS 90 11.47 13.25 ±1.38 2.95 -118.46
P450IA2 OCS 42 54.50 80.95 ±10.84 7.92 -292.22
Non-OCS 87 78.04 109.58 ±12.02 11.58 -607.62
5.1.7 Effect of Cigarette Smoke
P450IA activity was studied in 255 individuals of known smoking 
status; 70 subjects were smokers and 185 were nonsmokers. 
P450IA2 activity was determined in 254 of these subjects; 70 
were smokers and 184 were nonsmokers (Table 5.1.4). P450IA 
(Fig.5.1.1A) and P450IA2 (Fig.5.1.1B) activities were found to
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Figure 5.1.1 - The effect of cigarette smoking on A) P450IA 
and B) P450IA2 activities.
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Table 5.1.4 - P450IA and P450IA2 activities in smoking and
nonsmoking healthy populations
Enzyme Group n Median Mean activity 
± SEM
Range
P450IA Smokers 70 13.76 16.55 ± 1.94 1.15 -118.46
Nonsmokers 185 10.09 12.21 ± 0.57 2.95 - 54.89
P450IA2 Smokers 70 85.48 118.66 ±12.49 7.92 -607.62
Nonsmokers 184 68.90 89.49 ± 5.74 1.58 -550.23
Subpopulations of smokers and nonsmokers were also studied, to 
determine the effect of cigarette smoking on P450IA (Table
5.1.5) and P450IA2 (Table 5.1.6) activities of groups with 
different gender and OCS/HRT use.
When the nonsmoking populations were studied, P450IA and P450IA2 
activities were not significantly different between males and 
females, whether they were taking OCS/HRT or not (p>0.1). In 
addition, P450IA and P450IA2 activities were not significantly 
different between male and female smokers (p>0.1), though 
results shew that the difference in enzyme activities between 
smokers and nonsmokers was greater in females than in males.
In the female population who were not taking OCS/HRT, the 
smokers had a significantly higher P450IA (p<0.0005) and P450IA2 
activity (p=0.05) than the nonsmokers. However, when the women 
using OCS/HRT were studied, there was no significant difference 
in P450IA (p>0.5) or P450IA2 (p>0.1) between smokers and 
nonsmokers. Similarly, when the male population was analysed,
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Table 5.1.5 - P450IA activity in smoking and nonsmoking
male and female populations




-smokers 35 12.08 15.86 ±2.20 3.06 -71.62
-nonsmokers 91 10.45 12.92 ±0.88 3.23 -38.90
Females
Non-OCS/HRT 90
-smokers 17 15.11 21.07 ±6.12 9.43 -118.46
-nonsmokers 73 10.06 12.29 ±1.26 2.95 -79.98
OCS/HRT 42
-smokers 18 11.24 13.62 ±2.39 1.15 -40.35
-nonsmokers 24 10.43 12.19 ±1.29 5.05 -34.82
although the smokers tended to have a higher P450IA (p>0.5) and 
P450IA2 activity (p>0.1) than the nonsmokers, the results were 
not significantly different.
In the group of 132 females, the combined effects of OCS or HRT 
administration and smoking status were studied (Tables 5.1.5 and
5.1.6). In the nonsmoking female population, P450IA activity was 
not significantly different whether females were taking OCS/HRT 
or not (p>0.1). In the smoking female population however, P450IA 
activity was significantly lower in females taking OCS/HRT than 
those who were not (p^ =0.05). Overall, in a female population of 
smokers and nonsmokers, P450IA activity remained unaffected by
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OCS use (p>0.5). P450IA2 activity was not significantly
different between women using OCS/HRT and those who were non-OCS 
users, whether the nonsmoking (p>0.05) or the smoking 
populations (p>0.1) were studied. Also, in the whole female 
population of smokers and nonsmokers, P450IA2 activity remained 
unaffected by OCS/HRT use (p>0.1). Finally, smoking women using 
OCS/HRT were compared to nonsmoking women who were non-OCS 
users, to test if OCS administration could reduce the high 
enzyme activities observed in female smokers. Results show this 
to be the case, as both P450IA and P450IA2 were not
significantly different between the two groups (p>0.5).
Table 5.1.6 - P450IA2 activity in smoking and nonsmoking 
male and female populations
Group n Median Mean activity Range 
± SEM
Males
-smokers 35 86.16 112.49 ±14.49 8.56 -308.92
-nonsmokers 90 73.09 83.69 ±5.47 13.26 -242.41
Females
Non-OCS/HRT 87
-smokers 17 102.95 149.78 ±37.61 41.63 -607.62
-nonsmokers 70 66.30 99.82 ±11.71 11.58 -550.23
OCS/HRT 42
-smokers 18 83.94 101.27 ±17.66 7.92 -247.74
-nonsmokers 24 43.89 66.13 ±12.99 15.72 -292.22
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5.1.8 Genetic control of P450IA and P450IA2 activities
P450IA Activity
The frequency distribution histogram for P450IA activity in 277 
control volunteers is depicted in Fig. 5.1.2. The summary
statistics for this distribution are shewn in Table 5.1.7. 
113-fold variation in P450IA activity existed in 277 volunteers. 
It can be seen from the histogram and Table 5.1.7 that the 
distribution is skewed.
a) The positive skewness coefficient of 5.23 shews that the 
distribution is strongly positively skewed. The kurtosis value 
of 35.66 is higher than the coefficient of zero that would be 
expected frcm a normal distribution. In addition, the 
standardized coefficients in Table 5.1.7 are both outside the 
range of -2 to +2 that would be expected from a normal
distribution and therefore indicate that the data for P450IA
activity may depart significantly from normality.
b) The non-linear normal probability plot (Fig. 5.1.3) also 
indicates that the data deviates from a normal distribution.
c) This is confirmed by both the K-S test (p<0.00001) and
Chi-square test (p<0.00001), which show highly significant
difference frcm normality.
d) In addition, the Lilly-Fors test was employed to test for 
bimodality and deviation of the data frcm a normal distribution. 
The results for P450IA activity were significantly different 
(p<0.01) from those expected from a normal distribution.
Of the environmental factors tested, only cigarette smoking 
seemed to affect P450IA activity to a significant degree. 
Therefore, in addition to the whole population, we studied the 























-7  5 17 29 41 53 05 77 09  101 113 125 137 130
P450IA ACTIVITY
Figure 5.1.2 - Frequency distribution histogram of P450IA 










Figure 5.1.3 - Normal probability plot of P450IA activity in 277 
volunteers.
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nonsmokers. The histograms are shewn in Figs.5.1.4 and 5.1.5, 
respectively and the summary statistics for these distributions 
are shewn in Table 5.1.8. As discussed in Section 5.1.7, smokers
had a significantly higher P450IA activity than nonsmokers
(p<0.05). For the smoking population there was a 103-fold
variation in P450IA activity, whereas the nonsmokers exhibited 
only a 19-fold difference. As seen in Table 5.1.8, the
distributions of P450IA activity for both smokers and nonsmokers 
were positively skewed, although the smokers tended to shew a 
less normal distribution than the nonsmokers. This could be seen 
more clearly when normal probability plots were compared. The 
plot for smokers (Fig.5.1.6) was non-linear and statistical 
tests confirmed that the data deviated from normal (K-S test, 
p<0.0001; Chi-square test, p<0.00001; Lilly-Fors test, p<0.01).
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Figure 5.1.4 - Frequency distribution histogram of P450IA 
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Figure 5.1.5 - Frequency distribution histogram of P450IA 
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Figure 5.1.7 - Normal probability plot of P450IA activity in 185 
nonsmoking volunteers.
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Table 5.1.8 - Summary Statistics for P450IA activity in 





Standard error 1.94 0.57




Standardized skewness 14.73 11.39
Kurtosis 23.67 6.06
Standardized kurtosis 40.42 16.81
Similarly, the normal probability plot for P450IA activity in 
nonsmokers (Fig.5.1.7) was non-linear and possibly bimodal (K-S 
test, p<0.005; Chi-square test, p<0.00001; Lilly-Fors test, 
p<0.01).
Due to the skewness of P450IA activity data, whether smokers or 
nonsmokers were considered, the data were logged and restudied 
in an attempt to detect bimodality of the distributions. The 
frequency distribution histogram for log P450IA activity in 277 
control volunteers is shewn in Fig.5.1.8. The summary statistics 
for this population are shewn in Table 5.1.9.
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Table 5.1.9 - Summary Statistics for log P450IA activity in a





Results in Table 5.1.9 suggest that the distribution was not 
normally distributed. Although both the K-S test (p>0.4) and the 
Chi-square test (p>0.3) results indicated that the data did not 
differ significantly frcm a normal distribution, the more 
sensitive Lilly-Fors test suggested that log P450IA activity was 
significantly different from normal and possibly bimodal 
(p<0.05).The summary statistics for log P450IA activity in 
smokers and nonsmokers are shewn in Table 5.1.10.
Table 5.1.10 - Summary Statistics for log P450IA activity in 




Standardized skewness -0.74 1.38
Kurtosis 2.40 -0.08
Standardized kurtosis 4.10 -0.22
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Figure 5.1.8 - Log frequency distribution histogram of P450IA 
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Figure 5.1.9 - Frequency distribution histogram of P450IA2 
activity in 254 volunteers.
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Hie only coefficient that differed frcm that of a normal 
distribution was the degree of kurtosis of log P450IA activity 
in smcking subjects. In addition, the Chi-square test shewed 
that the data deviated frcm a normal distribution (JK0.005) and 
the Lilly-Fors test indicated that P450IA activity in smokers 
might be bimodal (p<0.05). Conversely, for nonsmoking subjects, 
it seemed unlikely that P450IA activity was bimodally 
distributed (K-S test, p>0.5; Chi-square test, p>0.5; Lilly-Fors 
test, p>0.05).
As the possibility of a bimodal distribution for P450IA activity 
cannot be rejected, a cut-off point was arbitrarily assigned in 
the frequency distribution to separate control volunteers in the 
skewed region with relatively high P450IA activity frcm those 
with enzyme activities in the normal unskewed part of the 
distribution. In order to achieve such separation, the apparent 
antimode at 26 was used (Fig.5.1.2). Any subject with a 
metabolite ratio greater than 26 was classified as having high 
P450IA activity (Table 5.1.11).
Table 5.1.11 - The proportion of control volunteers with high 
P450IA activity
Group P450IA activity
High % Lew %
All 25/277 (9.0%) 252/277 (91.0%)
Smokers 8/ 70 (11.4%) 62/ 70 (88.6%)
Nonsmokers 12/185 (6.5%) 173/185 (93.5%)
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9% of the 277 subjects studied were found to have high P450IA 
activity. 11.4% of the 70 smokers (Fig.5.1.4) and 6.5% of the 
185 nonsmokers (Fig.5.1.5) were found to have high P450IA 
activity. The Chi-square test for comparing proportions 
indicated that the number of smoking and nonsmoking subjects 
with high P450IA activity were not significantly different 
(p>0.05).
P450IA2 Activity
The frequency distribution histogram for P450IA2 activity in 254 
control volunteers is depicted in Fig.5.1.9. The summary 
statistics for this distribution are shown in Table 5.1.12.
Table 5.1.12 - Summary Statistics for P450IA2 activity in a 











77-fold variation in P450IA2 activity existed in 254 volunteers.
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It can be seen from the histogram and Table 5.1.12 that the
distribution is skewed.
a) The positive skewness coefficient of 2.43 shewed that the
distribution was strongly positively skewed, although not to the 
extent of the distribution for P450IA activity. The kurtosis 
value of 8.33 was also higher than the coefficient of zero that 
would be expected from a normal distribution. The standardized 
coefficients in Table 5.1.12 were both outside the range of -2 
to +2 that would be expected from a normal distribution.
b) The non-linear normal probability plot (Fig.5.1.10) also
indicated that the data deviates from a normal distribution.
c) This was confirmed by the K-S test (p<0.00001) and the
Chi-square test (p<0.00001) results, which both shewed highly 
significant difference from normality.
d) In addition, the Lilly-Fors test was employed to test for 
bimodality and deviation of the data from a normal distribution. 
P450IA2 activity was highly significantly different (p<0.01) 
from that expected from a normal distribution, as was the case 
for P450IA activity.
The frequency distributions for P450IA2 activity in smokers and 
nonsmokers are shewn in Figs.5.1.11 and 5.1.12, respectively and 
the summary statistics for these distributions are shown in 
Table 5.1.13.
As discussed in Section 5.1.7, smokers had a significantly 
higher P450IA2 activity than nonsmokers (p<0.05). For the
smoking population there was a 77-fold variation in P450IA 
activity, whereas the nonsmokers exhibited 48-fold difference. 
As seen in Table 5.1.12, the distributions of P450IA2 activity 
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Figure 5.1.10 - Normal probability plot of P450IA2 activity 
in 254 volunteers.
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Figure 5.1.11 - Frequency distribution histogram of P450IA2 




























Figure 5.1.12 - Frequency distribution histogram of P450IA2 
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Figure 5.1.15 - Log frequency distribution histogram of 
P450IA2 activity in 254 volunteers.
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Table 5.1.13 - Summary Statistics for P450IA2 activity in 





Standard error 12.49 5.74




Standardized skewness 7.53 13.56
Kurtosis 6.96 8.53
Standardized kurtosis 11.88 23.13
in this case -unlike P450IA activity, nonsmokers tended to show 
a less normal distribution than smokers.
The normal probability plot for smokers (Fig.5.1.13) was 
non-linear (K-S test, p<0.005; Chi-square test, p<0.00005; 
Lilly-Fors test, p<0.001). Similarly, the normal probability 
plot for P450IA2 activity in nonsmokers (Fig.5.1.14) was 
non-linear and possibly bimodal (K-S test, p<0.00001; Chi-square 
test, p<0.00001; Lilly-Fors test, p<0.01).
The data for P450IA2 activity were also logged in an attempt to 
detect bimodality of the distributions. The frequency 
distribution histogram for log P450IA2 activity in 254 control 
volunteers is shewn in Fig.5.1.15. The summary statistics for
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this population are shown in Table 5.1.14.
Table 5.1.14 - Summary Statistics for log P450IA2 activity 





Statistical tests indicate that log P450IA2 activity did not 
differ significantly from a normal distribution and was unlikely 
to be bimodally distributed (K-S test, p>0.5; Chi-square test, 
p>0.1; Lilly-Fors test, p>0.05). The summary statistics for log 
P450IA2 activity in smokers and nonsmokers are shewn in Table 
5.1.15.
Table 5.1.15 - Summary Statistics for log P450IA2 activity 




Standardized skewness -1.43 0.89
Kurtosis 0.34 -0.20
Standardized kurtosis 0.58 -0.57
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Log P450IA2 activity for smoking subjects was not significantly 
different from normal (K-S test, p>0.5; Chi-square test, p>0.3; 
Lilly-Fors test, p>0.05). It also seemed unlikely that log 
P450IA2 activity in nonsmoking subjects was bimodal ly 
distributed (K-S test, p>0.5; Chi-square test, p>0.5; Lilly-Fors 
test, p>0.05).
As the unlogged data for P450IA2 activity suggested that the 
distribution was bimodal, a cut-off point was arbitrarily 
assigned in the frequency distribution to separate the control 
volunteers in the skewed region with relatively high P450IA2 
activity from those with enzyme activities in the normal 
unskewed part of the distribution. In order to achieve such 
separation, the apparent antimode at 162 was used (Fig.5.1.9). 
Any subject with a metabolite ratio greater than 162 was 
classified as having high P450IA2 activity (Table 5.1.16).
Table 5.1.16 - The proportion of control volunteers with 
high P450IA2 activity
Group P450IA2 activity
High % Lew %
All 42/254 (16.5%) 212/254 (83.5%)
Smokers 19/ 70 (27.1%) 51/ 70 (72.9%)
Nonsmokers 23/184 (12.5%) 161/184 (87.5%)
16.5% of the 254 subjects were found to have high P450IA2 
activity. 27.1% of the 70 smokers (Fig.5.1.11) and 12.5% of the
119
184 nonsmokers (Fig.5.1.12) were found to have high P450IA2
activity. The Chi-square test for comparing proportions
indicates that smoking subjects have higher P450IA2 activity
than nonsmoking subjects (p<0.01).
5.1.9 Discussion
Effect of Environmental Factors
The mean P450IA activity determined in the caffeine test 
involving collection of 0-8 h urine (n=127) was not 
significantly different from that measured in the test involving 
collection of a spot urine sample 2-6 h after a CCB (n=150), in 
control volunteers. P450IA2 activity determined in the 0-8 h 
test was also not significantly different from the activity
measured in the 2-6 h test. This was expected following our 
observation that the caffeine MRs used to determine P450IA and 
P450IA2 activities were not altered by either the time of urine 
collection or the or the amount of caffeine consumption (Chapter 
4). George et al (1986) also found that caffeine pharmacokinetic 
values were similar whether subjects abstained from
methylxanthine- containing products for 1 week prior to the 
study or if they consumed 6 cups of coffee daily, for 1 week 
before the study. Values for enzyme activities in the two 
control groups were thus combined and treated as one group.
During this study, a strong correlation between P450IA and 
P450IA2 activities was found (r^ =0.4228; p<0.00001) which
suggests that either P450IA2 catalyses both reactions or if 
P450IA1 is involved in 1,7-DMX demethylation, it is very closely
related to P450IA2. It is known that these isozymes are under
close genetic regulation and coordinately expressed. As P450IA1
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has been detected in human liver following exposure to certain 
environmental chemicals (Quattrochi et al. 1985; Wrighton et al. 
1986; Jaiswal et al, 1987; Cresteil & Eisen, 1988; Ikeya et al, 
1989) and it is possible for P450IA1 to metabolise 1,7-EMX (as 
discussed in Chapter 3), it may be the case that P450IA1 
contributes to a proportion of 1,7-EMX demethylation.
No correlation between subject age and either the degree of 
P450IA or P450IA2 activity existed. Grant et al (1983b) also 
found that caffeine metabolite recoveries and profiles in 
healthy volunteers (aged 16 to 65 y) was unrelated to subject 
age. It is knewn that caffeine biotransformation is altered in 
the young (Ginchansky & Weinberger, 1977; Aldridge et al, 1979: 
Grygiel & Birkett, 1980; Tsemg et al, 1981; Pons et al, 1988) 
and elderly (Schnegg & Lauterburg (1986) but it was unlikely 
that caffeine metabolism would be affected in the present study 
as only 22 of the 277 healthy subjects studied were 65 y of age 
or older.
Decreased hepatic clearance of drugs in old age is related to 
loss of liver volume rather than changes in the function of the 
microsomal enzymes and should not therefore be detected by 
metabolite ratios. Indeed there is no difference in drug 
metabolism in vitro by microsomes isolated from young and aged 
livers (Varagnolo et al, 1989). Hence, measurements of caffeine 
clearance may be of more use than metabolite ratios when trying 
to quantitate liver function in the elderly (Renner et al, 1984; 
Varagnolo et al, 1989).
EMI had no effect on P450IA or P450IA2 activities, in agreement 
with a study by Grant et al (1983a). Grant et al (1983b) also
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found no correlation between subject weight and caffeine
metabolite ratios. It is possible that obesity might alter 
caffeine disposition, as Kamimori et al (1987) shewed that obese 
volunteers had a longer caffeine half life than lean volunteers. 
Only three volunteers however, were studied for each group. As 
only a few of the volunteers in our study had BMI values outside 
the ideal weight range, the effect of obesity could not be 
examined. Caraco et al (1991) also found that caffeine
pharmacokinetic parameters were not altered in severely obese 
subjects.
P450IA and IA2 activities were not found to be altered by 
subject gender. This was the case whether males were compared to 
the whole female population including OCS and non-OCS users, or 
to the non-OCS user females only. The observation that subject 
gender has no effect on caffeine metabolism is in agreement with 
Patwardhan et al (1980) who found that pharmacokinetic
parameters were similar between males and females. Callahan et 
al (1983) and Grant et al (1983b) also found that caffeine 
metabolism was not significantly different between males and
ovulating females.
When the effect of cigarette smoke was investigated, it was 
found that it increased P450IA and P450IA2 activities to a large 
extent. However, a slight difference in the extent of induction 
was observed between the sexes, as following induction by 
cigarette smoke, the females tended to have higher enzyme 
activities than the males. In fact, while female smokers had 
significantly higher P450IA and P450IA2 activities than female 
nonsmokers, this was not the case for males. Smith et al (1990)
also found a sex difference in the susceptibility to
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polyhalogenated biphenyl (PHB) induced hepatic uroporphyria in 
rats. Whereas the total P450 content was higher in control or 
induced male rats compared to females, hepatic P450IA1 and IA2 
were more highly induced in female rats. As female rats are 
considerably more sensitive to induction of porphyria, their 
results were consistent with the association of P450IA with 
porphyria development. In the present study, the increased 
responsiveness of females to the inductive effect of cigarette 
smoke was likely to be due to the effect of subject gender and
not age or EMI, as no significant difference in either age or
EMI existed between the sexes. Overall however, no significant 
difference in mean enzyme activities between males and females 
existed, whether smoking, nonsmoking or whole populations were 
compared.
The fact that smokers had significantly higher enzyme activities 
than nonsmbkers, despite the large interindividual differences 
in caffeine metabolism that exist, indicates that smoking has a 
large effect on the enzymes of interest. A similar result was
found by Kotake et al (1982) who found that the rate of caffeine
metabolism in the caffeine breath test (CBT) was doubled in
smokers compared to nonsmokers. Several other studies also 
showed that cigarette smoke markedly affected caffeine 
metabolism (Parsons & Neims, 1978; May et al, 1982; Campbell et
al. 1987; Sesardic et al, 1990) and had a similar effect on
theophylline disposition (Jenne et al, 1975; Hunt et al, 1976; 
Grygiel et al, 1984; Cusack et al, 1985). A study by Brown et al 
(1988) investigated the effects of tobacco abstinence on the 
pattern of caffeine metabolism in 9 habitual smokers. Caffeine 
metabolism was considerably higher while the volunteers were
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smoking, whereas a 60% decrease in caffeine clearance occurred
after only 3-4 days of cigarette abstinence. Smoking was found
to accelerate both primary and secondary demethylation pathways, 
in agreement with our results, while the ratio of 1,7-DMU/ 
1,7-EMX did not differ between smoking and nonsmoking phases.
The increased P450IA2 activity that we observed in smokers 
compared to nonsmokers is in agreement with previous studies
(Pantuck et al, 1974; Sesardic et al, 1988) which shewed that
phenacetin O-deethylation, catalysed by P450IA2 activity in 
human liver, was induced by cigarette smoke. Earlier work on AHH 
activity (a proportion of which is catalysed by P450IA1), found 
that smokers had higher AHH activity than nonsmokers in 
extrahepatic tissues, including placenta (Nebert et al, 1969; 
Vaught et al, 1979; Pasanen & Pelkonen, 1981), human monocytes 
(Jett et al, 1978; Rudiger et al, 1980) and lymphocytes (Karki & 
Huhti, 1978; Jett et al, 1978; Hopkin & Evans, 1980; Gurtoo et 
al. 1983). EROD activity of placenta (Pelkonen et al, 1979) and 
7-ethoxycoumarin activity of human lung samples (Oesch et al, 
1980), proportions of which are catalysed by P450IA1, were also 
induced by cigarette smoke, while placental P450IA1 activity was 
induced in Chinese women exposed to contaminated rice oils 
containing PCBs (Wong et al, 1986). P450IA1 can also be induced 
in human breast cell lines following exposure to airborne 
particles (Roepstorff et al, 1990). Interestingly, AHH activity 
in human liver is not increased by cigarette smoking (Vahakangas 
et al. 1983; Pelkonen et al, 1979); probably because it is 
catalysed by P450IIC and P450IIIA (Kawano et al, 1987) and not 
by P450IA1 (Fujino et al, 1984), as occurs in human placenta 
(Fujino et al, 1982; Wong et al, 1986; Pasanen et al, 1989). As
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caffeine is metabolised mainly in the liver and it is uncertain 
whether P450IA1 is involved in its metabolism, it was not 
possible to assess P450IA1 levels extrahepatically. However, 
demethylation of 1,7-EMX in the liver (a proportion of which may 
involve P450IA1) was also increased in smokers compared to 
nonsmokers in the present study.
OCS or HRT administration was found to have only a small effect 
on caffeine metabolism because although P450IA and P450IA2 
activities tended to be lower in OCS-user females than women not 
using OCS, the results were not significantly different. Other 
studies found a signif icantly lower plasma clearance of caffeine 
and a significantly prolonged caffeine half-life in OCS-user 
females (Patwardhan et al, 1980; Abemethy & Todd, 1985; Meyer 
et al, 1988). A similar result was observed for theophylline 
disposition (Gardner et al, 1983). Also, Campbell et al (1987) 
found that nonsmoking OCS users had lcwer mean caffeine 
metabolite ratios than nonusers. As caffeine metabolism is 
prolonged during pregnancy (Knutti et al, 1981) it is possible 
that steroid administration suppresses the MFO system involved 
in caffeine metabolism (Patwardhan et al, 1980).
Females using OCS/HFT were studied further for their smoking 
status to see whether this altered the results. In nonsmoking 
females, P450IA activity was not significantly different in 
women who were OCS/HRT or non-OCS users. This was also the case 
for P450IA2 activity. However, in smoking females, P450IA 
activity was significantly lower in OCS/HRT users than in 
non-OCS users. In contrast, this relationship was not found for 
P450IA2 activity.
Although OCS or HRT administration per se did not appear to
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alter caffeine metabolism, it did have an effect on P450IA 
activity, particularly in the smoking population, as concurrent 
OCS/HRT use actually inhibited the effect of cigarette smoke on 
enzyme activities. That is, the smokers had a similar P450IA 
activity to nonsmokers if women were taking these steroids, 
whereas in non-OCS females, smokers had a much greater P450IA 
activity than nonsmokers. A similar finding was observed by 
Gardner et al (1983), who studied the combined effects of 
cigarette smoke and OCS administration on caffeine metabolism.
The modest effect of OCS on caffeine metabolism observed in the 
present study may be explained by the wide interindividual range 
in enzyme activities observed. Variation due to genetic factors, 
may well override the inhibitory effects of OCS administration 
and results would suggest that OCS administration does not 
affect P450IA or P450IA2 to as great an extent as other 
environmental factors, such as cigarette smoking.
Effect of Genetic host factors
Large interindividual differences in caffeine metabolism exist 
in a group of control volunteers. Frequency distributions for 
both P450IA and IA2 were positively skewed and statistical tests 
performed on the data indicated that P450IA and P450IA2 
activities strongly deviated from a normal distribution. Even 
when the smoking subjects were studied separately, in order to 
try and reduce seme of the variability observed, P450IA activity 
still ranged 103-fold for smokers and 19-fold for nonsmokers. 
P450IA2 activity ranged 77 -fold for smokers and 48-fold for 
nonsmokers.
The possibility of genetic differences in AHH inducibility in
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man was first described by Kellermann et al (1973a) who claimed 
that humans could be separated into three groups of lew (45%), 
intermediate (46%) and high (9%) inducibility. Gahmberg et al 
(1979) also found that 15% of a Finnish population exhibited 
high AHH inducibility, although they obtained a bimodal 
distribution for AHH activity. It was also found by other 
workers that considerable variation in AHH activity existed in 
human tissues, including lymphocytes (Arnott et al, 1979; Gurtoo 
et al. 1983), human pulmonary alveolar macrophages (Cantrell et 
al. 1973), placenta (Pelkonen et al, 1979), bronchi (Harris et 
al. 1976), lung biopsy tissue (Oesch et al, 1980; Roberts et al, 
1986), bone marrow cells (Brown et al, 1976) and human foreskin 
(Levin et al, 1972). Human lung cytosol samples were also found 
to exhibit striking heterogeneity in Ah receptor concentrations 
(Roberts et al, 1986). Jaiswal et al (1985) shewed genetic 
differences in the inducibility of P450IA1 mRNA in human
lymphocytes and polymorphisms of the P450IA1 gene were then 
discovered (Jaiswal & Nebert, 1986). Three P450IA1 genotypes 
existed in 104 healthy subjects - the frequency of which showed 
excellent agreement with the trimodal AHH inducibilities 
(Kawajiri et al, 1990).
In order to detect whether bimodality in frequency distributions 
of data existed in the present studies, the activities were 
logged and studied further in the form of histograms and 
cumulative distributions. Log transformation of data often 
allcws clearer visualisation of different phenotypes and 
therefore clearer bimodality of distributions under monogenic 
control (Jackson et al, 1986). The frequency distributions for
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P450IA activity was still skewed when the logged data were 
studied, and the Lilly-Fors test which tests specifically for 
bimodality of distributions, showed that P450IA activity was 
likely to be bimodal. As no clear subgroups of individuals with 
high P450IA activity were evident, a cut-off point in the 
frequency distribution at a ratio of 26 was arbitrarily 
assigned, to separate those subjects in the skewed region of the 
distribution with high P450IA activity. In this way 9% of 
control volunteers in the present study had high P450IA 
activity, in good agreement with results from groups studying 
AHH activity (Kellermann et al, 1973a; Kawajiri et al, 1990). 
Conversely, P450IA2 activity appeared to be normally distributed 
when the data were logged, which again suggests differences in 
the two pathways of caffeine metabolism. Large differences in 
P450IA2 activity have been described (Wrighton et al; 1986; 
Davies et al; 1987). Hie metabolism of aminobiphenyl (Butler et 
al. 1989a) and 2-naphthylamine (Hammons et al, 1985) which is 
catalysed by P450IA2, varied 30-60 fold and the metabolism of 
phenacetin varied 180-fold in only 28 human liver samples 
(Shimada et al, 1989; Sesardic et al, 1988). In addition, 
caffeine 3-demethylation, which is catalysed by P450IA2 in human 
liver was found to vary greatly (Butler et al, 1989a; Sesardic 
et al. 1990). Most of these workers have suggested the 
possibility of a genetic polymorphism in P450IA2 to explain such 
large interindividual variation.
In accordance with other studies, the population was divided 
into arbitrary groups with high and lew P450IA2 activity, using 
the metabolite ratio of 162 as the cut-off point. In this way, 
16.5% of healthy subjects were found to have high P450IA2
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activity in this study. Bartsch et al (1990) found that 25% of 
100 healthy white males had high P450IA2 activity, using the 
paraxanthine/ caffeine metabolite ratio.
Although nodes or subgroups of individuals with different P450IA 
and P450IA2 activities are not clearly evident, the possibility 
of a pharmacogenetic polymorphism in the activity of one or both 
of these enzymes cannot be ruled out. For many genetic traits 
there is considerable variation within phenotypes either for 
genetic reasons or because of environmental factors (Jackson et 
al. 1989a). Such variability may obscure the separation between 
phenotypes thereby complicating the detection of a polymorphism. 
If it were possible routinely to genotype individuals, these 
problems would be overcame. However, the molecular biology of 
the enzymes involved suggests that the underlying genetic basis 
for their activity is complex (Guengerich et al, 1987). 
Therefore, polymorphisms are still being detected on the basis 
of phenotypic expression of enzyme activity, even though 
statistical proof of bimodality in population distributions is 
difficult.
Although genetic polymorphism causes marked variability in the 
response to drugs and environmental chemicals (Ayesh & Smith, 
1989), environmental factors are particularly important for the 
variability of drug dispostion involving the cytochromes P450, 
as their activity is greatly altered by environmental exposure 
to inducing and inhibiting agents. As distributions for P450IA 
and P450IA2 activities do not shew clear subgroups of 
individuals with high and low activity, it is difficult to 
distinguish between the environmental and genetic factors
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contributing to the observed variability. Nevertheless, in order 
to try and determine the degree of variation in P450IA and IA2 
activities due to genetic factors, smoking and nonsmoking 
subjects were studied separately in the present study, as 
cigarette smoke is known to be one of the largest environmental 
contributions to P450IA and IA2 variability.
The 103-fold variation in P450IA activity in subjects who were 
all smokers indicates that the degree of inducibility of this 
enzyme is very different, even in subjects who may smoke the 
same number of cigarettes - and therefore be exposed to PAH to a 
similar degree. Several other workers also found that AHH 
activity varied markedly between individuals who smoked a 
similar number of cigarettes (Welch et al, 1969; Harris et al, 
1976; Vaught et al, 1979; Sabadie et al, 1981). Some of this
variation may be attributed to different amounts of tobacco 
smoked or to varying patterns of inhalation or airflow in the 
bronchial tree, which would clearly alter the dose of carcinogen 
delivered to the bronchial mucosa and peripheral lymphocytes
(Hopkin & Evans, 1980). However, although plasma thiocyanate is 
higher in smokers than nonsmokers (Vahakangas et al, 1983), the 
levels correlated weakly with placental AHH activity of smoking 
women, which suggests that there is likely to be a genetic
component controlling AHH variability (Pelkonen et al, 1979). 
Statistical tests performed on the logged data, suggest that
P450IA activity is bimodal for smoking subjects.
The nonsmokers only exhibited a 19-fold range in P450IA 
activity, which suggests that it is the degree of inducibility 
that varies more markedly between subjects than basal enzyme 
levels. Kellermann et al (1973b) found that basal AHH levels
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varied within a smaller range than induced levels, although 
basal and induced AHH levels were highly correlated. Nebert 
(1991) also suggested that differences in P450IA1 and P450IA2 
activities are likely to represent differences in the the human 
Ah receptor gene controlling inducibility of the enzymes.
In contrast to smokers, bimodality in log P450IA activity for 
nonsmokers was not evident. The distributions for logged P450IA2 
activity were unimodal whether smokers, nonsmokers or the whole 
population were studied.
Nevertheless, considerable evidence in favour of a large genetic 
effect leading to variation in enzyme activities exists and 
results from the reproducibility tests, discussed in Section 
4.1, further support this theory. P450IA and P450IA2 activities 
were highly reproducible when the same caffeine test was 
performed three months apart, whether subjects were smokers or 
nonsmokers. Such a large genetic effect may explain why same of 
the subjects with high enzyme activities were in fact
nonsmokers. It may be possible then, to use the caffeine test to 
measure P450IA and P450IA2 activities, in order to study the 
degree of inducibility that occurs in smokers and to determine 
the nonsmoking subjects who have particularly high enzyme
activities.
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5.2 P450IA AND P450IA2 ACraVITTES IN PATIENTS WITH CARCINOMA
OF THE LUNG. HEAD AND NECK
5.2.1 Introduction
Given that large variations in P450IA and IA2 enzyme activities 
exist in healthy subjects and that these enzymes can be induced 
by cigarette smoking, P450IA and IA2 activities were measured in 
patients with carcinoma of the lung, head and neck. Lung cancer 
patients have been shewn to exhibit the high P450IA1
inducibility phenotype (Kawajiri et al, 1990), which may be the 
biochemical basis for the observation that lung cancer occurs 
more frequently in both smoking and nonsmoking relatives of lung 
cancer patients (Anderson, 1975). Thus the differential
susceptibility of the human population to chemical carcinogens 
may be partially attributed to individual differences in
carcinogen metabolism. Examination of the levels of such enzymes
in humans may contribute to an understanding of the genetic and
environmental factors which affect the susceptibility of an 
individual for cancer.
By giving caffeine as a probe drug to a group of patients with
carcinoma of the lung, head and neck, and measuring the
metabolites of interest in urine, P450IA and P450IA2 activities 
were determined and compared to those from a population of 
control volunteers (Section 2.3.2).
5.2.2 Results
The mean enzyme activities for the patients with cancer are 
shown in Table 5.2.1. When compared to control subjects, the 
patients with lung cancer had a highly significantly greater 
P450IA activity (p<0.01) (Fig.5.2.1). Hcwever, there was no
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Table 5.2.1 - P450IA and P450IA2 activities in patients with
carcinoma of the lung, head and neck and healthy 
subjects
Enzyme Grot?) n Median Mean activity 
± SEM
Range
P450IA Control 277 11.64 14.52 ± 0.87 1.15 -130.33
Cancer 51 15.32 18.16 ± 1.71 5.13 - 62.69
P450IA2 Control 254 74.68 97.29 ± 5.45 7.92 -607.62
Cancer 51 65.91 92.30 ±12.55 17.39 -411.97
significant difference in P450IA2 activity between the patients 
with lung cancer and the control subjects (p>0.5) (Fig.5.2.2). 
The mean age of 51 patients with carcinoma of the lung, head and 
neck was 67.92 + 1.41 y. This was significantly higher than the 
mean age of 40.24 + 0.95 y for 277 control volunteers 
(p<0.0001).
5.2.3 Effect of Cigarette Smoke
P450IA and P450IA2 activities were studied in 51 patients with 
carcinoma of the lung, head and neck of known smoking status; 16 
were smokers and 35 were nonsmokers. The results are shown in 
Table 5.2.2. Athough smokers did tend to have a higher P450IA 
activity than nonsmokers, results were not significantly
different in the patients with lung cancer whether they were 
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Figure 5.2.1 - P450IA activity in patients with carcinoma of 
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Figure 5.2.2 - P450IA2 activity in patients with carcinoma of 
the lung, head and neck, compared to controls. 
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Table 5.2.2 - P450IA and P450IA2 activities in smoking and
nonsmoking cancer patients
Enzyme Group n Median Mean activity 
+ SEM
Range
P450IA Smokers 16 17.23 20.00 ± 3.12 6.96 - 49.51
Nonsmokers 35 14.89 17.33 ± 2.06 5.13 - 62.69
P450IA2 Smokers 16 102.03 133.32 ±24.47 42.99 -371.78
Nonsmdkers 35 51.57 73.56 ±13.56 17.39 -411.97
In contrast, patients with lung cancer who were smokers had a 
higher P450IA2 activity than nonsmokers (p<0.005). Enzyme 
activities between smokers and nonsmdkers from each population 
were compared separately. The results are shewn in Table 5.2.3. 
The smoking cancer patients had a higher mean P450IA activity 
than smoking control volunteers, but not significantly so 
(p>0.05). Nonsmoking patients with lung cancer had significantly 
higher P450IA activity than nonsmoking controls (p<0.005). In 
fact, P450IA activity in nonsmoking cancer patients tended to be 
higher than that of control smokers.
P450IA2 activity in smoking cancer patients was not 
significantly different to that of control smokers (p>0.1). 
P450IA2 activity in nonsmoking cancer patients was also not 
significantly different from that of nonsmoking controls
(p>0.1).
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Table 5.2.3 - P450IA and P450IA2 activities in smoking and
nonsmoking cancer patients and healthy subjects
Enzyme Group n Median Mean activity Range 
± SEM
P450IA Smokers
-control 70 13.76 16.55 ±1.94 1.15 - 118.46
-cancer
Nonsmdkers
16 17.23 20.00 ±3.12 6.96 - 49.51




35 14.89 17.33 ±2.06 5.13 - 62.69
-control 70 85.48 118.66 ±12.49 7.92 - 607.62
-cancer
Nonsmdkers
16 102.03 133.32 ±24.47 42.99 - 371.78
-control 184 68.90 89.49 ±5.74 11.58 - 550.23
-cancer 35 51.57 73.56 ±13.56 17.39 - 411.97
5.2.4 Effect of Cancer Cell Type
P450IA and P450IA2 activities were studied in 43 patients with
carcinoma of the lung, head and neck of known cell type. 30
patients had tumors of squamous cell origin; 10 were of oat cell
origin; 1 tumor was of swan cell type and 2 were
adenocarcinomas.
The enzyme activities for each group are shown in Table 5.2.4.
The patient who had a tumor of the swan cell type had the lowest 
P450IA and P450IA2 activities measured. Patients with the three
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Table 5.2.4 - P450IA and P450IA2 activities in patients with
carcinoma of the lung, head and neck of different 
cell type
Enzyme Group n Median Mean activity Range 
± SEM
P450IA Squamous 30 16.76 18.31 + 2.29 5.61 - 62.69
Oat 10 23.27 23.17 ± 3.00 12.47 - 42.60
Adenocarcinoma 2 16.18 16.18 ± 1.29 14.89 - 17.47
Swan 1 7.14 7.14
P450IA2 Squamous 30 55.10 96.35 ±18.26 22.51 -411.97
Oat 10 88.25 123.66 ±27.64 51.57 -318.59
Adenocarcinoma 2 75.96 75.96 ± 2.92 73.04 - 78.87
Swan 1 17.39 17.39
other types of cell tumors seemed to have comparable enzyme 
activities. As only two patients presented with adenocarcinoma, 
only results for the squamous and oat cell types were compared 
statistically. Although patients with lung, head and neck tumors 
of oat cell origin tended to have higher P450IA and P450IA2 
activities than those with tumors of squamous cell types, there 
was no significant difference between the two groups (p>0.1) for 
either P450IA activity or P450IA2 activity.
5.2.5 Effect of Tumor Location
P450IA and P450IA2 activities were studied in 41 patients with 
carcinoma of the bronchus and in 10 patients with cancer of the
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head and neck. The enzyme activities for each group are shewn in 
Table 5.2.5. P450IA activity was virtually identical in patients 
with cancer of the bronchus and cancer of the head and neck and 
the results were not significantly different (p>0.5).
Table 5.2.5 - P450IA and P450IA2 activities in patients with
carcinoma of the bronchus and cancer of the head 
and neck
Enzyme Group n Median Mean activity Range
+ s m
P450IA Bronchus 41 15.32 18.03 + 1.92 5.13 - 62.69
Head & neck 10 15.71 18.70 ± 3.96 8.34 - 50.91
P450IA2 Bronchus 41 69.40 98.64 ±14.48 17.39 -411.97
Head & neck 10 36.25 66.36 +23.43 22.51 -266.30
Bronchial cancer patients alone had a significantly higher 
P450IA activity than the control population (p<0.05). Even the 
small group of patients with head and neck cancer (n=10) had a 
higher P450IA activity than control subjects (jrO.Ol).
P450IA2 activity tended to be higher in patients with bronchial 
carcinoma than head and neck patients but results between the 
two groups were not significantly different (p>0.1). Therefore, 
P450IA2 activity was not significantly different between
controls and cancer patients, whether bronchial or head and neck 
cancer.
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5.2.6 Genetic Control of P450IA and P450IA2 Activities
P450IA Activity
The frequency distribution histogram for P450IA activity in 51 
patients diagnosed with carcinoma of the lung, head and neck is 
depicted in Fig. 5.2.3. The summary statistics for this 
distribution are shewn in Table 5.2.6.
Table 5.2.6 - Summary Statistics for P450IA activity in 51











12 fold variation in P450IA activity exists in 51 patients with 
lung cancer. It can be seen from the histogram and Table 5.2.6 
that the distribution is strongly positively skewed and shews a 
degree of kurtosis. The standardized coefficients are both 
ouside the range of -2 to +2 that would be observed for a normal 
distribution and therefore indicate that the data may deviate 
significantly from normality. This is confirmed by the Chi-
139
-7 5 17 29 41 53 65 77 89 101
P450IA ACTIVITY
Figure 5.2.3- Frequency distribution histogram of P450IA 
activity in patients with carcinoma of the lung, head and neck
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Figure 5.2.4 - Log frequency distribution histogram of P450IA 
activity in 51 patients with carcinoma of the lung, head and
-square and the Lilly-Fors test which indicate that P450IA 
activity was highly significantly different from that expected 
from a normal distribution.
As the data shew a strong degree of skewness and kurtosis, the 
data were logged and re-examined in order to detect bimodality 
of the distribution. Hie frequency distribution histogram for 
log P450IA activity in 51 patients with carcinoma of the lung, 
head and neck is shewn in Fig. 5.2.4. The distribution is 
slightly positively skewed but statistical tests performed on 
the data also suggested that P450IA activity was unimodal.
21.6% of the patients with cancer of the lung, head and neck had 
high P450IA activity (Fig.5.2.3). This was significantly higher 
than the proportion (9%) of control volunteers with high P450IA 
activity (p<0.01). 31.3% of the smoking cancer patients had high 
P450IA activity, compared to 11.4% of the control smokers 
(p<0.05) and 17.1% of the nonsmoking cancer patients had high 
P450IA activity, compared to only 6.5% of the control nonsmokers 
(p<0.05). The proportion of smoking and nonsmoking cancer 
patients with high P450IA activity was not significantly 
different (p>0.05).
P450IA2 Activity
The frequency distribution histogram for P450IA2 activity in 51 
patients diagnosed with carcinoma of the lung, head and neck is 
depicted in Fig.5.2.5. The summary statistics for this 
distribution are shewn in Table 5.2.8.
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Table 5.2.7 - The proportion of lung, head and neck cancer





Cancer 11/51 (21.6%) 40/51 (78.4%)
-Smokers 5/16 (31.3%) 11/16 (68.7%)
-Nonsmokers 6/35 (17.1%) 28/35 (82.9%)
Control 25/277 (9.0%) 252/277 (91.0%)
-Smokers 8/ 70 (11.4%) 62/ 70 (88.6%)
-Nonsmokers 12/185 (6.5%) 173/185 (93.5%)
Table 5.2.8 - Summary Statistics for P450IA2 activity in 51 
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Figure 5.2.5 - Frequency distribution histogram of P450IA2 
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Figure 5.2.6 - Log frequency distribution histogram of 
P450IA2 activity in 51 patients with carcinoma of the lung, head 
and neck.
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24-fold variation in P450IA2 activity existed. It can be seen 
from the histogram and Table 5.2.7 that the distribution is 
strongly positively skewed and shews a degree of kurtosis. The 
standardized coefficients suggest that the data may deviate 
significantly from normality. This is confirmed by both the 
Chi-square and K-S test results, which are significantly 
different from normal. In addition the Lilly-Fors test suggested 
that P450IA2 activity may form a bimodal distribution.
The frequency histogram for log P450IA2 activity in 51 patients 
with carcinoma of the lung, head and neck is depicted in 
Fig.5.2.6.
The distribution for log P450IA2 activity is positively skewed 
to a greater extent than that for P450IA activity, but the 
statistical tests performed on the data suggest that P450IA2
activity is unimodal, even when the smokers and nonsmokers were 
considered separately.
The proportion of cancer patients with high P450IA2 activity 
(ratio >162) is shewn in Table 5.2.9.
13.7% of the patients with cancer of the lung, head and neck 
were found to have high P450IA2 activity (Fig.5.2.5). This was 
not significantly different from the proportion (16.5%) of
control subjects with high P450IA2 activity (p>0.05). The
proportion of smoking (25%) and nonsmoking cancer patients 
(8.6%) with high P450IA2 activities were not significantly
different from those found in the control smoking (27.1%) and 
nonsmoking (12.5%) subjects (p>0.05).
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Table 5.2.9 - The proportion of lung, head and neck cancer
patients with high P450IA2 activity
Grot?) P450IA2 activity
High % lew %
Cancer 7/51 (13.7%) 44/51 (86.3%)
-Smokers 4/16 (25.0%) 12/16 (75.0%)
-Nonsmokers 3/35 (8.6%) 32/35 (91.4%)
Control 42/254 (16.5%) 212/254 (83.5%)
-Smokers 19/ 70 (27.1%) 51/ 70 (72.9%)
-Nonsmokers 23/184 (12.5%) 161/184 (87.5%)
5.2.7 Discussion
Early studies on the relationship between enzyme activities and 
cancer susceptibility shewed that the AHH enzyme could 
metabolise BP and other such PAH, resulting in the formation of 
DNA adducts (Digiovanni et al, 1983) and cancer initiation in 
animal (Nebert & Felton, 1975; Heidelberger et al, 1980) and 
human tissues (Yang et al, 1977). A good correlation existed 
between BP activation, the degree of DNA binding and sensitivity 
to the carcinogen in vitro (Grunberger & Theall, 1983). The 
extent of the carcinogenicity of PAH and aromatic amine 
compounds appeared to correlate with the degree of induction of 
the P450IA enzymes (Creaven & Parke, 1966; Ayrton et al, 
1990a,b). Following the observation that large variations in AHH 
activity existed in human lymphocytes (Kellermann et al, 1973a) 
such that a trimodal distribution was formed, several workers
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measured AHH activity in patients with lung cancer. Kellermann 
et al (1973b) found that 30% of bronchial carcinoma patients 
were of the high AHH inducibility phenotype compared to 9% in 
healthy subjects. Several other groups also found that AHH 
activity was higher in human lymphocytes from patients with lung 
cancer than healthy controls (Coombes et al, 1976; Guirgis et 
al. 1976; Karki & Huhti, 1978; Emery et al, 1978; Gahmberg et 
al, 1979; McLemore et al, 1979; Amott et al, 1979; Kouri et al, 
1982) and that the number of BP-DNA adducts formed in these 
patients was higher, as a result of their increased AHH activity 
(Rudiger et al, 1980).
In addition, studies on P450IA1 itself (Kawajiri et al, 1990) 
have shown that individuals with the homozygous rare allele of 
the polymorphism for the CYPIA1 gene were at a 3-fold risk for 
lung cancer and at a 5- fold risk for the squamous cell type in 
particular. Moreover, the proportion of patients with the rare 
allele was the same as that with the high AHH inducibility 
phenotype (30%) studied by Kellermann (1973b). Nakachi et al 
(1991) found that patients with the homozygous rare P450IA1 
allele contracted lung cancer after smoking fewer cigarettes 
than other genotypes possibly due to differences in metabolic 
activation of carcinogens between different genotypes. More 
evidence in favour of this comes from a recent study by Kawajiri 
et al (1991) who found that the polymorphism in CYPIA1
cosegregated with the inducibility phenotype of P450IA1, which 
suggests that the susceptible genotype may have increased 
metabolism of procarcinogens in cigarette smoke. Therefore, the 
risk of lung cancer in individuals with the rare CYPIA1 allele 
may be explained by their high P450IA activity. The importance
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of P450IA in the cancer process is shewn by the fact that guinea 
pigs and steppe lemmings which are resistant to chemical 
carcinogens, are also resistant to P450IA induction by PAH 
(Ioannides & Parke, 1987).
P450IA activity in the present study was found to be 
considerably higher in patients with lung cancer than controls, 
even in the presence of 113-fold variation in P450IA activity in 
healthy subjects. It is tempting to speculate that the P450IA 
isozyme involved in 1,7-DMX N-demethylation is in same way 
related to the AHH enzyme, and may thus be used as a marker of 
susceptibility for cancer of the lung, head and neck.
P450IA activity was not found to alter between smoking and 
nonsmoking patients with carcinoma of the lung, head and neck. 
P450IA activity in smoking cancer patients was not significantly 
different from that in healthy smokers but the proportion of 
smoking patients with high P450IA activity (31.3%) was 
significantly higher than that in healthy smokers (11.4%). In 
contrast, the nonsmoking cancer patients had a much higher 
P450IA activity than nonsmoking healthy subjects and the 
proportion of these patients with high P450IA activity (17.1%) 
was much higher than that in healthy nonsmokers (6.5%). These 
findings strongly suggest that factors other than cigarette 
smoke are contributing to the high P450IA activity observed in 
the cancer subjects. Most of the patients classified as 
nonsmokers in this study were in fact exsmokers for at least one 
month prior to the time of the caffeine test. As Cantrell et al 
(1973) shewed that AHH activity returned to basal levels within 
2 months cessation of smoking and Brown et al (1988) found that 
caffeine metabolite patterns returned to basal levels following
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3-4 days of cigarette abstention, high P450IA activities in the 
nonsmoiking cancer population are unlikely to be due to the 
effects of cigarette smoke.
When the frequency distribution for P450IA activity was studied, 
the cut-off ratio of 26 determined from 277 healthy volunteers 
fitted well with the distribution for the cancer patients. 21.6% 
of the cancer population had high P450IA activity compared to 
only 9% of control subjects. This is slightly less than the 
proportion of lung cancer patients with high AHH inducibility 
(Kellermann et al, 1973b) and the rare CYPIA1 allele (Kawajiri 
et al. 1990). Nonetheless, patients with cancer of the lung, 
head and neck -particularly the nonsmokers had a much greater 
P450IA activity than the control population, in agreement with 
Gahmberg et al, (1979).
The 12-fold range in P450IA activity for the patients with 
cancer is similar to that found for AHH in lung tissue by 
Sabadie et al (1981) and supports the idea that the patients 
with cancer are a more homogeneous group, with high P450IA 
activity, then control subjects.
The possibility that high P450IA activity is due to the presence 
of the tumour itself cannot be ruled out but seems unlikely as 
Idle et al (1981) found that the metabolism of mephenytoin and 
antipyrine were unaltered in cancer cases, compared to controls.
P450IA2 activity was not found to alter significantly between 
cancer patients and controls. The proportion of patients with 
high P450IA2 activity (13.7%) was less than that in control 
subjects (16.5%). In fact, nonsmoking cancer patients tended to 
have an even lower P450IA2 activity than control nonsmokers, in
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total contrast to P450IA activity. Current knowledge shows that 
P450IA2 activity has not been determined in lung cancer 
patients. Results from the present study shew that there are 
large fundamental differences in the enzymes catalysing the 
caffeine and 1,7-EMX demethylation steps. Although P450IA2 
activity is induced by cigarette smoking, both in this study and 
in those by Sesardic et al (1988) and Pantuck et al (1974), it 
does not appear to play an important role in the initiation of 
lung cancer. This may have something to do with the substrate 
specificity of the enzymes. P450IA2 preferentially metabolises 
arylamines (Thorgeirsson & Nebert, 1977; Kamataki et al, 1983; 
Hammons et al, 1985; Shimada & Okuda, 1988; Shimada et al, 1989; 
Butler et al, 1989a; Aoyama et al, 1989; Gonzalez et al, 1990) 
and hepatocarcinogenic aromatic amines are selective liver 
inducers of P450IA2 in the rat (Degawa et al, 1989). On the 
other hand, P450IA1 preferentially metabolises PAH (Kadlubar & 
Hammons, 1987). As both of these inducing compounds are present 
in cigarette smoke, one might expect P450IA2 activity to be 
higher in smokers than nonsmokers. While P450IA2 activates 
4 -aminobipheny 1 to form haemoglobin-adducts in human lung tissue 
which correlate with the quantity of tobacco smoked, this enzyme 
does not appear to constitute an independent risk factor for 
lung cancer (Weston et al, 1991). It appears that PAH are more 
important in initiating lung cancer and may explain why P450IA2 
activity is not altered in patients with this disease. As a 
large difference in the degree of 1,7-DMX demethylation (P450IA 
activity) in lung cancer patients has been found in this study, 
it seems very likely that P450IA1 is contributing to this 
pathway.
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The current studies found no difference in P450IA or P450IA2 
activities between the patients with carcinoma at different 
locations. P450IA activity was higher in patients with bronchial 
cancer and even the small group of 10 patients with carcinoma of 
the head and neck than that measured in the control population. 
AHH activity was found to be higher in patients with oral 
carcinoma (Trell et al, 1978; Trell & Korsgaard, 1978), 
pharyngeal cancer (Amott et al, 1979) and laryngeal cancer 
(Trell et al, 1976) than healthy volunteers, which supports the 
findings in this study and is consistent with squamous cell 
cancer of the oral cavity being a smoking related cancer, in 
addition to squamous cell cancer of the lung (Trell & Korsgaard, 
1978). AHH activity is high in patients with lung cancer, 
regardless of the position of the pulmonary tumour (Kauri et al, 
1982).
Patients with tumors of squamous, adenocarcinoma and oat cell 
types were studied together in order to recruit a large number 
of subjects in accordance with Kellermann et al (1973b) and 
McLemore et al (1979). No significant differences in P450IA and 
P450IA2 activities existed between patients with tumors of 
different histological type, although one patient with a tumor 
of swan cell origin had the lowest P450IA activity. Therefore, 
for P450IA activity, the patients with squamous cancer and even 
the small group of patients with oat cell cancer had higher 
activities than the control population.
AHH activity was not significantly different in squamous and 
adenocarcinoma cell types by Sabadie et al (1981) and unaffected 
by histological type by Kouri et al (1982). Also, in one study 
where a quarter of the cancer population had adenocarcinoma,
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patients with lung cancer were still found to have a much 
greater activity than healthy controls (Kellermann et al. 
1973b). Kawajiri et al (1990) however, found that more of the 
patients with squamous cell lung cancer were of the rare CYPIA1 
genotype corresponding to high AHH inducibility, than other cell 
types. Therefore, individuals with this rare genotype were at a 
5-fold risk for squamous cell cancer, compared to a 3- fold risk 
for lung cancer of a different cell type.
One major point of concern while conducting this type of study 
is the relationship between hepatic P450IA activity determined 
by the caffeine test and levels of the same enzyme in lung. Test 
systems other than the lung have to be used in lung cancer 
patients because AHH activity is reduced in malignant tissue 
(Sabadie et al, 1981) although good correlations between AHH 
activities in lung and lymphocytes (McLemore et al, 1979) and 
human bronchus and colon and duodenum (Autrup & Harris, 1983) 
exist. Although human lung and respiratory nasal mucosa and 
olfactory tissue in rats (Foster et al, 1986) contain P450IA 
enzymes, the relationship between these and the hepatic P450IA 
enzymes is not yet clear, due to the tissue specificity that 
seems to characterise this P450 family.
Although the mean age of the cancer patients was greater than 
that for control volunteers, it is unlikely that high P450IA 
activity in lung cancer patients is a result of their advanced 
age, as no trend in increasing P450IA activity with age was 
shewn to exist in healthy subjects. In fact, seme investigators 
have reported that older patients have lower AHH activity and 
inducibility compared to young patients (Paigen et al, 1977;
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Amott et al, 1979). Kouri et al (1982) found that AHH activity 
was not affected by patient age nor by the presence of 
noncancerous, respiratory disorders, such as chronic obstructive 
airway disease. Therefore, it also seems unlikely that high 
P450IA activity in lung cancer patients is due to poor 
respiratory function. Patient gender is also unlikely to cause 
the high P450IA levels observed, as enzyme activity is 
unaffected by healthy subject gender in the current study in 
agreement with Amott et al (1979). It would appear that high 
P450IA activity reflects inherent susceptibility of an 
individual to lung cancer. A genetic component controlling part 
of the process of lung cancer would not be unusual (Anderson, 
1975; Mulvihill, 1975; Knudson, 1977; Schimke, 1978; Harris et 
al. 1980) and the disease occurs more frequently in the 
relatives of patients with lung cancer (Paigen et al, 1977).
As cancer of the lung is a disorder which remains silent during 
most of its pathologic evolution, its clinical onset is subtle 
and thus extremely difficult to diagnose early enough for 
effective therapy (Sanderson & Jett, 1989). Important measures 
should be taken to detect individuals with high P450IA activity 
at an early stage as this study shews that there is both an 
increased frequency of high P450IA activity in nonsmoking cancer 
patients and high P450IA inducibility in smoking cancer 
patients. Therefore, P450IA but not P450IA2 activity, as 
determined by the caffeine test may be of extreme value as a 
marker for detection of susceptibility to carcinoma of the lung, 
head and neck, by virtue of its possible genetic polymorphic 
status coupled with its ability to metabolise certain chemical 
carcinogens.
152
5.3 P450IA AND P450IA2 ACnVITIES IN PATIENTS WITH LEUKAEMIA
5.3.1 Introduction
Targe inter individual differences in P450IA and IA2 activities 
exist in a group of healthy subjects. Subjects with high P450IA 
activity seem to be predisposed for lung cancer, which supports 
observations in the murine model that high AHH inducibility 
leads to increased susceptibility for lung car cinema. In 
contrast, mice with lew AHH inducibility are at increased risk 
for leukaemia and aplastic anaemia. Thus the differential 
susceptibility of the human population to chemical carcinogens 
in various tissues may be partially attributed to individual 
differences in the degree of carcinogen metabolism.
By giving caffeine as a probe drug to a group of patients with 
leukaemia and measuring the caffeine metabolites of interest in 
urine, P450IA and P450IA2 activities were determined and 
compared to those from a control population (Section 2.3.2).
5.3.2 Results
The enzyme activities for the patients with leukaemia are shown 
in Table 5.3.1. When compared to control volunteers, P450IA 
(Fig.5.3.1) and P450IA2 (Fig.5.3.2) activities in patients with 
leukaemia were not significantly different (p>0.3). The mean age 
of 54 patients with leukaemia was 61.85 + 2.13 y. This was
significantly higher than the mean age of 40.24 + 0.95 y for 277 
control volunteers (pcO.OOl).
5.3.3 Effect of Cigarette Smoke
P450IA and P450IA2 activities were studied in 54 patients with 
leukaemia of known smoking status; 7 were smokers and 47 were
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Table 5.3.1 - P450IA and P450IA2 activities in patients
with leukaemia and control volunteers
Enzyme Group n Median Mean activity Range
± SEM
P450IA Control 277 11.64 14.52 + 0.87 1.15 -130.33
Leukaemia 54 13.13 15.81 ± 1.40 1.91 - 46.99
P450IA2 Control 254 74.68 97.29 + 5.45 7.92 -607.62
Leukaemia 54 68.42 85.81 + 8.78 5.50 -294.03
nonsmokers. The results are shewn in Table 5.3.2.
Table 5.3.2 - P450IA and P450IA2 activities in smoking and 
nonsmoking leukaemia patients
Enzyme Group n Median Mean activity 
± SEM
Range
P450IA Smokers 7 10.70 15.97 ± 4.09 5.22 - 33.24
Nonsmokers 47 13.55 15.79 ± 1.51 1.91 - 46.99
P450IA2 Smokers 7 76.88 99.37 ±35.41 11.58 - 294.03
Nonsmokers 47 64.13 83.79 + 8.78 5.50 - 260.86
Although P450IA and P450IA2 activities tended to be higher in 
smoking patients with leukaemia than nonsmokers, the results 
were not significantly different (p>0.5).
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Figure 5.3.1 - P450IA activity in patients with leukaemia, 
compared to controls.
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Figure 5.3.2 - P450IA2 activity in patients with leukaemia, 
compared to controls.
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In order to compare any difference in enzyme activities between 
healthy subjects and patients with leukaemia further, smokers 
and nonsmokers from each population were also compared 
separately. The results are shown in Table 5.3.3.
Table 5.3.3 - P450IA and P450IA2 activities in smoking and 
nonsmoking patients with leukaemia and control 
volunteers
Enzyme Group n Median Mean activity Range
± SEM
P450IA Smokers
-control 70 13.76 16.55 ± 1.94 1.15 - 118.46
-leukaemia 7 10.70 15.97 ± 4.09 5.22 - 33.24
Nonsmoker
-control 185 10.09 12.21 ± 0.57 2.95 - 54.89
-leukaemia 47 13.55 15.79 + 4.09 5.22 - 33.24
P450IA2 Smokers
-control 70 85.48 118.66 ±12.49 7.92 - 607.62
-leukaemia 7 76.88 99.37 ±35.41 11.58 - 294.03
Nonsmokers
-control 184 68.90 89.49 ± 5.74 11.58 - 550.23
-leukaemia 47 64.13 83.79 ± 8.78 5.50 - 260.86
P450IA and P450IA2 activities in smoking leukaemia patients were 
not significantly different than that of smoking control 
subjects (p>0.5).
When the nonsmoking population was studied, it was found that 
P450IA and P450IA2 activities were not significantly different
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in nonsmoiking patients with leukaemia and control nonsmokers 
(p>0.05).
5.3.4 Effect of Leukaemia Type
P450IA and P450IA2 activities were studied in 37 patients with 
leukaemia of known type. 29 patients had chronic and 8 had acute 
leukaemia. The enzyme activities for each group are shown in 
Table 5.3.4.
Table 5.3.4 - P450IA and P450IA2 activities in patients with 
chronic and acute leukaemia
Enzyme Group n Median Mean activity 
± SEM
Range
P450IA Chronic 29 14.91 18.47 ± 2.15 1.91 - 46.99
Acute 8 10.87 14.47 ± 3.45 5.48 - 32.29
P450IA2 Chronic 29 71.29 93.11 ±12.66 9.95 - 294.03
Acute 8 71.63 89.10 ±19.57 27.07 - 183.06
P450IA and P450IA2 activities were not significantly different 
in patients with chronic or acute leukaemia (p>0.5) and similar 
to those determined in the control population.
5.3.5 Genetic Control 
P450IA Activity
The frequency distribution histogram for P450IA activity in 54 
patients with leukaemia is depicted in Fig.5.3.3. The summary 
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Figure 5.3.4 - Log frequency distribution histogram of P450IA 
activity in 54 patients with leukaemia.
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5.3.3 - Frequency distribution histogram of P450IA 
activity in 54 patients with leukaemia.












25-fold variation in P450IA actviity exists in 54 patients. It 
can be seen from the histogram and Table 5.3.5 that the 
distribution is positively skewed and shews a small degree of 
kurtosis. Statistical tests shew that the data is significantly 
different from normal and possibly bimodal (Chi-square test, 
p<0.05; Lilly-Fors test, p<0.01).
As the data show a strong degree of skewness and kurtosis, the 
data were logged and re-examined in order to detect bimodality 
of the distribution. The frequency distribution histogram for 
log P450IA activity in 54 patients with leukaemia is shewn in 
Fig.5.3.4.
The logged distribution is slightly positively skewed 
statistical tests performed on the data suggested that P450IA 
activity was unimodal.
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The proportion of leukaemia patients with high P450IA activity 
(ratio >26) is shown in Table 5.3.6.
Table 5.3.6 - The proportion of leukaemia patients with high 
P450IA activity
Group P450IA activity
High % Low %
Leukaemia 8/54 (14.8%) 46/54 (85.2%)
-Smokers 2/ 7 (28.6%) 5/ 7 (71.4%)
“Nonsmokers 6/47 (12.8%) 41/47 (87.2%)
Control 25/277 (9.0%) 252/277 (91.0%)
-Smokers 8/ 70 (11.4%) 62/ 70 (88.6%)
-Nonsmokers 12/185 (6.5%) 173/185 (93.5%)
The proportion of leukaemia patients with high P450IA activity 
was 14.8% (Fig.5.3.3). This was not significantly different to 
the proportion (9%) of control volunteers with high P450IA 
activity (p>0.05). The proportion of smoking leukaemia patients 
(28.6%) with high P450IA activity was not significantly 
different to that in control smokers (11.4%) (p>0.05). The
proportion of nonsmoking leukaemia patients (12.8%) with high 
P450IA activity was also not significantly different to that of 
control nonsmokers (6.5%) (p>0.05). The proportion of smoking
and nonsmoking leukaemia patients with high P450IA activity was 
not significantly different (p>0.05).
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P450IA2 Activity
The frequency distribution histogram for P450IA2 activity in 54 
patients with leukaemia is depicted in Fig.5.3.5. The summary 
statistics for this distribution are shewn in Table 5.3.7.












53-fold variation in P450IA2 activity exists in 54 patients. It 
can be seen from the histogram and Table 5.3.6 that the 
distribution is strongly positively skewed and shews a degree of 
kurtosis. The standardized coefficients indicate that the data 
may deviate significantly frcm normality which is confirmed by 
statistical tests (Chi-square test, p<0.005; Lilly-Fors test,
p<0.01).
As the data shew a strong degree of skewness and kurtosis, the 
data were logged and re-examined in order to detect bimodality
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Figure 5.3.5 - Frequency distribution histogram of P450IA2 
activity in 54 patients with leukaemia.
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Figure 5.3.6 - Log frequency distribution histogram of P450IA2
activity in 54 patients with leukaemia
of the distribution. Ihe frequency distribution histogram for 
log P450IA2 activity in 54 patients with leukaemia is shewn in 
Fig.5.3.6. Ihe distribution is slightly positively skewed but 
the the data is likely to ccme from a normal distribution as 
statistical tests performed on the data suggested that P450IA2 
activity in leukaemia patients was unimodal.
Ihe proportion of leukaemia patients with high P450IA2 activity 
(ratio >162) is shewn in Table 5.3.8.
Table 5.3.8 - Ihe proportion of leukaemia patients with high 
P450IA2 activity
Group P450IA2 activity
High % Lew %
Leukaemia 6/54 (11.1%) 48/54 (88.9%)
-Smokers 1/ 7 (14.3%) 6/ 7 (85.7%)
-Nonsmokers 5/47 (10.6%) 42/47 (89.4%)
Control 42/254 (16.5%) 212/254 (83.5%)
-Smokers 19/ 70 (27.1%) 51/ 70 (72.9%)
-Nonsmokers 23/184 (12.5%) 161/184 (87.5%)
The proportion of leukaemia patients with high P450IA2 activity 
was 11.1% (Fig.5.3.5). This was not significantly different to 
the proportion (16.5%) of control subjects with high P450IA2 
activity (p>0.05). The proportion of smoking leukaemia patients 
(14.3%) with high P450IA2 activity was not significantly 
different to that in control smokers (27.1%) (p>0.05). The
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proportion of nonsmoking leukaemia patients (10.6%) with high 
P450IA2 activity was also not significantly different to that of 
control nonsmokers (12.5%; p>0.05). Ihe proportion of smoking
and nonsmoking leukaemia patients with high P450IA2 activity was 
not significantly different (p>0.05).
5.3.6 Discussion
P450IA activity determined in 54 patients with leukaemia did not 
differ significantly from that measured in 277 control
volunteers. Results from the present study would therefore 
suggest that P450IA activity is not a contributing factor in 
leukaemia development.
Several studies have shewn that mice with high AHH inducibility 
(Ah responsive) are at increased risk for PAH induced pulmonary 
tumors and solid tumors at the site of PAH inoculation (Kauri, 
1976; Kouri et al, 1980; Nebert, 1980b) whereas mice with lew 
AHH inducibility had increased susceptibility for oral
drug-induced leukaemia and aplastic anaemia (Nebert et al. 1977; 
Duran-Reynals et al, 1978; Nebert & Jensen, 1979; Nebert et al, 
1980b). As less P450IA induction occurs throughout the body in 
nonresponsive mice, less chemical is metabolised into active 
metabolites in lung and skin but more of the chemical reaches 
distant tissues, including the bone marrow, where it may be 
activated and bind to DNA (Nebert, 1981b). The nonr espons ive 
mouse is therefore more prone to chemically induced lymphcma, 
leukaemia and bone marrow toxicity (Nebert, et al, 1980b).
Support for the murine model occurring in man came from a study 
on 37 patients with acute leukaemia of childhood (Blumer et al, 
1979). A greater proportion of these patients were of the low
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inducibility phenotype, compared to healthy subjects. Results 
from the present study shew that smoking leukaemia patients have 
similar P450IA activity to nonsmoking patients, unlike lung 
cancer patients. It is possible therefore that P450IA is not 
induced in leukaemia patients to the same extent as it is in 
patients with other types of cancer, in support of Blumer et al 
(1979). Results from this study do not support the theory of lew 
P450IA activity causing increased susceptibility for leukaemia, 
as P450IA activity in the patients was similar to that measured 
in healthy subjects, in agreement with Levine et al (1984). 
However, unlike the study by Kellermann (1973a) where a trimodal 
distribution was obtained, the distribution for P450IA activity 
in this study appeared to be bimodal, such that subjects with 
homozygous low P450IA activity could not be identified. 
Therefore, although the proportion of leukaemia patients with 
high P450IA activity was not significantly different from that 
in control subjects, we cannot rule out the possibility that the 
proportion of patients with low activity may be different from 
that in control volunteers.
It seems unlikely that smoking status was responsible for the 
lack of lew P450IA activity in these patients, as smokers had a 
similar enzyme activity to nonsmokers in this study.
P450IA2 activity was also not significantly different in 
patients with leukaemia compared to the control population. 
While P450IA1 has been detected in bone marrow tissue (Schnier 
et al. 1989), it is not thought that P450IA2 activity is induced 
in such tissue. It seems unlikely therefore that differences in 
P450IA2 activity will be important in leukaemia initiation.
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5.4 P450IA AND P450IA2 ACTIVITIES IN PATIENTS WITH COLORECTAL
CARCINOMA AND FAMmAL ADENOMATOUS POLYPOSIS
5.4.1 Introduction
P450IA2 activity appears to be expressed in all human liver 
samples tested, unlike P450IA1 (Wrighton et al, 1986). P450IA2 
has high specificity for the N-hydroxylation of a number of 
aromatic amines (Kadlubar & Hammons, 1987). For primary 
arylamines, metabolic N-oxidation by hepatic cytochrcxne P450IA2 
is generally regarded as the initial activation step leading to 
carcinogenesis (Nebert et al, 1987; Hammons et al, 1985; Butler 
et al, 1989a,b) and in humans, P450IA2 appears to be primarily 
responsible for the mutagenic activation of several heterocyclic 
amines (Shimada et al, 1989; Battula et al, 1990). Since we have 
shewn that considerable interindividual variability in this 
enzyme activity exists in human populations, it is possible that 
such variation, due to environmental and/or genetic factors, may 
contribute to individual differences in susceptibility to
arylamine-induced cancers.
By giving caffeine as a probe drug to a group of patients with 
familial adenomatous polyposis and colorectal carcinoma, P450IA 
and P450IA2 activities were determined and compared to those of 
a control population and a group of relatives at risk for 
developing FAP (Section 2.3.2).
5.4.2 Results
P450IA activities for the patients with FAP and colorectal 
carcinoma are shewn in Table 5.4.1. P450IA activities in 
patients with FAP (p>0.05) (Fig.5.4.1) and their relatives at 
risk for FAP (p>0.5) (Fig. 5.4.2) were not significantly
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Figure 5.4.1 - P450IA activity in patients with FAP, compared 
to controls.
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Figure 5.4.2 - P450IA activity in relatives at risk for FAP, 
compared to controls.
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Figure 5.4.3 - P450IA activity in patients with FAP, compared 







Figure 5.4.4 - P450IA activity in patients with colorectal 
carcinoma, compared to controls.
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Table 5.4.1 - P450IA activities in patients with colorectal
carcinoma and FAP
Group n Median Mean activity
± sm
Range
Control 277 11.64 14.52 ± 0.87 1.15 -130.33
Colorectal 12 8.83 12.97 + 2.91 4.55 - 38.76
FAP 37 14.04 18.37 ± 2.43 3.40 - 65.60
At Risk 16 10.85 14.74 ± 2.37 4.23 - 39.72
different from those determined in control subjects. P450IA 
activity was not significantly different between FAP patients 
and the group at risk for FAP (p>0.5) (Fig.5.4.3). Patients with 
bowel cancer had similar P450IA activities to the control 
population (p>0.5) (Fig.5.4.4).
P450IA2 activities for patients with colorectal carcinoma, FAP 
and their relatives at risk for FAP are shewn in Table 5.4.2. 
P450IA2 activity was significantly greater in patients with FAP 
(p<0.005) (Fig. 5.4.5) and in their relatives (p<0.05) 
(Fig.5.4.6) than control volunteers. The mean enzyme activity in 
FAP patients was not significantly different from that in the 
group at risk for FAP (p>0.5) (Fig.5.4.7). In contrast, P450IA2 
activity in the patients with colorectal carcinoma was not 
significantly different from that of control subjects (p>0.1) 
(Fig.5.4.8).
Ihe mean age of 37 patients with FAP was 36.38 + 2.44 y. This 
was not significantly different from the mean age of 40.24 +
169
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Figure 5.4.5 - P450IA2 activity in patients with FAP, compared 
to controls.
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Figure 5.4.7 - P450IA2 activity in patients with FAP, compared 
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Figure 5.4.8 - P450IA2 activity in patients with colorectal 
carcinoma compared to controls.




Table 5.4.2 - P450IA2 activities in patients with colorectal
carcinoma and FAP
Group n Median Mean activity 
± SEM
Range
Control 254 74.68 97.29 + 5.45 7.92 - 607.62
Colorectal 12 51.88 64.76 ± 10.60 23.89 - 129.94
FAP 35 108.21 190.02 ± 35.85 6.25 - 846.67
At Risk 16 104.02 157.04 ± 34.58 18.04 - 502.45
0.95 y for 277 control volunteers (p>0.1). The mean age of 16 of 
their relatives at risk for polyposis was 31.25 + 4.06 y, which 
was not significantly different from the mean age of the FAP 
patients (p>0.1), but significantly less than the mean age of 
the control volunteers (p<0.05). The mean age of the patients 
with colorectal carcinoma was 70 + 2.8 y. This was significantly 
greater than the mean age of the control volunteers (p<0.001).
5.4.3 Effect of Cigarette Smoke
P450IA activity was studied in 5 smokers and 27 nonsmokers with 
FAP and in 6 smoking and 10 nonsmoking relatives at risk for 
FAP. None of the patients with colorectal carcinoma were 
smokers. The results are shown in Table 5.4.3.
P450IA activity tended to be higher in smoking patients with FAP 
than nonsmoking patients (p>0.1). This was also the case for the 
relatives at risk for FAP (p>0.1).
P450IA2 activity was studied in 5 smokers and 25 nonsmokers with
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Table 5.4.3 - P450IA activity in smoking and nonsmoking patients
with FAP and their relatives at risk for FAP.
Group n Median Mean activity 
± SEM
Range
FAP Smokers 5 19.86 26.53 + 8.20 8.85 - 55.08
Nonsmokers 27 12.11 16.78 ± 2.78 3.40 - 65.60
At Risk Smokers 6 14.38 17.42 ± 4.89 7.89 - 39.72
Nonsmokers 10 10.84 13.13 + 2.50 4.23 - 31.02
FAP and in 6 smoking and 10 nonsmoking relatives at risk for 
FAP. Ihe results are shewn in Table 5.4.4.
Table 5.4.4 - P450IA2 activity in smoking and nonsmoking
patients with FAP and their relatives at risk for 
FAP
Group n Median Mean activity 
± SEM
Range
FAP Smokers 5 543.69 454.86 ±122.68 99.30 - 802.84
Nonsmokers 25 103.31 152.86 ± 36.27 6.25 - 846.67
At Risk Smokers 6 177.11 216.40 + 64.30 64.16 - 502.45
Nonsmokers 10 78.30 121.43 + 37.87 18.05 - 380.15
P450IA2 activity was significantly greater in smoking patients
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with FAP than nonsmoking patients (p<0.01) and tended to be 
higher in smoking relatives at risk for FAP than in nonsmoking 
relatives (p=0.01). Due to the increased P450IA2 activity in 
patients with FAP and relatives at risk for FAP, smokers and 
nonsmokers were studied separately and compared to control 
subjects. The results are shewn in Table 5.4.5.
Table 5.4.5 - P450IA2 activity in smoking and nonsmoking FAP 
patients and healthy subjects
Group n Median Mean activity 
± sm
Range
Smokers -Control 70 85.48 118.66 + 12.49 7.92 -607.62
-FAP 5 543.69 454.86 ±122.68 99.30 -802.84
-At Risk 6 177.11 216.40 ± 64.30 64.16 -502.45
Nonsmokers-Control 184 68.90 89.49 + 5.74 11.58 -550.23
-FAP 25 103.31 152.86 ± 36.27 6.25 -846.67
-At Risk 10 78.30 121.43 + 37.87 18.05 -380.15
5 smoking patients with FAP had a significantly higher P450IA2 
activity than control smokers (p<0.001). 6 smoking relatives at 
risk for FAP also tended to have higher P450IA2 activity than 
control smokers (p^0.052). P450IA2 activity in smoking FAP
patients was not significantly different from smoking relatives 
at risk for the disease (p>0.1).
The nonsmoking patients with FAP had a significantly higher 
P450IA2 activity than control nonsmokers (p<0.05). P450IA2
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activity in the control group of nonsmoking relatives was not 
significantly different from control nonsmokers (p>0.1). P450IA2 
activity in nonsmoking FAP patients was not significantly
different to that of their relatives at risk for FAP (p>0.5).
As the patients with large bcwel cancer were all nonsmokers, 
they were compared to control nonsmokers. P450IA2 activity was 
not significantly different between these two groups (p>0.1).
5.4.4 Genetic Control 
P450IA Activity
The frequency distribution histogram for P450IA activity in 37 
patients with FAP is depicted in Fig. 5.4.9. The summary
statistics for this distribution are shown in Table 5.4.6.
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Figure 5.4.9 - Frequency distribution histogram of P450IA 
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Figure 5.4.10 - Log frequency distribution histogram of P450IA 
activity in 37 patients with FAP.
19-fold variation in P450IA activity exists in FAP patients. It 
can be seen from the histogram and Table 5.4.6 that the 
distribution is strongly positively skewed and shews a large 
degree of kurtosis. The Chi-square test, but not the K-S test, 
is significantly different from normal (p<0.0005) and suggests 
that the data deviates from normality. In addition the 
Lilly-Fors test indicated that P450IA activity was highly 
significantly different from those expected for a normal
distribution (p<0.01). However, the logged data were found to be 
not significantly different from normal (Fig.5.4.10).
The frequency distribution histogram for P450IA activity in 16 
relatives at risk for FAP is depicted in Fig.5.4.11. The summary 
statistics for this distribution are shown in Table 5.4.7.
Table 5.4.7 - Summary Statistics for P450IA activity in 16 





















Figure 5.4.11 - Frequency distribution histogram of P450IA 
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Figure 5.4.12 - Log frequency distribution histogram of P450IA 
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9-fold variation in P450IA activity existed. It can be seen from 
the histogram and Table 5.4.7 that the distribution is strongly 
positively skewed and shews a degree of kurtosis. The frequency 
distribution histogram for log P450IA activity in the 16 
subjects is shewn in Fig.5.4.12. All of the statistical tests 
performed on the data suggested that P450IA activity was 
unimodal in these subjects.
The proportion of FAP patients and their relatives at risk for 
FAP with high P450IA activity (ratio >26) is shewn in Table 
5.4.8.
Table 5.4.8 - The proportion of FAP patients and relatives at 
risk for FAP with high P450IA activity
Group P450IA activity
High % Lew %
FAP 9/37 (24.3%) 28/37 (75.7%)
-Smokers 2/ 5 (40.0%) 3/ 5 (60.0%)
-Nonsmokers 5/27 (18.5%) 22/27 (81.5%)
At Risk 2/16 (12.5%) 14/16 (87.5%)
-Smokers 1/ 6 (16.7%) 5/ 6 (83.3%)
-Nonsmokers 1/10 (10.0%) 9/10 (90.0%)
Control 25/277 (9.0%) 252/277 (91.0%)
-Smokers 8/ 70 (11.4%) 62/ 70 (88.6%)
-Nonsmokers 12/185 (6.5%) 173/185 (93.5%)
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24.3% of FAP patients had high P450IA activity (Fig.5.4.9). This 
was significantly greater than the proportion (9%) of control 
volunteers with high P450IA activity (p<0.01). The proportion of 
smoking FAP patients with high P450IA activity (40%) tended to
be greater than the same proportion of control smokers (11.4%). 
The number of nonsmoking FAP patients with high P450IA activity 
(18.5%) was significantly greater than the control nonsmokers
with a high enzyme activity (6.5%) (p<0.05). The number of
smoking FAP patients with high P450IA activity was not
significantly different from that in nonsmokers (p>0.05).
The proportion of relatives at risk with high P450IA activity 
(12.5%) (Fig.5.4.11) was not significantly different frcrn that 
in the control population (9%) (p>0.05) or in the patients with 
FAP (24.3%) (p>0.05). The proportion of smoking or nonsmoking
relatives with high P450IA activity was not significantly 
different to the proportion of control smokers and nonsmokers 
with high P450IA activity (p>0.05). The number of smoking 
relatives at risk for FAP with high P450IA activity was also not 
significantly different from that in nonsmokers (p>0.05).
The frequency distribution histogram for P450IA activity in 12 
patients diagnosed with colorectal cancer is depicted in 
Fig.5.4.13. The summary statistics for this distribution are 
shown in Table 5.4.9. 9-fold variation in P450IA activity 
existed. It can be seen from the histogram and Table 5.4.9 that
the distribution is positively skewed, although the K-S test and 
the Lilly-Fors test indicate that it is unlikely that the data 
for this distribution deviates from normality. The log frequency 
distribution for P450IA activity in the 12 colorectal cancer
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Figure 5.4.13 - Frequency distribution histogram of P450IA
activity in 12 patients with colorectal cancer.
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Figure 5.4.14 - Log frequency distribution histogram of P450IA 
activity in 12 patients with colorectal cancer 
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Table 5.4.9 - Summary Statistics for P450IA activity in 12











patients is normally distributed and is shewn in Fig.5.4.14.
The proportion of large bcwel cancer patients with high P450IA 
activity (ratio >26) is shewn in Table 5.4.10.
8.3% of the patients with colorectal carcinoma had high P450IA 
activity (Fig.5.4.13). This was not significantly different to 
the proportion of control subjects with high P450IA activity 
(9%) (p>0.05). All of the patients with large bcwel cancer were
nonsmokers. The proportion of these patients with high P450IA 
activity was also not significantly different from the 
proportion of control nonsmokers (6.5%) with high P450IA
activity (p >0.05).
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Table 5.4.10 - The proportion of colorectal cancer patients
with high P450IA activity
Group P450IA activity
High % Lew %
Colorectal cancer 1/12 (8.3%) 11/12 (91.7%)
Control 25/277 (9.0%) 252/277 (91.0%)
-Nonsmokers 12/185 (6.5%) 173/185 (93.5%)
P450IA2 Activity
The frequency distribution histogram for P450IA2 activity in 35 
patients diagnosed with FAP is depicted in Fig.5.4.15. The 
summary statistics are shewn in Table 5.4.11.
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Figure 5.4.15 - Frequency distribution histogram of P450IA2 
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Figure 5.4.16 - Log frequency distribution histogram of 
P450IA2 activity in 35 patients with FAP 
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Figure 5.4.17 - Frequency distribution histogram of P450IA2 
activity in 16 relatives at risk for FAP.
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Figure 5.4.18 - Log frequency distribution histogram of P450IA2
activity in 16 relatives at risk for FAP. 
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135-fold variation in P450IA2 activity existed. It can be seen 
from the histogram and Table 5.4.11 that the distribution shews 
very large degrees of positive skewness, deviates from normailty 
and is probably bimodal (Chi-square test, p<0.00001; K-S test, 
p<0.01; Lilly-Fors test, p<0.01). However, the logged data were 
found to be unimodally distributed (Fig.5.4.16).
The frequency distribution histogram for P450IA2 activity in 16 
relatives at risk for FAP is depicted in Fig.5.4.17. The summary 
statistics for this distribution are shewn in Table 5.4.12. 
28-fold variation in enzyme activity occurs in only 16 subjects. 
It can be seen from the histogram and Table 5.4.12 that the 
distribution is positively skewed and possibly bimodal
(Lilly-Fors test, p<0.01). The log frequency distribution
depicted in Fig.5.4.18 was found to be unimodally distributed.
Table 5.4.12 - Summary Statistics for P450IA2 activity in 16 












The proportion of patients with FAP and their relatives at risk 
for the disease with high P450IA2 activity is shown in Table 
5.4.13.
Table 5.4.13 - The proportion of FAP patients and their
relatives at risk for FAP with high P450IA2 
activity
Group P450IA2 activity
High % Low %
FAP 10/35 (28.6%) 25/35 (71.4%)
-Smokers 4/ 5 (80.0%) 1/ 5 (20.0%)
-Nonsmokers 5/25 (20.0%) 20/25 (80.0%)
At Risk 5/16 (31.3%) 11/16 (68.7%)
-Smokers 3/ 6 (50.0%) 3/ 6 (50.0%)
-Nonsmokers 2/10 (20.0%) 8/10 (80.0%)
Control 42/254 (16.5%) 212/254 (83.5%)
-Smokers 19/ 70 (27.1%) 51/ 70 (72.9%)
-Nonsmokers 23/184 (12.5%) 161/184 (87.5%)
28.6% of the patients with FAP had high P450IA2 activity 
(Fig.5.4.15). This was not significantly different frcan the 
proportion of control subjects with high P450IA2 activity 
(16.5%) (p>0.05). The number of smoking FAP patients with high
P450IA2 activity was greater than the number of nonsmoking 
patients (p<0.01). The number of smoking FAP patients with high 
P450IA2 activity was greater than the number of control smokers
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P450IA2 ACTIVITY
Figure 5.4.19 - Frequency distribution histogram of P450IA2
activity in 12 patients with colorectal cancer.
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Figure 5.4.20 - Log frequency distribution histogram of P450IA2
activity in 12 patients with colorectal cancer. 
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(p<0.05). However, the proportion of nonsmoking FAP patients 
with high P450IA2 activity was not significantly different from 
that in nonsmoking control subjects (p>0.05). The number of FAP 
patients with high P450IA2 activity was not significantly 
different from that in the relatives at risk for FAP (p>0.05). 
fIhe proportion of relatives at risk for FAP with high P450IA2 
activity was 31.3% (Fig.5.4.17) which was not significantly 
different from the proportion of control subjects with high 
P450IA2 activity (p>0.05). The number of smoking relatives at 
risk, with high P450IA2 activity was not significantly different 
from the number of nonsmoking relatives (p>0.05). Neither the 
smoking or nonsmoking groups of relatives at risk had a greater 
proportion of subjects with high P450IA2 acrtivity than the 
control smokers or nonsmokers (p>0.05).
The frequency distribution histogram for P450IA2 activity in 12 
patients diagnosed with colorectal cancer is depicted in
Fig.5.4.19. The summary statistics for this distribution are 
shewn in Table 5.4.14. 5-fold variation in P450IA2 acrtivity 
existed. It can be seen from the histogram and Table 5.4.14 that 
the distribution is only very slightly skewed results and seems 
to fit a normal distribution. The log frequency distribution for 
P450IA activity in the 12 colorectal cancer patients is normally 
distributed and is shown in Fig.5.4.20.
The proportion of large bowel cancer patients with high P450IA2 
activity (ratio >162) is shown in Table 5.4.15. Although none of 
the patients with large bowel cancer had high P450IA2 activity 
(Fig.5.4.19), this was not significantly different from that in 
the control population (16.5%) (p>0.05). Since all of the
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Table 5.4.14 - Summary Statistics for P450IA2 activity in 12











Table 5.4.15 - The proportion of colorectal cancer patients 
with high P450IA2 activity
Group P450IA2 activity
High % Lew %
Colorectal cancer 0/ 12 (0%) 12/ 12 (100%)
Control 42/254 (16.5%) 212/254 (83.5%)
-Nonsmokers 23/184 (12.5%) 161/184 (87.5%)
colorectal cancer patients were nonsmokers, they were compared 
to the nonsmoking control subjects. There was no significant 
difference between the proportion of subjects with high P450IA2
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activity between these two groups (p>0.05).
5.4.5 Discussion
P450IA2 activity in 254 control volunteers was shewn to vary 
77-fold in the present study (Section 5.1). Such large variation 
in the metabolism of aminobiphenyl (Butler et al, 1989a), 
2-naphthylamine (Hammons et al, 1985), phenacetin (Shimada et 
al. 1989; Sesardic et al, 1988) caffeine (Butler et al, 1989b) 
and in the activity of P450IA2 itself are frequently described 
(Wrighton et al, 1986; Davies et al, 1987; Sesardic et al, 1988; 
Ikeya et al, 1989). Many of these workers have suggested that 
P450IA2 may be subject to genetic polymorphism, in order to 
explain such large inter individual variation. Since the 
N-oxidation of arylamines is a critical step in the metabolic 
activation of these carcinogens, the existence of a genetic 
polymorphism in P450IA2 activity would suggest that some 
individuals with high activity may have a genetic predisposition 
to arylamine-induced cancers.
Patients with FAP were found to have higher P450IA2 activity 
than healthy controls, even in the presence of large variation 
in P450IA2 activity observed in healthy subjects. Not all FAP 
patients had high P450IA2 activity, suggesting that this enzyme 
system is not solely responsible for any abnormal hepatic 
metabolism of carcinogens in FAP. This is not surprising since 
CYPIA2 is inherited on chromosome 15, whereas FAP is an 
autosomal dominant condition involving chromosome 5. This 
difference in the pattern of inheritance does not, hcwever, 
preclude a relationship between FAP and P450IA2 activity. It has 
been shown in the past that inherited disorders, such as FAP can
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be influenced by environmental factors. For example, American 
patients with multiple polyposis have far fewer gastric polyps 
than Japanese patients. It is thought that the Japanese diet, 
already incriminated in the high rate of stomach cancer, may 
enhance the expression of gastric neoplasm by the polyposis gene 
(Utsuncmiya et al, 1974).
The response of FAP patients to the inductive effects of 
cigarette smoke was similar to that observed in control 
subjects, in that smoking patients with FAP had a greater 
P450IA2 activity than nonsmokers and the proportion of high 
P450IA2 activity in smokers was greater than in nonsmokers. In 
fact, the 5 smoking patients with FAP had a higher P450IA2 
activity than 70 control smokers, which might suggest that 
factors in addition to cigarette smoke are involved in the 
increase in P450IA2 activity observed in FAP patients. The 25 
nonsmoking patients with FAP had higher P450IA2 activities than 
control nonsmokers, to such an extent that they even tended to 
have higher mean activities than control smokers. Undoubtedly, 
the most remarkable finding in this study was the fact that 
P450IA2 activity varied 135-fold in the FAP patients studied, in 
contrast to the 77-fold variation observed in control 
volunteers. Taken together these results suggest that genetic 
factors may play a more important role than environmental 
factors, in determining the degree of P450IA2 activity of some 
individuals. Moreover, it appears that genetic differences in 
P450IA2 activity, in addition to a genetic defect involving 
chromosome 5, may be involved in FAP susceptibility.
Hepatic P450IA2 is responsible for the N-oxidation and thus 
metabolic activation of aromatic amines (Thorgeirsson & Nebert,
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1977; Kamataki et al, 1983; Hammons et al, 1985; Shimada & 
Okuda, 1988; Shimada et al, 1989; Guengerich et al, 1990), 
promutagens and procarcinogens (Aoyama et al, 1989; Gonzalez et 
al, 1990). The enzyme itself is induced by such compounds 
(Degawa et al, 1989) and it appears that a relationship exists 
between the carcinogenicity of aromatic amines and their ability 
to induce hepatic P450IA2 in the rat (Ayrton et al, 1990a, b). 
Ring-hydroxylation and conjugation of arylamines are 
detoxification pathways.
Patients with bladder cancer more commonly have high P450IA2 
activity (Bartsch et al, 1990). N-OH-arylamines formed by 
hepatic P450IA2 are transported in the form of glucuronides 
(Poupko et al, 1979) in the blood stream to the kidney, where 
they are filtered and subsequently reach the urinary bladder 
lumen. At slightly acidic pH, the conjugates are hydrolysed 
(Flammang et al. 1985) and the N-OH-arylamines, which are much 
more potent carcinogens than the parent compounds (Miller & 
Miller, 1981) are capable of reacting directly with DNA in the 
urothelium. For colorectal carcinogenesis by arylamines, 
metabolic N-oxidation by hepatic P450IA2 is likewise regarded as 
the important activation step (Kadlubar & Hammons, 1987). 
Conjugation by hepatic N-glucuronidation is thought to result in 
biliary transport of the metabolites to the colonic lumen 
(Poupko et al, 1979; Meerman et al, 1982), where bacterial 
beta-glucuronidases can regenerate N-OH-arylamines (Kadlubar & 
Beland, 1985). These findings suggest that an analogous 
situation might occur in FAP.
FAP is a premalignant condition conferring a high risk of 
duodenal cancers and adenomas. Such neoplasms cluster around the
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ampulla of Vater (Spigelman et al, 1991) but are found rarely in 
the stomach. When gastric adenomas are present, they usually 
occur in the distal stomach, in association with duodeno-gastric 
reflux of bile. This pattern of foregut tumours in patients with 
FAP could be explained by the transport of carcinogens in bile. 
One may hypothesise that patients with FAP have greater 
concentrations of carcinogenic compounds excreted into bile, due 
to their higher hepatic P450IA2 activity than control subjects. 
This theory is supported by the animal model for colorectal 
cancer. A similar distribution of intestinal tumours occurs in 
the animal model, when a carcinogen, adminstered subcutaneously 
or orally, is excreted into the bile duct after undergoing 
hepatic metabolism.
As P450IA2 is not induced extrahepatically it is probably not 
present in human bladder (Damin et al, 1984) or gut (Vang et al, 
1990). Father, it appears that the hepatic activity of P450IA2 
is important in the onset of bladder cancer and possibly FAP.
The fact that P450IA2 activity was unaltered in patients with 
carcinoma of the lung, head and neck and leukaemia suggests that 
high P450IA2 activity in the FAP patients is not an effect of 
malignancy per se.
The 16 relatives of FAP patients did not have polyps at the time 
of the caffeine test but were considered to be at risk for FAP 
because it was not known whether they carried the mutant gene 
for FAP development. While this small group of relatives also
had higher P450IA2 activities than control subjects, the
proportion of them with high P450IA2 activities was not
different to that in controls. Also, there was no significant
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difference in P450IA2 activity between the smoking and
nonsmoking relatives. While the smoking relatives tended to have 
higher P450IA2 activities than control smokers, which might 
suggest that factors other than cigarette smoke can affect 
P450IA2 in this group of subjects as well as FAP, the nonsmoking 
relatives had similar P450IA2 activities to nonsmoking control 
subjects. The disparity of results between FAP patients and
their relatives at risk for FAP is unlikely to be due to the 
younger mean age of the group at risk for FAP because P450IA2 
activity is unaltered by subject age. The difference is likely 
due to the fact that not all of the relatives tested would have 
had the mutant gene for FAP development. The 50% risk of 
inheriting the gene means that while some of the relatives will 
inevitably develop FAP, and therefore probably have high P450IA2 
activity, others will not have inherited the gene and would 
therefore be expected to have normal levels of P450IA2 activity.
As overall, P450IA2 activity is greater in the control group of
relatives at risk for FAP than control subjects, one might
hypothesise that more relatives have the mutant gene than have 
not. It is tempting to speculate that the relatives with high 
P450IA2 activity will eventually develop FAP.
P450IA activity was not altered in FAP or relatives at risk for
FAP compared to control subjects. Smoking FAP patients tended to 
have higher P450IA activity than nonsmokers, as expected 
following the observation in control subjects that both P450IA 
and IA2 are induced by cigarette smoke. A similar pattern was 
observed between smoking and nonsmoking relatives at risk for 
FAP. The fact that P450IA2 activity was grossly altered in FAP
whereas P450IA was not significantly different from that in
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control volunteers again suggests that P450IA and IA2 are 
different isozymes. While P450IA activity appears to important 
in the susceptibility of an individual to carcinomas of the 
lung, head and neck, P450IA2 activity does not (Chapter 4.2). 
Conversely, while P450IA2 activity appears to be involved in 
bladder cancer and possibly FAP, we have shewn that P450IA 
activity is not altered in this latter group of patients. Other
workers have found that P450IA1 activity, unlike P450IA2
activity, is not involved in cancer of the renal pelvis and
ureter (Trell et al, 1977) or urinary bladder cancer (Kellermann 
et al, 1973b; Trell et al, 1978; Paigen et al, 1979).
In contrast to FAP patients and their relatives at risk for FAP, 
P450IA2 and P450IA activities in patients with large bcwel 
cancer were not different from that in the control population. 
Weston et al (1991) found elevated amounts of arylamine- 
haemoglobin adducts in nonsmoking patients with colon cancer, 
compared to controls which suggests that arylamines are involved 
in colorectal cancer. Results from the present study however 
suggest that high P450IA2 is not entirely responsible for
intestinal cancer risk; other polymorphic enzyme systems such as 
N-acetyltransferase are also involved in the metabolism of 
carcinogenic arylamines and may play an important role in 
colorectal cancer.
While the patients with cancer of the large bcwel have a much 
higher mean age than the control population, the lack of high 
P450IA2 activity in this group of patients is probably not an 
age-related effect, as we have shown that P450IA2 activity and 
subject age are unrelated. Nonetheless, cancer of the colon and
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rectum increases with age, probably as a result of a constantly 
present carcinogen in the environment (Moller-Jensen, 1983). 
Although first degree relatives of patients with colorectal 
cancer have an increased risk for colonic cancer, and familial 
clusters of colorectal cancer cases have frequently been 
observed (Burt et al, 1985), it is kncwn that environmental 
factors, such as the diet play an important role in bcwel 
cancer. Mutagens such as heterocyclic arylamines, which are 
present in charred surfaces of fish and beef, grilled chicken 
and roasted coffee beans (Kawachi et al, 1979; Sugimura, 1986) 
are activated by P450IA2 (Battula et al, 1990) and are capable 
of producing colon tumours in animals (Sugimura, 1986). Meats 
prepared by smoking, curing and barbecueing have also been found 
to be positively associated with colon cancer (Worlleb et al, 
1990). In addition, it has been hypothesised that the amount of 
dietary fat determines the composition of the gut microflora, 
which can activate carcinogens in the large bcwel (Reddy et al, 
1980). Fecal bacterial 7-alpha-dehydroxylase can convert cholic 
acid to secondary bile acids which may act as colon tumor 
promoters and beta-glucuronidase can hydrolyse N-QH-arylamines 
conjugates in the bowel. Both enzymes are present in high 
concentrations in high fat/ meat diets. At present, it remains 
unknown whether the carcinogen exists as such in the diet 
characteristic of populations at high risk for bcwel cancer, or 
whether the active compounds are formed by hepatic enzymes and 
gut flora from metabolites of the affluent diet.
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CHAPTER SIX
N-ACETYLTRANSFERASE ACTIVITY IN HUMAN VOLUNTEERS
6.1 N-ACETYLTRANSFERASE ACTIVITY IN HEALTHY INDIVIDUALS
6.1.1 Introduction
N-acetyltransferase (NAT) is subject to genetic polymorphism 
(Evans et al. 1960) such that some subjects are slew acetylators 
while others are fast acetylators (Weber & Hein, 1985). Most 
tests for acetylator phenotyping involve administration of a 
drug, such as sulphamethazine and monitoring its metabolism via 
plasma and urine sampling (Evans, 1989). It may be possible to 
use a simpler, noninvasive test to determine acetylator
phenotype in healthy populations, by measuring a caffeine 
metabolite ratio (Tang et al, 1991). By giving caffeine as a 
probe drug to healthy volunteers and studying the urinary 
excretion of its metabolites, the effects of both environmental 
and genetic factors on N-acetylation capacity were examined.
6.1.2 Results
Following the observation that the caffeine metabolite ratio 
used to determine NAT activity was not altered by the amount of 
caffeine consumption (Section 4.1) or the time of urine 
collection (Section 4.2), results for NAT activity in 0-8h and 
2-6 h tests were combined. The mean NAT activity determined in 
277 control volunteers was 0.45 + 0.01 and ranged between 0.077 
and 0.886 - an eleven-fold range in activity. Of the 277
subjects studied, 59% were classified as slew acetylators and 
41% as rapid acetylators, the cut-off point in enzyme activity 
being 0.48.
198
6.1.3 Effect of Age
277 healthy subjects with recorded dates of birth were studied. 
Their mean age was 40.42 ± 0.96 y and ranged between 17 and 91
y. No correlation between subject age and the degree of NAT
activity was found (r=-0.0994, p>0.05). The effect of age was
also studied for each phenotype separately (Evans, 1989). The 
mean age of the 160 slew acetylators was 42.54 ± 1.40 y and 
ranged between 18 and 90 y. The mean age of the 117 rapid 
acetylators was 37.50 ± 1.18 y and ranged between 17 and 62 y. 
While age was found to have no effect on the degree of NAT
activity in subjects with the rapid acetylator phenotype 
(r=-0.043, p>0.5), the degree of NAT activity in the slew
phenotype subjects appeared to decrease with age (r=-0.1334, 
p=0.09). NAT activity in elderly subjects (>60 y) was highly 
significantly less than that determined in subjects under 60 y 
of age (pxO.OOOl).
In addition, the effect of age on NAT activity was studied 
separately for elderly and young subjects. For the 29 elderly 
subjects (mean age 72.90 + 1.70 y; range 60 - 90 y) no
significant correlation between age and NAT activity existed 
(r=-0.0538, p>0.5). Similarly, age was not found to effect NAT
activity when the younger group of subjects aged <60 y were 
studied (mean age 36.62 + 0.75 y; range 17 - 59 y) (r=0.0207,
p>0.5).
6.1.4 Effect of Body Mass Index
254 subjects with recorded heights (m) and weights (kg) were 
studied. Body mass index values for 129 females ranged between 
17.40 and 52.14 (23.72 ± 0.37). The values for 125 males ranged
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between 17.04 and 34.33 (24.45 +0.26) and were not significantly 
different from the values determined in females (p>0.1). No 
correlation was found between EMI values and the activity of NAT 
(r^ -0.0874, p>0.1).
EMI values for the elderly subjects (mean 24.52 ± 0.57; range 
17.91 - 31.16) were not significantly different from values 
determined in subjects under 60 y of age (mean 24.01 + 0.24; 
range 17.04 - 52.14) (p>0.1). No correlation between NAT
activity and EMI values was found in 29 elderly subjects 
(r^ =-0.1049, p>0.5) or in 248 subjects under 60 y of age
(r=-0.0976/ p>0.1).
6.1.5 Effect of Subject Gender
The effect of subject gender was examined in 129 males and 119
females who were under the age of 60 y, as differences in liver
mass and hormonal status between the sexes may alter enzyme 
activities. Of the females, 42 were using oral contraceptive 
steroids (OCS) or hormone replacement therapy (HRT), while 77 
were non-OCS users. The results are shewn in Table 6.1.1.
NAT activity was not significantly different between males and 
females, whether males were compared to non-OCS user females 
(p>0.5) or the whole female population, including OCS and
non-OCS users (p>0.1) (Fig. 6.1.1).
In addition, no significant difference in NAT activity was found 
between 16 males and 13 females aged 60 y or more (p>0.5) (Table 
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Figure 6.1.2 - Effect of cigarette smoke on NAT activity.
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Table 6.1.1 - NAT activity in male and female populations under
60 y of age
Group n Mean activity Median Range
± SIM
Males 129 0.459 ± 0.015 0.446 0.077 -0.886
Females
(All) 119 0.482 ± 0.015 0.468 0.104 -0.864
(Non-OCS) 77 0.463 ± 0.018 0.459 0.104 -0.864
Table 6.1.2 - NAT activity in male and female populations aged 
60 y or more
Group n Mean activity Median Range
± SEM
Males 16 0.329 + 0.037 0.296 0.121 - 0.667
Females 13 0.289 ± 0.026 0.265 0.162 - 0.475
6.1.6 Effect of Oral Contraceptive Steroids
In order to determine any effect of OCS/HRT use on NAT activity, 
42 females using OCS or HRT were compared to 77 non-OCS users 
(Table 6.1.3). Mean NAT activities were not significantly 
different between the two groups (p>0.05).
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Table 6.1.3 - NAT activity in OCS and non-OCS using females 
under 60 y of age
Group n Mean activity 
± SEM
Median Range
OCS 42 0.517 + 0.026 0.528 0.140 - 0.851
Non-OCS 77 0.463 ± 0.018 0.459 0.104 - 0.864
Table 6.1.4 - NAT activity in smoking and nonsmoking healthy 
populations under 60 y of age
Group n Mean activity 
+ SEM
Median Range
Smokers 64 0.460 ±0.023 0.443 0.104 -0.866
Male 31 0.423 ±0.031 0.410 0.142 -0.844
Female -OCS 18 0.524 ±0.039 0.580 0.213 -0.851
-nonOCS 15 0.460 ±0.056 0.458 0.104 -0.864
-all 33 0.495 ±0.033 0.525 0.104 -0.864
Nonsmokers L62 0.486 ±0.013 0.494 0.077 -0.886
Male 79 0.493 ±0.019 0.516 0.077 -0.886
Female -OCS 24 0.512 ±0.034 0.491 0.140 -0.799
-nonOCS 62 0.464 ±0.019 0.461 0.148 -0.781
-all 86 0.478 ±0.017 0.466 0.140 -0.799
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6.1.7 Effect of Cigarette Smoke
As cigarette smoke is an inducer of certain P450 enzymes, its 
effect on NAT activity was also studied in subjects under 60 y 
of age. The results are shewn in Table 6.1.4. NAT activity in 
smoking subjects was not significantly different from that 
determined in healthy nonsmokers (p>0.1) (Fig.6.1.2). While male 
smokers tended to have lower NAT activity than male nonsmokers 
(p<0.05) NAT activity in female smokers was not significantly 
different from female nonsmokers, whether the women were using 
OCS (p>0.5) or not (p>0.5). In addition, NAT activity in female 
smokers was similar whether the women were using OCS or not 
(p>0.1). NAT activity in female nonsmokers was also unaltered by 
OCS administration (p>0.1).
Table 6.1.5 - NAT activity in smoking and nonsmoking healthy 
populations aged 60 y or more
Group n Median Mean activity Range
+ SEM
Smokers 6 0.292 0.320 + 0.076 0.121 - 0.667
Male 4 0.292 0.343 ± 0.116 0.121 - 0.667
Female 2 0.274 0.274 ± 0.050 0.224 - 0.323
Nonsmokers 23 0.292 0.309 ± 0.023 0.145 - 0.592
Male 12 0.296 0.325 + 0.035 0.145 - 0.592
Female 11 0.265 0.292 ± 0.030 0.162 - 0.475
NAT activity was also determined in smokers and nonsmokers, aged
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60 y or more (Table 6.1.5). NAT activity in healthy elderly 
smokers was not significantly different from that measured in 
healthy elderly nonsmokers (p >0.5). This was also the case when 
elderly male (p >0.5) and female smokers and nonsmokers (p >0.5) 
were studied separately. NAT activity in male smokers was not 
significantly different from that in female smokers (p >0.5). 
Similarly, NAT activity in male nonsmokers was not significantly 
different from that in female nonsmokers (p >0.5).
6.1.8 Genetic Control of N-Acetvltransferase Activity 
The frequency distribution for NAT activity in 277 healthy 
volunteers is depicted in Fig.6.1.3. The summary statistics for 
this distribution are shewn in Table 6.1.6.
Table 6.1.6 - Summary Statistics for NAT activity in a 












The mean NAT activity is 0.45 + 0.01 and ranged from 0.077 to 
0.886 - an 11-fold range in activity. It can be seen from the
histogram and Table 6.1.6 that the distribution is only slightly 
positively skewed. The following are worth noting:
a) The standardized coefficient indicates that this degree of 
skewness is probably not different from that expected from a 
normal distribution. The distribution for NAT activity does shew 
a degree of kurtosis however, and the negative standardized 
kurtosis coefficient suggests that the distribution is flatter, 
with shorter tails than would be expected from a normal 
distribution.
b) Although there are no clear breaks in the normal probability 
plot (Fig.6.1.4), an inflection in the curve exists at a point 
equivalent to an NAT activity of 0.48. It can also be seen from 
the frequency histogram that different modes are present within 
the normal distribution range, such that a ratio value of 0.48 
appears to separate the two major modes observed (Fig.6.1.3).
c) The Chi-square and K-S tests (p>0.1) however, indicate that 
NAT activity in a population of 277 control volunteers is likely 
to fit a normal distribution.
d) The Lilly-Fors test also suggests that the data are unlikely 
to fit a bimodal curve (p>0.05).
These results were unexpected following the observation by 
several other workers that NAT activity is subject to genetic 
polymorphism and bimodally distributed.
Frequency histograms of NAT activity were also studied 
separately for 248 subjects aged under 60 y of age and 29 
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Figure 6.1.4 - Normal probability plot of NAT activity in 277 
controls.
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Figure 6.1.5 - Frequency distribution histogram of NAT activity 
in 248 subjects, under 60 y of age.
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Figure 6.1.6 - Frequency distribution histogram of NAT activity 
in 29 subjects, over 60 y of age.
nodes of NAT activity in the younger subjects (Fig.6.1.5) than 
when the whole population was studied. However, statistical 
tests performed on the data and the Lilly-Fors test (p>0.05) 
indicated that NAT activity is unlikely to be bimodal. When the 
frequency histogram (Fig.6.1.6) of NAT activity were studied for 
29 elderly subjects, bimodality of NAT activity was not 
observed.
In order to detect the different phenotypes which are known to 
exist for NAT activity, the data were logged, as bimodality of 
distributions is often easier to observe when log transformation 
of the data is performed (Jackson et al, 1986). The frequency 
distribution for log NAT activity and the summary statistics for 
this distribution in 277 healthy subjects are shown in Fig.6.1.7 
and Table 6.1.8, respectively.
Table 6.1.8 - Summary Statistics for log NAT activity in a 











This distribution is highly negatively skewed and shews a large 
degree of kurtosis. Both standardized coefficients and 
statistical tests indicate that the data deviates from normality 
and may be bimodal in nature (Chi-square test, p<0.0001; K-S 
test, p=0.09; Lilly-Fors test p<0.01). Although two distinct 
modes are not clearly evident in the log frequency curve for NAT 
activity in 277 healthy subjects, there appears to be an 
antimode at a metabolite ratio of -0.30 (Fig.6.1.7). This value 
equates to an NAT activity of 0.50 when antilogged, which fits 
well with the point of inflection of 0.48 evident from the 
normal probability plot (Fig.6.1.4).
Due to the effect of age on NAT activity, log frequency 
distributions for subjects aged under 60 y were studied 
separately from subjects >60 y. For the younger subjects there 
was a clearer separation of the modes in the log frequency 
histogram at a metabolite ratio value equivalent to 0.501 
(Fig.6.1.8). The chi-square test (p<0.00001), K-S test (p<0.05) 
and Lilly-Fors test results (p<0.01) indicated that NAT activity 
for these younger subjects is significantly different from 
normal and probably bimodal in nature. The log frequency 
distribution for NAT activity in 29 elderly subjects is shewn in 
Figs.6.1.9. The antimode of -0.36 is lower in the elderly than 
that observed for the younger subjects and equates to a 
metabolite ratio of 0.44. Therefore, for subjects under 60 y, 
0.48 was taken as the segregation point between slew and rapid 
phenotypes in the present study, such that subjects with a 
metabolite ratio <0.48 were classified as slow acetylators and 
those with a ratio >0.48 were classified as rapid acetylators. 
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Figure 6.1.7 - Log frequency distribution histogram of NAT 
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Figure 6.1.8 - Log frequency distribution histogram of NAT 
activity in 248 subjects, under 60 y of age. 
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Figure 6.1.9 - Log frequency distribution histogram of NAT 
activity in 29 subjects, over 60 y of age.
Table 6.1.8 - The proportion of healthy subjects with slew 
and rapid NAT phenotypes
Group NAT activity
Slow % Rapid %
<60 y 134/248 (54.0%) 114/248 (46.0%)
>60 y 25/ 29 (86.2%) 4/ 29 (13.8%)
slow frc*n rapid acetylators. The proportion of young and elderly 
subjecrts with slew and rapid phenotypes is shewn in Table 6.1.8. 
The proportion of slow acetylators in elderly subjects (86.2%)
2 1 2
is highly significantly different from that in subjects under 60 
y (54%) (p<0.01).
6.1.9 Discussion
Effect of Environmental Factors
The effect of age on NAT activity is subject to conflicting 
reports. In the present study, no correlation between subject 
age and NAT activity was found when a population of 277 healthy 
young and elderly subjects was examined. This is in agreement 
with several other workers who also used caffeine metabolite 
ratios to determine NAT activity (Grant et al, 1983b; Bartsch et 
al, 1990; Vineis et al, 1990). Age also had no effect on NAT 
activity determined with probe drugs other than caffeine (Evans 
et al, 1960; Farah et al, 1977; Clarke et al, 1982; Evans et al, 
1983; Mommsen & Wolf, 1985; Philip et al, 1987a). No significant 
correlation between acetylation rate and age was found when slew 
and rapid phenotypes were examined separately and NAT activity 
was unaffected by age when the younger and elderly subjects were 
studied as separate groups, in agreement with Pontiroli et al
(1985). However, NAT activity was significantly lower in the 
elderly (>60 y) than in subjects <60 y. Furthermore, age did 
seem to have a slight effect on the degree of NAT activity 
within the slew phenotype, such that NAT activity tended to 
decrease with increasing age. Iselius & Evans (1983) also found 
that acetylation capacity was affected by age, while Kergueris 
et al (1986) observed that isoniazid metabolism decreased with 
age in the slow phenotype but was unaffected by age in rapid 
acety labors.
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The present study shews that 54% of healthy subjects <60 y are 
slow acetylators, compared to 86% of elderly subjects.
Similarly, Gachalyi et al (1984) found there were 50% slew 
acetylators in 128 subjects <60 y and 66.4% slew acetylators in 
125 subjects >60 y. Szorady et al (1987) found that 66% of 
elderly subjects (>60 y) were slew acetylators compared to 50%
in the age range 19-59 y. 68% of a group of control subjects 
were found to be slew acetylators in the study by Lang et al
(1986). Although they do not give the mean age of this group,
one might presume that they are relatively elderly subjects as 
they are age-matched with a group of colorectal cancer patients. 
Ilett et al (1987) also found an excess of slew acetylators in 
old control subjects in comparison with younger controls. In 
contrast, Ladero et al (1991) and Philip et al (1987a) found 
that the distribution of the slew acetylator phenotype in
healthy elderly subjects was around 60% and not different to 
that found in younger control groups. Evans et al (1989) used 
caffeine to determine acetylator phenotype in children and
adolescents between the ages of 3 and 21 y and found that only 
37.5% were slew acetylators. The reason for the apparent change 
in acetylation capacity with age is unknown.
As the antimode for the frequency distribution of NAT activity 
in elderly subjects was lower than that for younger subjects, 
one might conclude that there is same diminution in acetylating 
capacity with age. This observation is in agreement with several 
other studies although it would appear that any variation 
conferred by age is slight in comparison with that of genetic 
origin, in that a proportion of elderly subjects do exhibit 
rapid acetylation.
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Body mass index was found to have no effect on NAT activity in 
either healthy young or elderly subjects. Grant et al (1983b) 
and Philip et al (1987a) also found that subject weight did not 
alter acetylation capacity in healthy volunteers.
NAT activity was not found to differ with subject gender in 
either elderly or younger volunteers, in agreement with several 
other workers, who have either used caffeine (Grant et al, 
1983b; Tang et al, 1991) or other drugs to determine acetylator 
status (Cartwright et al, 1982; Evans et al, 1983; Miller & 
Cosgriff et al, 1983; Mcfmmsen & Wolf, 1985; Ladero et al, 1991). 
In addition, acetylation capacity was not altered by OCS 
administration, in agreement with Hardy et al (1988) which 
indicates that while the cytochrome P450 enzymes may be 
susceptible to inhibition by steroids, NAT activity remains 
relatively unaltered.
NAT activity was unaffected by cigarette smoking in subjects <60 
y. Similarly, acetylator phenotype was not influenced by
cigarette smoking in the studies by Vineis et al (1990) and 
Bartsch et al (1990). Female smokers had a similar capacity for 
N-acetylation to nonsmokers, whether they were using OCS or not, 
which confirms the observation that NAT is a noninducible enzyme 
(Hein, 1988a). However, NAT activity in male smokers was less 
than in nonsmdkers. Tang et al (1991) using caffeine as a 
metabolic probe for NAT activity also found that smokers within 
the slow phenotype had significantly lower NAT activity than 
nonsmokers, irrespective of the metabolite ratio used to 
determine acetylator phenotype. Furthermore, Cartwright et al
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(1982) found that there was a slight excess of slew acetylators 
in smoking subjects compared to nonsmokers, although the 
frequencies between the two groups were not significantly 
different. The reason for these observations in younger subjects 
remains unclear but in elderly subjects NAT activity was 
unaffected by cigarette smoking whether males or females were 
studied. Other workers have also found that acetylation capacity 
was independent of smoking status (Cartwright et al, 1982; Evans 
et al. 1983; Miller & Cosgriff et al, 1983; Hardy et al, 1988).
Effect of Genetic Factors
The hepatic N-acetylation of arylamines is catalysed by 
acetylcoenzyme A (AcCoA) -dependent N-acetyltransferases which 
exhibits genetically mediated polymorphic expression in 
mammalian species (Evans et al, 1960; Weber & Hein, 1985; Hein, 
1988a). This enzymatic biotransformation of aromatic amines is 
controlled by simple Mendelian inheritance of 2 major alleles at 
a single gene locus (Weber & Hein, 1985; Hein, 1988 a,b). 
Genetic studies in humans (Kilbane et al, 1990) provide strong 
evidence for codcminant expression of these alleles which would 
account for the trimodal distribution of individuals into the 
rapid, intermediate and slow acetylator phenotypes, which have 
occaisionally been observed (Gascon et al, 1987; Tang et al. 
1987; Kilbane et al, 1990).
As reviewed by Weber & Hein (1985) and Smith (1989), a large 
number of in vivo methods for determining acetylation phenotype 
exist. Phenotyping tests should be quick and easy to perform, 
not hazardous and give unequivocal classification of individual
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phenotypes. These criteria have not been met by any one
phenotyping test to date. All involve administration of a 
foreign chemical to subjects and most are unable to clearly 
determine individual phenotype (Evans, 1989). More accurate 
techniques for estimating acetylator phenotype are elaborate, 
involving collection of timed blood samples and can therefore 
only be performed in small groups of subjects. Recent work has 
shewn that some of these problems may be overcame by using 
caffeine as a test drug to determine acetylation status (Rieder
et al. 1991) and results from the present study suggest that
caffeine might be used as a metabolic probe to phenotype
subjects as rapid or slow N-acetylabors.
NAT activity ranged 11-fold in 277 healthy subjects. Although 
different modes were apparent from the frequency distribution 
histogram of NAT activity, bimodality of the distribution was 
not obvious. However, logging the metabolite ratios resulted in 
a distribution that was likely to be bimodal in nature, with 
clearer separation between modes, in agreement with Jackson et 
al (1986). It may thus be possible to measure NAT activity and 
determine acetylator phenotype using the log metabolite ratio 
AAMtJ/ (AAMU + 1-MU + 1-MX), in agreement with Bartsch et al
(1990)
In addition to the differences in acetylation capacity observed 
between the elderly and subjects <60 y, the apparent antimodes 
in the frequency distributions for these two groups were 
slightly different. Whereas an antimode at a metabolite ratio of 
0.48 appeared to separate slew from rapid acetylators in 
subjects <60 y, the equivalent antimode in elderly subjects was 
0.44. As NAT activity seems to be reduced in old age, the same
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phenotype separation criteria should not be applied to both 
groups (Evans, 1989). 54% of the healthy population <60 y were
of the slew acetylator phenotype, while 46% were rapid 
acetylators. Similar frequencies of rapid and slew phenotypes 
were obtained in several other studies involving Caucasian 
volunteers (Grant et al, 1983a; Gascon et al, 1987; Tang et al, 
1987; Kilbane et al, 1990). In contrast, 84% of elderly subjects 
>60 y were slew acetylators, which is slightly greater than the 
frequency of slow acetylators found by Gachalyi et al (1984) and 
Szorady et al (1987).
While a simple technique involving urine collection, such as the 
caffeine test may be less sensitive in determining acetylator 
phenotype than tests involving collection of several blood and 
urine samples, it may prove to be very useful for large 
population studies, as originally proposed by Grant et al 
(1984). The main problem with nearly all of the chemical tests 
performed to date is that they are only capable of phenotyping 
and not genotyping individuals. While seme studies claim to 
distinguish the intermediate heterozygous acetylator phenotype 
(Tang et al, 1987; Kilbane et al, 1990; Irshaid et al, 1991), 
most methods do not allow such classification in vivo. In fact, 
most in vitro studies (Kirlin et al, 1989; Land et al, 1989), 
with the exception of that by Kirlin et al (1991), have also 
failed to separate rapid, intermediate and slew phenotypes. Tang 
et al (1987) and Kilbane et al (1990) both measured the AAMU/ 
(AAMU + 1-MX + 1-MU) metabolite ratio to determine NAT activity 
and claimed that the caffeine test could be used to genotype 
individuals. This study, like most others was unable to confirm 
such results as only two phenotypes could be observed following
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oral administration of caffeine. Tang et al (1987) assigned 
arbitary antimodes in the frequency distribution at 0.36 and 
0.58, while Kilbane et al (1990) assigned antimodes at 0.38 and 
0.66 to separate phenotypes. Although the present study has used 
the same metabolite ratio as these two groups, it is important 
that each study defines its own antimode, rather than take those 
assigned to frequency distributions in other studies because 
until the caffeine test is standardized, differences in 
methodology will inevitably result in variation between NAT 
activities determined in different laboratories.
The caffeine test for testing NAT phenotype is worthy of 
continued study in light of the fact that it requires oral 
intake of an innocuous compound for widespread use. Unlike tests 
using other probe drugs, it does not appear necessary to 
strictly monitor either the timing or the quantity of caffeine 
intake or urine collections during the test (Evans, 1989). Thus 
caffeine may permit the phenotyping and possibly genotyping of 
individuals for NAT with minimal inconvenience.
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6.2 N-ACETYLTRANSFERASE ACnVITY IN PATIENTS WITH FAP. 
COLORECTAL CARCINOMA AND OTHER NEOPLASTIC DISORDERS
6.2.1 Introduction
N-acetyltransferase is responsible for the metabolism of certain 
carcinogenic aromatic amines. While hepatic NAT activity is 
thought to represent a detoxification pathway (Beland & 
Kadlubar, 1986), an enzyme closely related to NAT in bowel 
tissue can activate arylamines into ultimate carcinogens that 
may bind to DNA (Flammang & Kadlubar, 1986). Since NAT is
subject to genetic polymorphism (Evans et al, 1960), phenotypic 
variation in the activity of this enzyme may contribute to
individual differences in susceptibility to arylamine-induced 
carcinogenesis.
6.2.2 Results
NAT activities in patients with colorectal cancer, leukaemia, 
carcinoma of the lung, head and neck and in patients with FAP
are shewn in Table 6.2.1. NAT activity of a group of 277 control
volunteers is also shown.
6.2.3 Effect of Age
No correlation between subject age and NAT activity existed in 
37 patients with FAP (r=0.0853; p>0.5) or in 16 of their
relatives at risk for the disease (r=0.3007; p>0.1). In
addition, age was found to have no effect on NAT activity in 12 
patients with colorectal carcinoma (r=0.0596; p>0.5). This
relationship was also found if the effect of age was studied for 
slow and rapid acetylator phenotypes separately.
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Table 6.2.1 - NAT activity in patients with FAP, their relatives
at risk for FAP, patients with neoplastic disease
and control volunteers
Group n Mean activity Median Range
± SEM
FAP 37 0.324 + 0.024 0.283 0.054 - 0.640
At Risk 16 0.414 + 0.031 0.388 0.249 - 0.697
Colorectal cancer 12 0.329 + 0.031 0.299 0.184 - 0.586
Lung, head & neck 51 0.405 + 0.019 0.387 0.170 - 0.728
Leukaemia 54 0.400 + 0.022 0.379 0.068 - 0.706
Controls 277 0.450 + 0.010 0.443 0.077 - 0.886
The mean age of 37 patients with FAP was 36.38 + 3.85 y and was 
not significantly different to the mean age of 36.62 + 3.43 y in 
a group of 248 control volunteers under 60 y of age (p>0.5). The 
mean age of 16 relatives at risk for FAP was 31.25 + 4.03 y and 
was also not significantly different from the mean age of 248 
controls (p>0.05).
The mean age of 12 patients with cancer of the large bowel was 
not significantly different from the mean age of 72.9 + 3.03 y 
in a group of 29 control subjects over 60 y (p>0.1).
The mean ages of 54 patients with leukaemia and 51 patients with 
carcinoma of the lung, head and neck were significantly lower 
(p<0.001 and p<0.05, respectively) than that of the elderly 
control group over 60 y old. Enzyme activities in patients with 
lung cancer and leukaemia were thus compared to both elderly
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Figure 6.2.2 - NAT activity in relatives at risk for FAP 
compared to age-matched controls.
2 2 2
controls and the control group <60 y.
NAT activity in patients with FAP was highly significantly less 
than that of 248 age-matched controls (p<0.000005) (Fig.6.2.1) 
and less than that of the whole control population of 277 
volunteers (p<0.00005).
NAT activity in relatives at risk for FAP was also less than 
that of 248 age-matched controls (p<0.01) (Fig.6.2.2) but not 
significantly different to that of the whole control population 
(p>0.1). NAT activity of FAP patients was significantly lower 
than that of their relatives at risk (p<0.05) (Fig.6.2.3).
NAT activities for patients with colorectal cancer, leukaemia 
and lung, head and neck cancer were compared to elderly 
age-matched and general population controls (Table 6.2.2). 
Patients with colorectal cancer had a mean NAT activity that was 
not significantly different from that of elderly age-matched 
controls (p>0.1) (Fig.6.2.4). Hcwever, NAT activity in these 
patients was significantly less than that of 277 general 
population controls (p <0.01). NAT acrtivity in 51 patients with 
carcinoma of the lung, head and neck was significantly higher 
than that of elderly controls (p<0.005) but similar to that of 
the whole population (p=0.05). NAT activity in 54 patients with 
leukaemia was also higher than that of elderly controls (p<0.05) 
but slightly less than that of the whole population (p=0.04).
The group of patients with FAP had lc»wer mean NAT activity than 
the patients with leukaemia (p<0.05) or carcinoma of the lung, 
head and neck (p<0.01). NAT activity in patients with FAP was 
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Figure 6.2.3 - NAT activity in patients with FAP, compared to 
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Figure 6.2.4 - NAT activity in patients with colorectal cancer, 
compared to age-matched controls.
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6.2.4 Genetic Control of N-Acetvltransferase Activity
The frequency distribution histograms for NAT activity in 37 
patients with FAP and 16 of their relatives at risk for FAP are 
depicted in Figs.6.2.5 and 6.2.6, respectively. The proportion 
of these patients and their relatives with slew NAT activity 
(ratio <0.48) is shewn in Table 6.2.3.
Table 6.2.3 - The proportion of FAP patients and their relatives 





FAP 29/ 37 (78.4%) 8/ 37 (21.6%)
Risk 10/ 16 (62.5%) 6/ 16 (37.5%)
Controls
-age-matched 134/248 (54.0%) 114/248 (46.0%)
-all 144/277 (52.0%) 133/248 (48.0%)
78.4% of the FAP patients were of the slew NAT phenotype 
(Fig.6.2.5). This was significantly greater than the proportion 
of age-matched controls with slow NAT activity (p<0.01) and also 
significantly greater than the proportion of slew acetylators in 
277 general population controls (pxO.Ol).
62.5% of the group at risk for FAP were of the slew NAT 
phenotype (Fig.6.2.6) which was not significantly different from 
number of age-matched controls (p>0.05) and general population 









Figure 6.2.5 - Frequency distribution histogram of NAT activity 
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Figure 6.2.6 - Frequency distribution histogram of NAT activity 
in 16 relatives at risk for FAP.
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acetylators in patients with FAP was not significantly greater
than that of their relatives at risk for FAP (p>0.05).
The proportion of 35 FAP patients with high P450IA2 activity and 
slew NAT activity was also calculated (Table 6.2.4) and compared 
to that of 226 age-matched controls (Table 6.2.5).
Table 6.2.4 - The proportion of FAP patients with slew NAT 
and high P450IA2 activity
P450IA2 activity 
Acetylation phenotype High % Lew %
Slow 9/35 (25.7%) 20/35 (57.1%)
Fast 1/35 ( 2.9%) 5/35 (14.3%)
Table 6.2.5 - The proportion of healthy controls <60 y with slew 
NAT and high P450IA2 activity
P450IA2 activity 
Acetylation phenotype High % Lew %
Slow 16/226 (7.1%) 99/226 (43.8%)
Fast 22/226 (9.7%) 89/226 (38.4%)
The proportion of FAP patients with both slew NAT activity and 
high P450IA2 activity is 25.7% in contrast to the proportion of 
7.1% in age-matched controls. While the proportion of subjects
with slew NAT and slow P450IA2 activities is similar for both 
groups studied, it appears that the number of fast acetylators 
is considerably reduced in FAP patients compared to age-matched 
controls.
The frequency distributions of NAT activity for patients with 
colorectal cancer, carcinoma of the lung, head and neck and 
leukaemia are shewn in Figs. 6.2.7, 6.2.8 and 6.2.9,
respectively. The proportion of these patients with the slew NAT 
phenotype (ratio <0.44) is shewn in Table 6.2.6.
Table 6.2.6 - The proportion of patients with colorectal cancer, 
leukaemia and carcinoma of the lung, head and neck 





Colorectal 10/ 12 (83.3%) 2/ 12 (16.7%)
Leukaemia 31/ 54 (57.4%) 23/ 54 (42.6%)
Lung,head & neck 29/ 51 (56.9%) 22/ 51 (43.1%)
Controls
-elderly 25/ 29 (86.2%) 4/ 29 (13.8%)
-all 144/277 (52.0%) 133/248 (48.0%)
83.3% of the patients with colorectal cancer were of the slew 
NAT phenotype (Fig.6.2.7). This was not significantly different 
from the proportion of slew acetylators in a group of elderly 
age-matched controls (p>0.05) but significantly different from
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Figure 6.2.7 - Frequency distribution histogram of NAT activity 
in 12 patients with colorectal cancer.
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Figure 6.2.8 - Frequency distribution histogram of NAT activity 
in 51 patients with carcinoma of the lung, head
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Figure 6.2.9 - Frequency distribution histogram of NAT activity 
in 54 patients with leukaemia.
the proportion of 277 general population controls with slow NAT 
activity (p<0.05). The proportion of slow acetylators in 
patients with colorectal cancer was not significantly different 
from that in patients with FAP (p>0.05) .
56.9% of patients with carcinoma of the lung, head and neck had 
slow NAT activity (Fig.6.2.8) which is significantly lower than 
the proportion of slow acetylators in elderly control subjects 
(p<0.01) but not significantly different from that of the 
general population (p >0.05). The proportion of lung cancer 
patients with slow acetylation phenotype was significantly less 
than that in patients with FAP (p<0.05).
Likewise, 57.4% of patients with leukaemia were slew acetylators 
(Fig.6.2.9) which was significantly lower than the proportion of
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elderly control subjects with slew NAT activity (p<0.01) hut not 
significantly different from general population controls 
(p>0.05). The proportion of slew acetylators in patients with 
leukaemia was significantly less than that in patients with FAP 
(p<0.05).
6.2.5 Discussion
The present study shews that a much greater proportion of 
patients with FAP were slew acetylators compared to control 
subjects. Relatives of the FAP patients, who are considered to 
be at risk for the disease also had lower mean NAT activity when 
compared to age-matched controls, although the proportion of 
slew acetylators in this group of relatives was not different to 
that of healthy subjects. The difference in proportion of 
acetylator phenotypes observed in patients with FAP may alter 
the way in which these patients metabolise carcinogenic 
arylamines.
N-CH-arylamines are recognised as proximate carcinogens and are 
generally more carcinogenic than their parent amines (Schut & 
Castonguay, 1984). Conversion of these proximate carcinogens to 
ultimate carcinogens, that bind to DNA, is thought to involve 
several acyltransferases (Schut & Castonguay, 1984; Kadlubar & 
Hammons, 1987). Hepatic NAT activity is thought to represent a 
detoxification pathway (Poupko et al, 1979; Beland & Kadlubar, 
1986). As patients with FAP tend to be slew acetylators, it is 
possible that they are less able to N-acetylate arylamines and 
detoxify activated N-OH arylamines in the liver. However, 
O-acetyltransferase (OAT) which is closely related to NAT 
(Flammang et al, 1985; Hein, 1988a; Land et al, 1989; Kirlin et
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al. 1989) is capable of activating N-OH arylamines into ultimate 
carcinogens (Flammang & Kadlubar, 1986). For species susceptible 
to arylamine-induced colon cancer, it has been proposed that 
biliary excretion of the N-OH-arylamine N-glucuronide (Foupko et 
al. 1979; Meerman et al, 1982), its deconjugation by bacterial 
b-glucuronidases and conversion of the N-OH-arylamine to an 
ultimate carcinogen, within the intestinal epithelium are 
critical steps leading to the initiation of tumorigenesis 
(Kadlubar & Beland, 1985). The glucuronidation of N-OH 
arylamines may be prevented by prior hepatic N-acetylation of 
the aromatic amine and thus N-acetylation of either the 
arylamine or the N-OH-arylamine is considered to be a 
detoxification step (King & Glcwinsky, 1983). Conversely, if the 
arylamine is initially N-hydroxylated, further activation may 
occur through O-acetylation. The pathway that predominates will 
therefore depend on levels of cytochrome P450, in addition to 
NAT (Beland & Kadlubar, 1986).
As NAT activity in bladder (Kirlin et al, 1989) and liver (Land 
et al. 1989) is much greater than OAT activity, for either slew 
or rapid acetylators, OAT mediated activation is probably minor 
in comparison to NAT-mediated detoxification of arylamines 
(Kirlin et al, 1989). This would also seem likely in view of the 
fact that the arylamine-DNA adducts in target tissues are 
non-acetylated derivatives (Beland et al, 1983; Kadlubar & 
Beland, 1985).
Results from the current study also suggest that the 
detoxification process involving hepatic NAT is more important 
than OAT activity in bowel tissue, as far more of FAP patients, 
who are at a high risk for developing bowel cancer, were slow
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acetylators. As a greater proportion of the FAP patients had 
high P450IA2 activity when compared to healthy subjects, in the 
present study, this strongly suggests that a large degree of 
activation of arylamines by P450IA2 and a low degree of 
detoxification of arylamines by NAT is occuring in FAP.
The importance of NAT activity can be illustrated by the fact 
that tissue susceptibility to N-OH-arylamines in the dog, can be 
correlated with the NAT enzyme system. For example, the 
administration of several arylamines to dogs leads to urinary 
bladder tumours, even though the dog has a total functional 
deficiency in the capacity to N-acetylate arylamines. These 
observations indicate that N-acetylation is not involved in 
arylamine activation in bladder carcinogenesis. The dog's 
inability to detoxify arylamines by NAT partly explains the high 
rate of arylamine-induced bladder cancer in this species (Lcwer, 
1982).
The fact that the present study recorded a greater proportion of 
slew acetylators in a group of patients with FAP is not unusual. 
Patients with bladder cancer are more commonly slew acetylators 
(CSrtwright et al, 1982; Evans et al, 1983; Hanssen et al, 1985; 
Ladero et al, 1985; Vineis et al, 1990) with high P450IA2 
activity (Bartsch et al, 1990). The highest arylamine- 
haemoglobin adducts measured in the study by Bartsch et al 
(1990) were found in the "slcw-acetylator and fast-oxidiser" 
group of subjects. Lowest adduct concentrations were found in 
the "fast-acetylator and slcw-oxidiser" group. It is proposed 
that individuals at risk for bladder cancer are less able to 
detoxify carcinogens that are activated hepatically by P450IA2, 
as they have the slew NAT phenotype and are more prone to
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bladder cancer than rapid acetylators (Hein, 1988a). The present 
results suggest that a similar situation exists for patients 
with FAP, in that a greater proportion of these patients have 
high P450IA2 activity and slew NAT activity than healthy 
controls. It is tempting to speculate that the relatives at risk 
for FAP with the slew- acetylation and fast-oxidation phenotypes 
are more susceptible to developing FAP. Thus, determining both 
phenotypes may allow a better prediction of the risk of FAP and 
bladder cancer, than measuring NAT phenotype alone. These 
findings support the role of NAT activity in the detoxification, 
and P450IA2 in the activation of arylamines.
DNA adducts have been found to be distributed in the same 
pattern as foregut tumours in patients with FAP and such adducts 
are present in significantly greater amounts in these patients 
compared to controls (Spigelman et al, 1991). Bile from patients 
with FAP was found to impart a greater adduct load on small 
bcwel target mucosa than bile from control subjects, implying 
that the excess of DNA adducts detected in FAP mucosa resulted 
from carcinogens transported in bile (Spigelman et al, 1991). 
The present study suggests that the observed difference of DNA 
adducts and tumours in the forgut mucosa of patients with FAP 
may be partially attributed to the defective detoxification of 
carcinogens by NAT in the liver.
NAT activity and the frequency of slew acetylators in patients 
with colorectal cancer was not significantly different from that 
measured in an age-matched control group. As patients with this 
type of cancer tend to have a higher mean age than control 
subjects (Cartwright et al, 1982; Ladero et al, 1985;
234
Moller-Jensen, 1983), it is essential that enzyme activities in 
patients are compared to age-matched controls. When the 12 
patients with colorectal carcinoma were compared to 277 general 
population controls, there was a highly significant over- 
representation of slow acetylators in the patient group, in 
contrast to an equal representation of slew acetylators between 
patients and age-matched controls.
P450IA2 activity in these patients was not different from that 
of healthy subjects. Taken together, these findings suggest that 
arylamine metabolism is not altered in colorectal cancer. This 
observation is contradictory to two studies which claimed that 
rapid acetylators were more prone to bowel cancer than control 
subjects (Lang et al, 1986; Ilett et al, 1987). There are 
several possible reasons for the disparity in results between 
our study and those by other groups.
Firstly, caffeine metabolite ratios were used in the present 
study to determine NAT activity, whereas Ilett et al (1986) and 
Lang et al (1987) used sulphamethazine to determine acetylation 
phenotype. In theory, this should not account for the difference 
in results, as complete concordance between caffeine and 
sulphamethazine tests has been shewn (Tang et al, 1991). 
However, in patients with neoplastic disease, it is possible 
that hypoalbuminaemia may be present (Webster et al, 1990). As 
sulphamethazine is highly bound to plasma albumin, the plasma 
concentrations may be altered in patients with cancer unless 
their liver function is normal. Neither of the studies listed 
above report on patients liver or kidney function, whereas the 
present work only studied patients with liver and kidney 
function values within the normal range.
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Secondly, it is essential that the ethnic composition of each 
group being studied is known (Evans, 1984) as the distribution 
of phenotypes varies in different ethnic and geographic 
populations (Weber & Hein, 1985; Evans, 1989). This study
therefore included Caucasian subjects only. The other studies 
hcwever, either failed to define the ethnic origin of their case 
and control groups, or included subjects of varying ethnic 
origin in their study, such as Hispanics, Orientals and American 
white and blacks. Whereas around 50% of Caucasian populations 
are slew acetylators, only 10% of the Japanese (Grant et al. 
1983 a,b; Deguchi et al, 1990) and 5% of Eskimos are slew
acetylators, while 68% of Arabians (Irshaid et al, 1991), 83% of
Egyptians and 90% of Moroccans are slew acetylators (Uetrecht & 
Woosley, 1981; Weber & Hein, 1985). While NAT phenotypes are 
presumed to be similar in frequency between white and black 
Americans (Evans et al, 1960), Rolling et al (1991) found a 
greater prevalence of fast acetylators among American black 
compared to white children. In addition, Tang et al (1991) 
shewed that Oriental slew acetylators had lewer NAT activity 
than slew white acetylators. Therefore, data from studies 
including American blacks, Orientals and Europeans should be
interpreted with caution, particularly when the study is 
investigating cancer incidence, since individual susceptibility 
for different cancers varies remarkably with ethnic and 
geographic location (Polednak, 1989).
Before any association between acetylator phenotype and a 
disorder can be made, satisfactory control groups are required 
(Evans, 1984). Patient groups in the present studies were 
compared to general population controls. Other patients who do
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not suffer from the disease being investigated are not
considered to be good controls (Evans, 1984). The illness of the 
control patients used in some studies (Lang et al, 1986; Ilett 
et al. 1987) may have some relationship to the NAT polymorphism 
or the disease condition being investigated may interfere with 
the phenotyping test. There is a possibility that acetylation 
capacity is increased in neoplastic disease (Evans, 1984) which 
may explain the over-representation of rapid acetylators in 
colorectal cancer patients found in some studies.
Although patients with bowel cancer had undergone colectomy, as 
in the other studies, it seems unlikely that colectomy altered 
the phenotyping test. Caffeine is almost exclusively hepatically 
metabolised (Bonati et al, 1982) and it is NAT activity in this 
organ that has been measured in the present study. Certainly no 
significant correlation between the time of tumour resection and 
acetylation phenotype was found in the study by Ilett et al
(1987). This is to be expected because NAT is an inherited, 
non-inducible phenomenen. Moreover, duodenal tumours may occur 
both before and after colectomy in patients with FAP, suggesting 
that the metabolic abnormality responsible for the putative 
excretion of carcinogens into bile is not greatly influenced by 
this operation.
The present study has found that patients with colorectal cancer 
have less acetylation capacity than healthy controls but similar 
acetylation capacity to healthy elderly, age-matched volunteers. 
Circumstantial evidence against rapid acetylation predisposing 
to bowel cancer is the fact that in Japan, where 90% of the 
population are rapid acetylators (Grant et al, 1983 a,b; Deguchi 
et al, 1990), the incidence of colorectal carcinoma is very lew
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(Moller-Jensen, 1983; Polednak, 1989). Also, an animal model for 
large bowel cancer utilises the rat, an animal which does not 
exhibit the acetylation polymorphism as all exhibit slew 
acetylation.
As the present study involves only 12 colorectal cancer 
patients, a number of well controlled studies are clearly needed 
to determine the role of NAT phenotype in bcwel carcinogenesis. 
The role of acyltransferases in activation and deactivation of 
arylamines is complex, as is the relative contribution of 
hepatic and extrahepatic mechanisms in the process leading to 
cancer initiation.
The proportion of patients with leukaemia and carcinoma of the 
lung, head and neck who were slew acetylators was not 
significantly different to that in a group of general population 
controls. The fact that fewer of these cancer patients had slow 
NAT activity compared to elderly controls is probably explained 
by the fact that acetylation capacity may be reduced with age. 
Philip et al (1987b) also found no association between NAT 
phenotype and the incidence of lymphoma in 101 white Caucasian 
subjects. Drozdz et al (1987) found that 83% of patients with 
carcinoma of the larynx were slew acetylators compared to 60% of 
control subjects, even though the patients were under 60 years 
old and age was not significantly different between the two 
groups. Ritter et al (1986) however, found that the distribution 
of acetylator phenotypes in patients with cancer of the larynx 
and pharynx was similar to that of controls. The fact that 
bronchial cancer does not appear to affect subject phenotype in 
the present study, is in agreement with several other studies
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(Burgess & Trafford, 1985; Philip et al, 1988; Roots et al. 
1988).
Few of the enzymes involved in arylamine metabolism (NAT, 
P450IA2, glutathione transferase) shew any type of co-ordinate 
regulation with each other in man (Ketterer et al, 1991). Thus, 
in pathways that involve catalysis by several different enzymes, 
one would expect to see several independent variations in the 
human population, interacting with each other. It is possible 
that a relationship between risk factors, such as NAT and 
P450IA2 phenotypes and macrcmolecular bound carcinogens derived 
from environmental exposure exist in FAP. A similar relationship 
between genetics and the environment is thought to exist in lung 
cancer aetiology, although the carcinogens are likely to be 





Hie present studies were undertaken to investigate the potential 
of caffeine as an in vivo probe for hepatic enzyme activities in 
man. Sensitive analytical techniques were developed to allcw 
accurate quantitation of caffeine and its metabolites in urine 
and to demonstrate the in vitro biotransformation of caffeine 
and paraxanthine by human cDNA expressed cytochrome P450IA1.
The urinary caffeine test, involving measurement of caffeine 
metabolite ratios was developed to estimate the activities of 
the P450IA isozymes and N-acetyltransferase, which may be of 
toxicological significance in the pathogenesis of chemically- 
induced cancers (Vineis et al, 1990; Kawajiri et al, 1991).
The complexity of caffeine biotransformation is well documented 
(Bonati et al, 1982; Tang et al, 1983; Amaud, 1984) with the 
potential for production of many urinary metabolites arising via 
combinations of N-demethylation, 8-hydroxylation and ring 
cleavage reactions. Difficulties to be encountered involve the 
potential for overlapping pathways of formation of a given 
caffeine metabolite, each of which may be mediated by different 
enzymes to varying degrees. In addition, the finding that 
polymorphic liver N-acetyltransf erase mediates the production of 
yet another caffeine metabolite means that it is necessary to 
quantify AFMU, a p>olar and chemically labile compound in order 
to estimate the relative importance of the caffeine pathways 
(Callahan et al, 1983). Nonetheless, accurate analytical 
determination of AAMCJ, the deformylated metabolite of AFMJ can 
be accomplished such that an index of acetylator p>henotype can 
be determined in man (Section 2.6.3).
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Considerable interindividual differences in P450IA activity were 
found in a healthy population, which reflect at least in part 
variation in genetic constitution as the distribution of 
activity within the population appeared to be bimodal (Section
5.1). As P450IA activity was higher in smoking subjects and in 
patients with carcinoma of the lung, head or neck compared to 
healthy nonsmokers, it would appear that the caffeine test is 
sensitive to induction by a component (s) of cigarette smoke and 
that P450IA activity, determined by the caffeine test may be of 
value as a marker for detection of susceptibility for lung, head 
or neck cancer (Section 5.2).
As P450IA2 activity is also subject to wide interindividual 
variation (Section 5.1) and is capable of activating aromatic 
amines (Nebert, 1991), identification of persons within the 
population with high P450IA2 activity may be important in 
determining susceptibility for aromatic amine-induced cancers. 
The observed increase in P450IA2 activity in patients with FAP 
(Section 5.4) may be due to induction by aromatic amines and may 
be involved in the development of FAP. In addition, the finding 
that more patients with FAP and colorectal carcinoma are of the 
slew acetylation phenotype than healthy subjects, such that 
fewer of these patients may be able to inactivate potential 
carcinogenic aromatic amines, further supports the involvement 
of polymorphic enzymes in chemically-induced diseases (Section
6.2).
In conclusion, results from the present study indicate that 
caffeine is of potential value as a probe for P450IA isozymes 
and N-acetyltransferase activities. In addition to detection of 
enzyme induction by environmental agents, such as cigarette
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smoke, the caffeine test may be of clinical value in determining 
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Appendix la -Effect of caffeine consumption on urinary metabolite profiles
1 CCB: 0—8 h urine
Vol Age Sex Weight Height Smoker OCS Urine Amount excreted in urine
(kg) (cm) vol 17-DMX 17-DMU 1-MX 1-MU AAMU CAFF
(ml) (mg)
#1 AS 22 F 63.6 178 — Y 1260 3.301 0.768 11.8 19.17 39.1 2.431
#2 SF 27 F 73.1 173 - Y 636 5.062 3.631 13.6 25.85 46.4 3.008
#3 SE 20 F 59.5 165 + 380 2.789 1.086 12.2 16.19 23.8 0.133
#5 FM 22 F 69.9 163 + Y 505 1.479 0.404 15.3 28.29 25.5 0.717
#6 BB 28 M 91.3 193 - 605 2.916 1.240 9.94 21.93 31.8 0.471
#7 RB 32 M 70 178 - 475 4.322 1.111 8.27 19.87 44.1 0.313
#8 DS 54 F 64.5 165 - 535 5.098 0.946 7.35 25.81 60.9 0.625
#9 SO 22 F 57.2 168 + Y 239 2.970 0.738 15.7 24.66 50.7 0.380
#10 EL 34 F 50 165 - 535 1.706 0.171 9.98 17.72 27.4 0.374
#11 JM 28 F 52.7 174 - 473 2.511 0.856 9.26 8.551 25.8 0.614
#12 JK 44 F 63.6 168 - 775 5.138 2.022 24.1 59.18 190. 0.550
#13 PL 23 M 54 178 - 383 4.703 0.543 12.6 9.479 38.1 1.206
#14 MB 30 M 82.6 183 + 250 5.455 0.752 25.8 36.14 21.5 0.367
#15 MH 31 M 66.7 165 - 870 6.96 1.096 5.88 16.05 76.0 1.827
#16 HH 24 F 60.4 168 - Y 512 4.449 1.454 11.0 13.83 25.2 2.135
#17 CP 23 M 63.6 169 + 360 2.350 0.507 8.27 8.614 17.3 0.118
#18 SA 34 M 73.1 178 - 495 6.301 1.148 26.4 24.77 48.8 0.455
Appendix lb -Effect of caffeine consumption on urinary metabolite profiles
1CCB: 0-8 h urine
Vol Age Sex Weight Height Smoker OCS Urine Amount excreted in urine
(kg) (cm) vol. 17-DMX 17-DMU 1-MX 1-MU AAMU CAFF
(ml) (mg)
#2 SF 27 F 73.1 173 - Y 500 4.115 1.095 6.65 12.87 32.9 0.495
#3 SE 20 F 59.5 165 + 627 1.435 0.332 11.4 14.00 20.8 0.062
#6 BB 28 M 91.3 193 - 440 2.745 1.328 15.9 16.77 23.9 0.374
#7 RB 32 M 70 178 - 555 3.313 0.610 3.90 9.906 28.6 0.516
#8 DS 54 F 64.5 165 - 503 2.625 0.477 6.82 19.16 36.3 0.150
#9 SO 22 F 57.2 168 + Y 369 5.826 1.055 23.6 38.37 99.7 1.051
#12 JK 44 F 63.6 168 - 775 2.945 0.627 12.1 29.68 88.6 0.193
#13 PL 23 M 54 178 - 432 5.374 0.760 10.6 8.959 27.3 0.855
#16 HH 24 F 60.4 168 - Y 266 2.189 0.928 10.1 12.16 13.9 0.585
#17 CP 23 M 63.6 169 + 785 3.336 0.447 19.3 23.33 33.3 0.423
Appendix 1c -Effect of caffeine consumption on urinary metabolite profiles
4 CCBs; 0-8 h urine.
Vol Age Sex Weight Height Smoker OCS Urine Amount excreted in urine
(kg) (cm) vol 17-DMX 17-DMU 1-MX 1-MU AAMU CAFF
(ml) (mg)
#2 SF 27 F 73.1 173 — Y 1089 4.072 0.794 5.21 14.20 26.5 0.522
#3 SE 20 F 59.5 165 + 400 4.012 0.568 11.1 16.52 21.4 0.116
#7 RB 32 M 70 178 - 390 7.062 1.298 10.3 24.16 53.0 0.897
#8 DS 54 F 64.5 165 - 618 5.654 1.341 13.4 37.76 60.1 0.729
#9 SO 22 F 57.2 168 + Y 525 6.856 1.606 21.7 33.36 90.1 1.701
#11 JM 28 F 52.7 174 - 275 2.868 0.836 12.6 11.19 32.6 0.343
#12 JK 44 F 63.6 168 - 495 2.192 0.970 10.0 25.81 82.7 0.311
#13 PL 23 M 54 178 - 385 15.04 2.225 17.2 13.81 52.7 1.978
#14 MB 30 M 82.6 183 + 415 4.872 1.477 30.5 35.44 29.5 1.506
#15 MH 31 M 66.7 165 - 690 7.410 0.903 12.9 34.90 56.9 0.227
#16 HH 24 F 60.4 168 - Y 315 12.72 1.335 23.4 29.28 36.8 0.973
#17 CP 23 M 63.6 169 + 555 6.676 0.388 20.4 37.00 46.6 1.287
#18 SA 34 M 73.1 178 - 1050 11.23 1.879 29.4 35.51 103. 2.436
#19 SH 50 F 62.3 161 - 775 9.462 1.154 18.1 28.00 77.5 2.821
#60 AG 25 M 82.8 184 - 860 12.04 0.928 28.9 34.90 34.4 0.507
#61 DB 39 F 63.2 168 + 180 6.951 2.608 30.3 23.01 14.4 0.775
#70 PB 23 M 66.7 165 - 330 7.748 1.296 39.9 7.923 107. 0.412
#71 YK 26 F 60.4 162 - 375 4.935 0.57 5.94 6.975 39.8 0.663
#86 HB 34 F 64.5 165 - 400 3.376 0.468 5.86 6.188 13.1 0.052
Appendix Id -Effect, of caffeine consumption on urinary metabolite profiles
1 CCB: 2-6 h urine.
Vol Age Sex Weight Height Smoker OCS Urine Amount excreted in urine
(kg) (cm) vol 17-DMX 17-DMU 1-MX 1-MU AAMU CAFF
(ml) (mg)
#2 SF 27 F 73.1 173 — Y 120 1.852 0.201 4.85 9.716 11.9 0.813
#4 -AT 28 F 60.3 161 - 85 0.821 0.041 0.90 2.106 10.7 0.048
#7 RB 32 M 70 178 - 115 1.420 0.194 2.79 5.874 16.4 0.570
#9 SO 22 F 57.2 168 + Y 240 3.372 0.343 12.7 9.837 41.4 0.794
#11 JM 28 F 52.7 174 - 70 1.204 0.645 3.60 3.670 7.80 0.379
#12 JK 44 F 63.6 168 - 205 1.582 0.576 6.69 16.38 55.6 0.444
#13 PL 23 M 54 178 - 120 3.008 0.471 3.01 2.409 8.85 0.709
#14 MB 30 M 82.6 183 + 96 1.392 0.133 5.34 8.4 5.83 0.348
#15 MH 31 M 66.7 165 - 195 2.154 0.265 4.30 12.77 19.6 0.520
#16 HH 24 F 60.4 168 - Y 120 2.428 0.331 4.5 5.496 7.84 1.034
#17 CP 23 M 63.6 169 + 50 0.433 0.069 1.88 4.61 4.58 0.207
#18 SA 34 M 73.1 178 - 130 2.853 0.240 5.49 8.591 27.8 0.473
#19 SH 50 F 57.2 152 - 120 2.109 0.148 3.36 5.102 12.5 0.738
#60 AG 26 M 79.4 183 - 39 0.929 0.053 1.65 2.110 7.12 0.084
#61 DB 38 F 63.6 168 + 130 3.399 0.299 9.43 11.42 10.2 0.208
#70 PB 23 M 66.2 185 - 110 1.837 0.217 7.13 7.568 24.9 0.269
#71 YK 32 F 52 160 - 79 1.087 0.105 1.35 1.899 13.0 0.255
#86 HB 39 F 61 165 - 150 4.000 0.306 5.53 11.30 16.3 0.028
Appendix 2a -Effect of timing of urine collection on urinary metabolite
profiles - 1 CCB.
Vol. Urine Amount excreted in urine Enzyme Activities
vol 1—MX 1-MU 17-DMU 17-DMX AAMU P450IA NAT XO
(ml) (mg)
#2 SF Blk 420 11.0 22.9 0.835 3.460 44.54 22.68 0.567 2.07
2hr 65 2.06 3.71 0.115 0.854 9.034 17.34 0.609 1.80
4hr 250 3.36 6.38 0.217 1.637 20.87 18.70 0.681 1.89
6hr 450 2.27 4.55 0.135 1.287 14.05 16.23 0.672 2.00
8hr 220 1.99 3.70 0.132 0.726 7.341 17.95 0.563 1.85
#9 SO Blk 325 10.0 18.8 0.490 2.392 33.31 26.04 0.534 1.87
2 hr 165 2.90 4.51 0.282 0.554 9.431 30.42 0.559 1.55
4 hr 180 4.21 6.06 0.176 1.018 15.91 25.71 0.607 1.43
6hr 90 3.34 4.58 0.18 0.98 11.68 20.02 0.595 1.36
8 hr 57 1.51 2.18 0.157 0.406 5.363 22.25 0.592 1.44
#12 JK Blk 190 8.25 19.2 0.376 2.202 36.36 29.01 0.569 2.33
2 hr 200 2.52 6.56 0.096 0.638 16.92 40.78 0.650 2.59
4 hr 225 1.93 4.32 0.137 0.634 14.12 32.13 0.692 2.22
6hr 195 2.33 6.22 0.064 0.608 13.48 36.24 0.611 2.66
8hr 51 1.27 3.10 0.062 0.414 7.184 27.92 0.621 2.44
#14 MB Blk 495 44.5 64.1 0.841 8.890 47.47 17.57 0.303 1.44
2hr 74 8.05 10.9 0.216 1.471 10.28 19.87 0.351 1.35
4hr 180 9.41 13.1 0.27 1.690 9.003 18.67 0.285 1.39
6hr 115 5.90 6.62 0.058 1.185 8.351 17.61 0.399 1.12
8hr 125 5.04 6.40 0.048 1.03 6.995 17.91 0.379 1.26
#16 HH Blk 265 12.9 15.4 2.003 6.601 20.00 7.338 0.413 1.19
2hr 93 4.52 5.55 0.558 2.189 6.880 7.747 0.405 1.22
4 hr 185 3.08 3.56 0.351 2.105 7.011 6.488 0.513 1.15
6hr 162 2.75 3.41 0.330 2.246 5.645 5.261 0.477 1.23
8 hr 51 1.99 2.38 0.241 0.854
Blk 325 22.2 31.1 1.342 9.756
2 hr 425 8.49 12.7 0.323 5.040
4 hr 272 4.86 6.45 0.443 3.557
6hr 200 2.6 4.23 0.23 2.168
8 hr 140 3.30 5.28 0.254 1.981
Blk 12 0.76 1.22 0.020 0.180
2 hr 130 5.95 9.72 0.288 4.355
4 hr 155 6.15 9.97 0.421 6.731
6hr 125 5.97 9.74 0.275 4.807
8 hr 100 6.75 9.84 0.271 3.652
3.644 9.388 0.454 1.19
92.17 14.91 0.633 1.40
35.15 11.18 0.623 1.49
15.98 7.677 0.585 1.32
11.36 8.395 0.624 1.63
14.20 11.50 0.623 1.59
2.676 25.79 0.573 1.59
22.10 8.676 0.584 1.63
20.13 5.387 0.555 1.61
18.68 7.155 0.543 1.63
27.41 12.05 0.622 1.45
Appendix 2b -Effect of timing of urine collection on urinary metabolite
profiles - 4 CCBs.
Vol.
Urine Amount excreted in urine Enzyme Activities
vol
(ml)
1-MX 1-MU 17-DMU 17-DMX AAMU 
(mg)
P450IA NAT XO
#2 SF Blk 450 16.0 27.8 0.949 5.652 52.17 16.99 0.543 1.74
2hr 200 3.21 6.1 0.292 2.768 12.96 8.049 0.581 1.89
4hr 760 3.47 7.21 0.562 4.21 20.33 7.368 0. 655 2.07
6hr 505 2.35 4.36 0.505 2.484 9.923 6.699 0.596 1.85
8hr 168 2.31 4.30 0.283 1.402 6.961 9.680 0.512 1.86
#9 SO Blk 200 14.8 28.6 0.872 3.568 71.01 32.09 0.620 1.93
2hr 38 3.28 4.69 0.122 0.546 12.28 37.08 0. 606 1.42
4hr 35 2.52 3.78 0.099 0.401 10.00 40.59 0.613 1.49
6hr 42 2.25 3.53 0.116 0.498 13.58 38.81 0.701 1.56
8hr 59 2.86 4.63 0.220 1.248 14.20 17.37 0. 654 1.61
#12 JK Blk 315 11.4 21.7 0.431 4.951 59.69 18.76 0.642 1.89
2hr 260 5.50 13.7 0.166 1.679 46.98 39.43 0.709 2.49
4hr 42 1.84 4.73 0.136 0.523 14.70 40.61 0. 691 2.57
6hr 41 2.39 6.22 0.688 0.9 20.37 32.22 0.702 2.59
8hr 42 1.72 4.22 0.184 0.553 14.21 36.43 0.704 2.44
#14 MB Blk 345 46.2 55.4 1.221 9.663 27.44 13.36 0.212 1.19
2hr 75 10.6 13.2 0.404 1.761 10.02 19.26 0.295 1.24
4hr 80 7.58 9.06 0.422 1.553 6.956 15.19 0.294 1.19
6hr 70 9.10 10.9 0.268 1.288 5.765 20.04 0.223 1.20
#16 HH Blk 273 6.46 9.03 1.193 4.206 10.43 6.167 0.402 1.39
2hr 62 2.83 3.14 0.300 0.813 4.545 12.93 0.432 1.11
4hr 212 2.99 3.58 0.438 2.253 4.594 4.957 0.411 1.19
6hr 82 1.62 1.94 0.319 1.111 3.999 6.814 0.528 1.19
8hr 56 2.14 2.58 0.346 1.172 3.275 6.824 0.409 1.20


















































Appendix 3 - 0-8 h urinary metabolite profiles: A population study, 
Vol Age Sex BMI Smoker OCS Urine 
vol 
(ml)
17-DMX 17-DMU 1-MX 1-MU AAMU CAFF
#2 SF 29 F 24.42
#4 AT 28 F 23.26
#7 RB 34 M 22.09
#9 SO 24 F 19.30
#11 JM 30 F 17.40
#12 JK 46 F 22.49
#13 PL 25 M 17.04
#14 MB 32 M 24.66
#15 MH 33 M 24.49
#16 HH 26 F 21.40
#17 CP 25 M 22.26
#18 SA 35 M 23.07
#19 SH 50 F 24.60
#20 TH 24 M 22.28
#21 CS 36 F 23.37
#22 PB 50 M 23.70
#23 MF 35 M 25.50
#24 DP 25 M —
#25 KM 25 M
#26 AY 25 M
#27 SH 27 M **
#28 AY 38 M
#29 JR 32 M
#30 SV 26 M —
#31 MK 29 M —
#32 RR 28 M
#33 IP 28 M
#34 LE 26 M **
#35 JS 28 M
Y 120 1.852 0.201 4.85 9.71 11.97 0.813
85 0.821 0.041 0.90 2.10 10.71 0.048
115 1.420 0.194 2.79 5.87 16.40 0.570
+ Y 240 3.372 0.343 12.7 9.83 41.40 0.794
70 1.204 0.645 3.60 3.67 7.800 0.379
205 1.582 0.576 6.69 16.3 55.63 0.444
120 3.008 0.471 3.01 2.40 8.856 0.709
+ 96 1.392 0.133 5.34 8.4 5.833 0.348
195 2.154 0.265 4.30 12.7 19.63 0.520
Y 120 2.428 0.331 4.5 5.49 7.848 1.034
4- 50 0.433 0.069 1.88 4.61 4.580 0.207
130 2.853 0.240 5.49 8.59 27.84 0.473
Y 120 2.109 0.148 3.36 5.10 12.50 0.738
+ 110 0.730 0.470 2.56 4.64 6.378 0.528
59 0.895 0.048 1.30 2.71 6.004 0.499
388 3.666 0.209 5.14 10.6 46.75 0.442
+ 325 2.060 0.123 7.21 12.0 14.75 0.848
_ 330 1.537 0.115 9.24 16.8 11.59 ND
— — 365 2.244 0.219 7.53 16.7 14.58 ND
— — 265 1.303 0.100 13.9 17.5 8.996 ND
— — 380 2.622 0.266 12.1 36.1 29.98 ND
— — 500 3.12 0.31 8.16 3.84 26.23 ND
— . — 900 10.22 0.126 14.2 24.6 14.29 ND
— 1250 11.62 0.325 18.9 31.5 32.2 ND
— 250 0.562 0.387 15.2 24.3 30.07 ND
— — 305 3.977 0.326 33.4 30.5 29.02 ND
— — 380 2.318 0.167 9.50 15.2 13.76 ND
— — 550 3.162 0.357 11.7 20.8 28.74 ND
— — 1100 14.52 0.253 11.6 28.3 43.56 ND




Vol Acre Sex BMI Smoker OCS U
17-DMX 1 7 -DMU 1-MX 1-MU AAMU CAFF
#36 JW 24 M —
#37 AE 29 M —
#38 AM 30 M —
#39 PH 32 M —*
#40 CB 39 F —
#41 JC 36 F —
#42 NT 27 M —
#43 DD 30 M —
#44 KS 29 F —
#45 JG 40 M —
#46 DL 43 F 22.18
#47 DP 54 F 28.71
#48 DK 43 F 21.41
#49 CG 61 M 26.22
#50 RG 52 M 24.14
#51 DH 47 M 25.29
#52 DF 50 M 21.49
#53 PS 34 M 25.69
#54 CD 33 F 22.45
#55 VH 55 F 29.26
#56 RD 61 M 25.49
#57 AG 39 M 18.62
#58 SS 56 M 34.25
#59 DD 57 M 30.47
#60 MW 46 M 22.62
#61 PB 45 M 22.53
#62 AB 52 M 28.13
#63 CH 28 M 26.48
#64 RB 20 M 27.36
— 280 2.752 0.067
— 280 0.660 0.316
— 500 5.195 0.28
— 530 3 .630 0.143
— 470 2.486 0.267
_ 260 2.446 0.140
— 800 4.656 0.312
— 420 3.133 0.394
— 650 4.459 0.201
— 625 7.281 0.75
780 10.55 1.365


















15.1 19.8 17.24 ND
23.0 42.4 20.58 ND
44.7 104. 57.18 ND
24.1 25.2 26.52 ND
11.2 19.9 21.94 ND
6.90 13.8 8.457 ND
27.9 22.1 19.82 ND
3.16 3.99 9.634 ND
11.5 13.0 33.16 ND
32.6 29.9 32.6 ND
25.3 34.9 20.99 1.099
20.4 23.3 23.91 0.920
26.3 27.3 42.78 0.225
12.6 27.5 15 1.815
35.2 55.3 101.6 5.699
43.0 56.8 68.21 2.565
29.3 41.4 83.41 1.024
72.8 87.0 32.99 5.865
28.0 20.5 26.77 4.509
16.9 17.7 11.43 0.189
35.1 30.6 65.80 1.787
64.6 51.3 173.9 7.506
31.7 22.1 20. 32 0.561
12.9 17.3 44.05 2.817
16.5 21.2 27.38 0.330
41.2 51.5 105.8 2.745
22.4 19.1 54.18 0.842
23.3 23.9 15.80 0.479
29.8 28.1 35.35 2.461
Appendix 3 - 0-8 h urinary metabolite profiles: A population study.
Vol Age Sex BMI Smoker ocs Urine
vol
(ml)
17-DMX 17-DMU 1-MX 1-MU AAMU CAFF
#65 AG 26 M 22.46 860 12.04 0.928 28.9 34.9 34.49 0.507
#66 DB 38 F 22.60 + Y 180 6.951 2.608 30.3 23.0 14.42 0.775
#67 RW 56 M 34.33 + 550 7.419 0.907 21.5 5.04 26.08 0.456
#68 AJ 32 M 26.97 + 1124 18.48 2.911 67.1 67.0 31.11 2.292
#69 MD 36 M 24.10 + 850 10.42 1.37.7 18.2 15.0 36.20 0.535
#70 RC 58 M 23.39 650 15.49 2.444 16.9 28.9 59.39 3.029
#71 BK 39 M 26.06 1050 18.59 1.89 31.7 40.0 26.13 1.039
#72 MB 32 M 24.93 1380 15.91 1.255 22.7 21.7 27.82 1.794
#73 AA 29 M 29.71 950 28.93 2.517 31.3 50.4 54.43 2.650
#74 SM 30 M 25.62 500 13.6 1.58 17.2 25.0 57.32 0.99
#75 PB 24 M 19.48 330 7.748 1.296 39.9 7.92 107.3 0.412
#76 YK 33 F 20.31 375 4.935 0.57 5.94 6.97 39.89 0.663
#77 SG 41 F 22.00 710 17.28 2.946 30.1 31.8 40.12 1.469
#78 JP 20 F 22.20 Y 475 10.75 1.092 35.6 39.6 27.27 2.09
#79 CA 20 F 20.89 Y 200 4.614 2.12 11.6 26.2 22.1 0.654
#80 CH 32 M 21.77 440 22.63 1.975 28.8 38.2 70.51 2.002
#81 AS 33 M 25.06 690 12.10 0.931 37.2 39.1 35.47 1.580
#82 PB 55 M 19.74 470 4.817 0.225 34.0 8.04 44.48 0.381
#83 WC 51 M 24.38 1020 11.66 1.193 14.4 20.5 53.10 1.785
#84 JY 55 M 26.09 785 8.870 0.949 6.76 11.2 33.68 0.855
#85 RP 62 M 24.80 1275 14.82 1.746 15.4 23.2 55.95 4.156
#86 AA 31 F 23.01 Y 410 5.428 1.467 5.76 7.02 19.67 1.738
#87 JC 34 F 22.12 1260 14.16 1.738 19.3 24.7 22.18 2.482
#88 WE 49 F 29.55 480 2.587 0.393 8.16 6.19 13.99 0.787
#89 JG 57 F 20.72 Y 525 6.536 0.934 8.4 11.3 51.69 1.795
#90 YC 38 F 21.52 185 6.630 1.250 25.2 30.0 40.92 0.762
#91 HB 38 F 21.10 400 3.376 0.468 5.86 6.18 13.18 0.052
#92 JH 25 F 24.80 + 470 6.222 1.015 13.3 19.1 54.52 0.869
#93 GW 33 F 22.49 + 1005 22.83 2.281 89.1 79.5 109.9 4.803
Appendix 3 - 0-8 h urinary metabolite profiles: A population study.
Vol Age Sex BMI Smoker OCS Urine
vol 17-DMX 17-DMU 1-MX 1-MU AAMU CAFF
(ml)
#94 MR 32 M 23.95 585 11.57 1.000 33.0 35.4 41.58 1.585
#95 MB 32 M 21.57 660 11.96 1.590 76.4 25.5 78.17 0.976
#96 SC 27 F 19.62 + Y 630 9.859 1.045 13.5 17.7 19.20 1.650
#97 PA 48 F 28.02 800 15.98 2.04 26.6 27.3 43.08 4.064
#98 SH 23 F 19.83 + Y 750 7.59 1.342 10.6 9.65 22.49 1.275
#99 AP 21 F 22.54 600 4.692 0.708 13.0 17.3 19.29 0.324
#100 NC 29 F 20.83 + 820 10.78 1.336 52.2 36.7 51.55 1.344
#101 HC 26 M 27.83 330 10.15 1.884 19.7 26.2 31.40 1.560
#102 TW 40 M 29.26 1350 16.86 1.363 19.5 36.0 14.66 0.607
#103 CL 57 M 24.72 860 25.93 2.107 28.6 39.2 96.39 3.534
#104 JP 58 M 23.17 1075 27.65 2.762 50.3 64.7 82.90 3.268
#105 AW 38 M 25.77 + 870 11.97 1.218 20.5 31.5 19.00 1.461
#106 WP 43 M 23.05 580 1.722 0.348 12.8 10.8 25.20 0.603
#107 SC 32 F 21.82 Y 185 4.649 1.800 7.98 14.3 42.97 1.320
#108 ER 49 F 20.09 1360 7.316 0.163 3.07 8.98 10.44 2.271
#109 MH 26 M 24.31 850 12.75 1.19 12.7 16.0 30.72 2.397
#110 JS 30 M 24.93 970 27.18 2. 386 32.6 63.0 146.4 2.628
#111 AF 39 M 28.08 235 3.823 1.621 6.63 10.7 47.84 0.589
#112 RB 41 M 25.77 510 12.28 1.555 20.1 41.3 113.9 1.744
#113 IB 53 M 27.32 685 13.50 2.000 10.4 24.8 13.04 2.363
#114 OC 57 M 26.09 375 8.73 1.646 10.2 17.4 63.53 2.531
#115 FW 60 M 22.53 + 1000 16.05 1.62 15.9 33.7 99.68 1.92
#116 LQ 23 M 22.91 + 405 6.253 1.036 12.6 22.1 66.74 0.441
#117 GS 62 M 23.35 + 755 13.03 0.747 26.5 46.0 33.26 0. 649
#118 KW 29 M 21.82 1380 18.20 0.828 22.7 75.5 37.99 2.373
#119 JB 59 M 26.92 275 8.175 1.240 9.55 17.6 63.50 1.012
#120 DM 51 M 27.99 620 17.40 1.760 12.0 22.1 89.47 4.098
#121 MC 47 M 24.82 370 1.302 0.266 10.0 13.3 21.03 0.188
#122 BT 44 M 20.26 440 8.549 1.064 15.6 32.5 12.36 3.586
Appendix 3 - 0-8 h urinary metabolite profiles; A population study.
Vol Age Sex BMI Smoker OCS Urine
vol 17-DMX 17-DMU 1-MX 1-MU AAMU CAFF
(ml)
#123 HL 40 M 24.76 450 4.653 1.197 24.5 47.3 70.17 2.137
#124 GB 35 M 23.87 530 3.943 0.492 9.10 14.7 48.56 0.540
#125 JA 24 M 23 .86 700 10.32 1.512 9.65 9.77 36.58 2.086
#126 VB 56 F 26.13 355 7.188 1.309 12.5 12.8 18.59 1.522
#127 MB 52 F 24.10 830 8.416 0.514 24.3 53.4 30.27 2.365
#128 MS 36 F 27.42 Y 410 10.48 1.439 15.4 17.4 32.89 2.537
#129 ML 47 F 38.01 + 520 9.172 0.759 31.4 78.4 28.63 1.435
#130 DB 53 M 25.12 1080 5.389 1.490 13.4 13.3 60.30 1.285
#131 FM 56 M 25.85 740 10.01 0.273 19.4 41.7 27.41 1.990
#132 SB 30 M 23 .95 + 2055 4.623 0.965 26.9 25.1 44.49 4.171
#133 SK 37 F 21.52 + 930 5.886 0.344 8.36 10.7 72.39 1.664
Appendix 4 - 2-6 h urinary metabolite
Vol Age Sex BMI Smoker OCS
#134 AD 18 F 22.57 + Y
#135 EC 49 F 23.07
#136 ST 42 F 25.99
#137 EP 41 F 26.09 Y
#138 KW 18 F 20.85 Y
#139 DM 24 F 20.70
#140 AM 32 F 24.93
#141 VH 57 F 25.98
#142 RW 45 F 27.85
#143 LH 20 F 26.95
#144 LP 21 F 20.75 + Y
#145 TH 17 F 21.63 +
#146 JN 22 F 22.67 + Y
#147 JW 25 F 22.00 Y
#148 JW 22 F 21.07 +
#149 MW 46 F 23.78
#150 CC 23 F 28.58 Y
#151 JD 50 F 28.00
#152 DE 47 F 22.17
#153 JWW 38 F 21.25 Y
#154 JH 22 M 17.45
#155 PA 37 F 21.14
#156 PL 22 M 22.06 +
#157 EW 25 F 25.52 + Y
#158 JH 26 F 20.56
#159 LT 20 F 20.09 + Y
#160 LW 21 F 23.17
#161 SP 26 F 19.64
#162 CD 32 F 20.90 Y
profiles: A population study.
Jrine
vol 17-DMX17-DMU 1-MX 1-MU AAMU CAFF
(ml)
200 0.806 0.272 6.09 7.46 18.9 0.236
90 0.548 0.146 7.98 6.80 15.2 0.134
100 0.709 0.267 3.14 3.99 4.92 0.476
220 1.249 0.211 7.09 4.49 7.52 0.371
110 0.509 0.042 1.06 1.33 1.72 0.139
200 2.116 0.42 14.2 7.74 36.2 0.754
180 0.961 0.151 2.03 2.80 4.18 0.208
180 0.932 0.102 3.96 4.82 7.53 0.169
380 4.145 0.399 6.06 11.6 10.3 0.209
245 0.644 0.080 1.50 1.67 6.12 0.034
125 1.468 0.401 3.16 4.85 10.8 0.256
120 0.326 0.03 0.92 1.17 3.97 0.034
8 0.096 0.021 0.29 0.32 1.14 0.007
150 1.278 0.226 3.70 2.68 2.57 0.297
300 1.335 0.339 5.16 4.89 12.7 0.225
90 0.823 0.077 2.26 2.65 6.09 0.044
120 0.536 0.154 0.92 0.86 7.13 0.032
100 1.113 0.089 1.21 0.85 3.60 0.071
80 0.6 0.067 2.37 3.45 4.98 0.075
100 0.391 0.105 1.44 5.73 6.44 0.074
140 1.26 0.103 2.04 3.54 3.56 0.123
60 0.277 0.052 0.84 0.74 2.00 0.010
50 0.359 0.078 0.63 2.15 2.79 0.055
180 0.594 0.100 3.54 1.48 10.0 0.064
70 0.833 0.078 1.17 4.16 1.36 0.077
70 0.569 0.052 0.57 1.49 3.05 0.491
80 1.044 0.14 1.28 4.07 4.98 0.065
100 2.652 0.376 2.06 8.86 8.95 0.234
110 1.043 0.206 2.41 2.19 5.18 0.244
Appendix 4 - 2-6 h urinary metabolite 
Vol Age Sex BMI Smoker OCS l
#163 TM 25 F 22.58 Y
#164 AB 80 M 24.66
#165 ST 20 F 21.48 + Y
#166 SB 24 M 21.57
#167 EL 38 F 52.14
#168 JD 47 F 23.79 + Y
#169 LH 34 F 22.18
#170 PD 42 M 25.62
#171 SaS 25 F 20.27 + Y
#172 SuS 49 F 20.07 +
#173 JB 50 F 32.88
#174 DF 48 M 24.12
#175 DB 31 F 20.20 Y
#176 GR 31 M 20.42 +
#177 JB 23 F 21.05 Y
#178 JB M +
#179 JK 31 F 20.44 + Y
#180 AS 33 F 23.80
#181 EB 54 F 21.09 +
#182 EM 23 F 21.81
#183 VB 24 F 22.57
#184 JK 20 M 25.05
#185 AH 24 M 23.19 +
#186 AD 23 M 23.37
#187 TC 33 M 24.42
#188 TA 25 M 23.62
#189 RL 27 M 22.29
#190 MD 27 M 26.39 +
#191 TL 31 M 23.27
profiles: A population study.
vol 17-DMX17-DMU 1-MX 1-MU AAMU CAFF
(ml)
70 0. 686 0.058 1.46 6.82 5.54 0.184
300 3.291 0.372 3.33 23.1 13.2 ND
50 0.331 0.035 1.59 3.93 4.21 0.046
50 0.396 0.025 1.70 1.47 2.55 0.064
150 1.065 0.127 2.44 4.8 11.8 0.309
90 1.096 0.075 1.14 2.48 5.53 0.094
100 1.125 0.084 3.37 3.12 9.13 0.123
110 1.377 0.145 1.67 4.81 15.4 0.226
50 0.429 0.022 0.58 0.84 3.04 0.029
200 1.578 0.126 3.89 8.08 13.2 0.64
200 2.408 0.244 7.31 11.8 28.5 0.56
200 2.564 0.192 5.16 10.0 12.1 0.818
250 1.382 0.16 1.56 4.03 13.7 0.18
125 1.131 0.067 2.82 4.73 10.5 0.21
50 0.380 0.191 0.59 1.49 1.66 0.275
110 0.149 0.010 0.78 1.56 8.36 0.035
80 2.424 0.032 1.30 2.32 1.61 0.404
150 1.231 0.111 2.15 3.83 3.65 0.127
70 0.461 0.028 2.09 3.93 0.85 0.035
100 0.831 0.027 0.63 1.03 1.78 0.037
90 0.948 0.013 1.75 2.79 3.29 0.162
178 0.936 0.167 5.22 7.13 15.1 0.300
75 1.629 0.007 3.71 8.28 6.34 0.203
130 2.236 0.300 8.29 16.4 13.1 1.024
205 2.843 0.014 6.21 6.80 18.9 0.276
165 0.638 0.095 5.38 10.9 5.86 0.166
52 0.931 0.017 1.20 1.28 2.98 0.244
160 1.345 0.161 4.12 4.33 2.88 0.054






























2-6 h urinary metabolite profiles: A population study.
Sex BMI Smoker ocs Urine
vol
(ml)
17-DMX 17-DMU 1-MX 1-MU AAMU CAFF
M 29. 02 + 73 0.727 0.008 0.95 1.38 1.72 0.094
M 27.86 95 0.717 0.062 1.07 1.54 3.01 0.086
F 31.84 140 2.069 0.123 7.17 6.77 9.45 0.337
F 21. 52 + 90 0.446 0.114 2.20 2.97 2.88 0.207
F 23.90 Y 70 0.321 0.056 0.89 1.51 1.82 0.040
F 26.29 30 0.310 0.007 0.47 0.74 1.95 0.044
F 23 .83 + 75 0.051 0.008 0.51 0.30 5.22 0.036
F 31.01 60 0.798 0.121 1.62 3.05 5.89 0.171
F 21.05 130 0.904 0.059 1.68 2.22 1.56 0.105
F 24.10 115 0.642 0.020 1.38 1.50 1.12 0.212
F 22.67 70 0.672 0.136 0.87 1.29 2.72 0.250
F 25.58 50 0.769 0.159 0.84 1.35 2.44 0.231
F 24.49 240 1.015 0.055 2.12 2.09 2.39 0.129
F 19.98 55 0.326 0.064 1.23 1.94 1.03 0.086
M 28.78 150 1.465 0.307 4.36 3.97 8.70 0.678
M 26.05 + 155 1.286 0.158 3.66 4.74 9.17 0.410
M 24.93 + 82 1.628 0.131 2.14 2.83 3.08 0.218
F 23.69 + Y 270 3.804 0.164 0.30 0.34 3.71 1.053
F 22.17 + 23 0.288 0.017 1.13 1.26 2.03 0.007
M 24.12 + 372 1.525 0.167 6.99 6.75 4.53 0.316
M 20.87 245 1.771 0.058 6.00 7.83 1.33 0.247
F 23.39 + Y 175 1.179 0.134 2.19 2.99 9.02 0.234
M 27.59 230 3.585 0.418 12.8 21.1 28.6 1.258
F 22.91 96 0.302 0.030 1.49 1.93 1.75 0.053
F 31.51 80 1.124 0.372 6 4.75 6.68 0.452
F 23.83 75 0.301 0.016 0.41 0.59 1.50 0.013
F 22.28 135 0.789 0.021 2.08 1.72 6.99 0.062
F 20.91 Y 155 0.463 0.062 1.00 1.36 3.86 0.063
































2-6 h urinary metabolite profiles: A population study.
Sex BMI Smoker OCS Urine
vol 17-DMX17-DMU 1-MX 1-MU AAMU CAFF
(ml)
F 23.59 Y 130 2.967 0.198 2.55 2.32 10. 0 0.848
F 21.37 150 1.252 0.109 2.57 3.93 4.91 0.048
F 22.00 100 0.639 0.024 0.78 1.20 1.75 0.34
F 22.92 55 0.400 0.033 0.99 1.60 1.25 0.090
F 24.84 Y 60 0.168 0.018 0.46 0.25 0.45 0.073
F 29.09 125 1.935 0.093 3.16 5.42 4.22 0.508
F 17.52 50 0.255 0.016 0.52 1.11 0.28 0.057
F 27.30 90 0.685 0.074 0.91 1.12 5.94 0.149
M 22.82 300 2.031 0.081 1.30 1.63 4.34 0.156
M 23.81 130 0.419 0.013 1.63 2.82 1.66 0.057
M 24.12 120 0.96 0.114 11.6 0.51 1.88 0.217
M 23.59 50 0.1 0.009 0.37 0.63 2.88 0.017
M 19.91 + 45 0.216 0.038 0.52 0.52 5.69 0.205
M 26.52 150 1.453 0.175 0.85 1.14 15.4 0.273
M 26.52 50 0.546 0.074 1.56 2.37 1.33 0.066
M 24.54 75 0.366 0.049 3.01 4.54 0.62 0.183
M 22.29 150 0.573 0.028 3.62 4.19 6.30 0.253
M 21.49 275 0.995 0.093 4.74 4.40 10.4 0.302
M 23.58 + 150 1.561 0.172 13.0 14.1 18.2 0.223
M 24.66 120 1.075 0.116 5.7 5.18 15.2 0.260
M 22.78 190 2.171 0.203 12.7 25.8 45.0 1.077
M 27.52 20 0.124 0.037 0.89 1.27 1.36 0.059
M 26.52 + 240 0.885 0.105 2.17 3.41 4.41 0.048
M 24.37 + 190 4.592 0.144 4.35 5.06 4.61 0.655
M 25.50 10 0.119 0.005 0.16 0.35 0.88 0.019
M 25.06 100 0.696 0.139 2.21 2.69 6.27 0.21
M 17.57 + 20 0.181 0.014 0.72 1.81 1.74 0.017
M 26.06 + 50 0.299 0.018 7.93 0.15 1.11 0.037





























2-6 h urinary metabolite profiles: A population study.
Sex BMI Smoker OCS Urine
vol 17-DMX 17-DMU 1-MX 1-MU AAMU CAFF
(ml)
M 22.72 + 75 0.205 0.012 0.67 1.04 1.13 0.166
F 21.01 Y 240 1.176 0.139 2.41 5.50 7.31 0.458
M 20.26 + 60 0.414 0.012 0.52 2.20 1.90 0.053
M 20.91 110 1.246 0.056 3.51 8.67 4.74 0.202
F 22.91 175 1.568 0.077 6.24 4.01 5.50 0.42
M 31.16 60 0.325 0.039 2.90 1.76 2.72 0.041
F 23.13 280 0.938 0.056 0.98 2.62 3.26 0.364
M 29.87 225 2.504 0.042 1.32 5.05 1.71 0.461
M 28.55 40 0.653 0.036 2.56 3.16 2.45 0.092
F 17.90 90 0.607 0.052 0.30 1.15 0.33 0.211
M 23.95 200 1.48 0.226 7.88 1.43 3.32 1.082
F 25.46 + 190 1.922 0.127 3.46 8.81 5.84 0.482
F 22.50 90 0.507 0.040 1.00 2.47 2.39 0.063
M 25.35 100 1.656 0.076 3.33 10.4 5.67 0.218
F 22.80 80 0.853 0.045 1.29 3.77 3.00 0.250
F 28.99 50 0.546 0.044 2.67 2.80 1.71 0.123
M 23.03 80 2.537 0.161 5.24 20.3 4.36 0.547
F 26.66 40 0.319 0.033 0.98 3.03 0.77 0.144
F 20.70 150 0.514 0.016 1.00 2.36 1.60 0.109
M 24.34 50 0.385 0.062 2.04 3.55 2.92 0.215
F 22.07 15 0.210 0.006 0.29 0.85 0.33 0.043
M 22.43 + 80 0.714 0.065 2.29 7.38 3.56 0.144
F 22.20 50 0.568 0.106 2.66 8.13 3.9 0.192
F 26.47 + 90 0.936 0.210 4.69 11.5 1.88 0.258
F 25.10 Y 95 1.493 0.136 1.51 4.25 5.25 0.249
F 22.63 65 0.801 0.118 2.53 5.45 2.10 0.243
F 23.59 + Y 100 1.312 0.263 4.95 10.3 7.03 0.289
F 30.22 + Y 196 1.791 0.213 5.51 9.70 11.2 0.343
F 21.64 90 1.009 0.032 1.50 3.07 0.83 0.314
Appendix 4 - 2-6 h urinary metabolite profiles: A population study.
roi Age Sex BMI Smoker OCS Urine
vol
(ml)
17-DMX 17-DMU 1-MX 1-MU AAMU CAFF
#279 MD 65 F 30.42 + 70 0.842 0.136 0.82 8.50 2.68 0.157
#280 PH 44 F 25.49 + 275 1.641 0.057 9.38 8.35 5.02 0.297
#281 DH 49 M 26.79 + 230 2.035 0.087 6.89 16.0 4.45 0.126
#282 MM 28 M 19.11 + 280 2.875 0.106 5.27 7.31 2.07 2.060
#283 CM 23 M 24.80 + 720 0.799 0.158 2.81 3.67 3.16 0.208
Appendix 5 -Urinary caffeine metabolites in patients
Vol Age Sex BMI Smoker Cancer Medication Urine
Type vol
(ml)
#28 DH 63 M 22.6 + S B Primadone 150
#29 AM 70 M 27.2 + A B Temazepam 40
#30 GP 79 M 20.2 S H Carbamazepine 70
#31 HH 71 M 20.1 + 0 B Heroin 45
#32 IT 65 M 25.7 + O B 10
#33 PE 47 M 25.1 A H Temazepam 60
#34 WG 76 M 22.0 O B GTN 70
#35 IB 76 M 26.9 S H 110
#36 SI 82 F 20.7 S B 120
#37 AD 69 M 23.3 + B 100
#38 TH 77 M 22.2 + B 125
#39 JB 78 M 31.8 Warfarin 155
#40 MT 71 F 19.7 B 55
#41 RK 79 M 25.4 S B 100
#42 RH 74 M 28.0 S B 50
#43 DR 74 M 28.5 B 140
#44 AH 79 M 27.9 B Nifedipine 10
#45 DJo 49 M 21.0 + S B 110
#46 HS 79 M 26.3 + S B Frumil 90
#47 JG 66 M 23.9 S B 180
#48 MA 48 M 17.3 + S B Ventolin 110
#49 DHu 63 F 24.0 0 B 55
#50 RP 62 M 25.2 + S B 100
#51 GJ 82 M 23.3 S B Lactulose 75
S Squamous, 0 Oat, SW Swan, B Bronchi, H Head or neck.
carcinoma of the lung, head and neck.
Amount excreted in urine 
17-DMX 17-DMU 1-MX 1-MU AAMU CAFF
0.741 0.033 2.41






































2.79 2.22 0. 019









Appendix 5 -Urinary caffeine metabolites in patients
Vol Age Sex BMI Smoker Cancer Medication Urine
Type vol
(ml)
#1 PW 70 M 22.8 + S B Coproximol 130
#2 LF 59 M 23.5 + O B 90
#3 JG 52 M 22.8 s B Frumil 125
#4 AP 66 M 20.9 s B Penicillamine 40
#5 HF 74 M 20.6 s B 50
#6 NS 63 M 26.0 0 B Regulan 120
#7 TT 63 M 21.3 + 0 B Temazepam 90
#8 MD 47 F 18.3 s B Metoprolol 30
#9 ECh 66 F 18.5 0 B 15
#10 ED 79 F 17.3 s H Lactulose 150
#11 JS 56 F 35.8 H Naproxin 120
#12 PS 54 M 23.5 s H Temazepam 180
#13 ECo 83 M 19.1 B Lactulose 50
#14 FG 64 F 20.3 0 B Codanthrusate 50
#15 BB 62 M 22.2 + s B 100
#16 EK 81 M 21.7 s B Codeine 40
#17 EP 69 F 27.6 s B 395
#18 LA 66 M 20.7 s H Paracetamol 60
#19 LE 66 M 25.0 s H 15
#20 PR 78 M 23.9 SW B Paracetamol 260
#21 PH 47 M 23.1 s H 100
#22 JH 66 M 21.7 s H 150
#23 IS 73 F 25.4 s B 150
#24 PD 78 M 24.9 0 B Ventolin 50
#25 CP 67 M 31.9 + s B 75
#26 LB 66 F 23.8 s B Oxazepam 5
#27 WW 70 M 18.6 + s B Dexamethasone 210
S Squamous, 0 Oat, SW Swan, B Bronchi, H Head or neck.
carcinoma of the lung, head and neck.
Amount excreted in urine 





















































0.76 1.95 0. 037
0.46 0.54 0. 013
5.69 3.43 0.273
Appendix 6 -Urinary caffeine metabolites in patients with leukaemia
Vol Age Sex BMI Smoker Cancer Medication Urine Amount excreted in urine
Type vol 17-DMX 17-DMU 1-MX 1-MU AAMU CAFF
(ml) (mg)
1 TT 51 F 21.1 L Ventolin 405 1.429 0.190 6.21 7.49 3.75 0.846
2 ML 74 F 31.7 CLL 70 0.435 0.017 0. 62 1.47 1.26 0.033
3 LB 69 M 27.1 CLL Warfarin 55 0.541 0.152 3.57 6.70 3.67 0.134
4 JH 71 F 26.3 CLL 80 0.472 0.082 2.67 6.28 5.58 0.093
5 MU 47 F 21.4 AML 400 1.14 0.08 1.68 3.08 1.48 0.276
6 DH 24 M 23.4 + HD 175 1.137 0.077 3.07 5.38 2.58 0.096
7 JS 53 M 25.9 NH 180 1.850 0.221 2.55 3.77 1.73 0.336
8 HW 86 F 17.3 CML Frumil 100 0.175 0.014 1.37 2.28 1.98 0.234
9 WN 78 M 24.5 M 100 0.346 0.018 0.70 2.78 1.99 0.11
10 GM 65 M 24.8 CML Fluconazole 375 4.14 0.172 5.70 10.1 35.8 1.545
11 MJ 76 F 17.9 CLL 90 0.300 0.048 1.08 3.92 6.69 0.102
12 GB 59 M 23.3 CLL 120 1.017 0.043 1.44 2.16 8 . 66 0.218
13 RH 43 M 28.5 + HD Prothiaden 70 1.563 0.088 2.86 6.16 11.8 0.277
14 AP 32 F 22.5 HD 85 0.737 0.058 1.99 1.95 6. 68 0.160
15 BE 62 F 26.8 CLL Codeine 60 3.485 0.026 1.78 2.91 1.97 0.052
16 JP 28 F 19.8 HD 25 0.062 0.007 0.16 0.37 1.08 0.029
17 MS 69 F 20.3 M Piroxicam 110 0.386 0.028 0.95 2.22 4.96 0.082
18 HW 51 F 20.5 CLL 100 0.876 0.104 3.96 5.33 7.69 0.264
19 IW 86 F 21.4 CLL Glibenclamide 80 0.455 0.035 1.90 7.56 2.20 0.071
20 VN 59 F 28.3 ALL Thyroxine 240 0.542 0.045 0.78 1.23 2.10 0.103
21 MM 81 F 26.4 + M 180 1.009 0.057 1.20 5.25 4.33 0.397
22 JW 71 M 21.8 M 250 0.38 0.005 1.37 0.31 0.66 0.017
23 SP 68 M 24.6 HAIRY Interferon 60 0.813 0.055 1.61 2.55 2.27 0.175
24 EHa 32 F 24.8 AML Acyclovir 175 1.221 0.068 6.43 11.0 2.84 0.206
25 ECh 70 F 19.8 AML Acyclovir 100 0.625 0.023 13.3 5.48 1.37 0.303
26 MD F 18.0 + CLL 90 0.400 0.046 2.21 6.32 4 .77 0.046
M Myeloma, L Lymphoma, ALL Acute Lymphocytic Leuk, CML Chronic Myeloid Leuk, HD Hodgkin's,
NH Non-Hodgkin's Lymphoma
Appendix 6 -Urinary caffeine metabolites in patients with leukaemia
Vol Age Sex BMI Smoker Cancer Medication Urine Amount excreted in urine
Type vol 17-DMX 17-DMU 1-MX 1-MU AAMU CAFF
(ml) (mg)
27 JS 61 F 30.3 CLL Frumil 75 0.711 0.078 2.20 3.41 3.54 0.155
28 PB 48 F 22.0 AML Thyroxine 75 0.246 0.022 0 . 86 1.82 3.63 0.036
29 RB 70 M 24.1 CLL Naproxin 60 0.408 0.017 0.97 1.75 3.34 0.112
30 MC 58 F 34.8 CLL Paracetamol 90 0.532 0.062 12.3 4.20 8.53 0.207
31 IWa 70 F 29.8 NH Prothiaden 50 0.737 0.065 2.45 7.18 7. 68 0.069
32 LP 73 M 20.5 CLL Propranolol 150 0.685 0.088 1.21 3.11 6.44 0.183
33 EHu 71 F 25.0 CGL 120 1.173 0.070 1.78 5.62 9.37 0. Ill
34 WT 80 F 19.2 NH 45 0.345 0.014 0.23 0.91 2. 64 0.152
35 HB 80 M 22.8 CLL 80 0.413 0.031 1.59 5.49 7.52 0.099
36 SS 30 M 20.5 ALL 50 0.309 0.022 0. 67 1.30 1.62 0. 025
37 AG 61 M 22.8 + CLL Interferon 275 1.523 0.079 1.38 3.99 2.57 0.825
38 HD 64 F 23.8 CLL 150 1.177 0.091 4.42 1.44 10. 0 0.234
39 AP 80 F 25.6 CML Paracetamol 70 0.719 0.025 0.72 2.18 1.52 0.159
40 DL 71 F 24.8 CLL 470 0.390 0.020 0.76 1.11 2.00 0.178
41 YV 53 F 23.7 + CLL Atenolol 325 1.462 0.185 14.6 19.6 8.75 0.581
42 JB 39 M 32.1 CGL 50 0.508 0.026 6.27 2.21 1.81 0.261
43 GM 78 M 18.6 CLL Prednisolone 60 0.072 0.013 0.13 0.43 0.51 0.006
44 JD 56 M 24.3 NH 275 5.403 0.123 2.91 9.69 4.37 4.094
45 JP 63 F 23.9 CLL 145 2.886 0.068 1.34 3.85 5.51 0.527
46 GC 56 M 26.9 HAIRY 110 2.214 0.113 3.85 6.15 3.36 0.55
47 BC 63 F 23.5 AML 160 1.664 0.075 3.30 4.64 2.55 0.236
48 EHe 77 M 20.4 CGL Digoxin 7 0.057 0.010 0.06 0.59 0.29 0.014
49 GM 61 M 25.3 HAIRY 50 0.172 0.035 1.25 0.50 0.37 0.026
50 DN 56 F 26.0 CLL lorazepam 100 0.714 0.034 1.10 3.88 3.91 0.97
51 RL 77 M 23.7 CLL 50 0.163 0.015 0.66 1.53 0.95 0.021
52 KT 43 M 23.3 + AML 50 0.749 0.068 1.91 3.32 2.33 0.112
53 FL 86 F 25.1 CLL Aspirin 220 2.378 0.033 1.10 4.38 3.38 0.44
54 SS 60 F 24.5 L 40 0.540 0.032 0.98 0.21 1.16 0.082
M Myeloma, L Lymphoma, ALL Acute Lymphocytic Leuk, CML Chronic Myeloid Leuk, HD Hodgkin's,
NH Non-Hodgkin's Lymphoma
Appendix 7 -Urinary caffeine metabolites in patients with colorectal carcinoma.
Vol Age Sex BMI Cancer Medication Urine Amount excreted in urine
Type vol 17-DMX 17-DMU 1-MX 1-MU AAMU CAFF
(ml) (mg)
#1 AH 54 F 21.4 A C Imodium 150 0.910 0.019 2.23 2.452 1.77 0.2355
#2 RT 73 M 18.9 A R Codeine 20 0.205 0.02 0.45 1.336 1.40 0.0554
#3 AR 71 M 14.8 C 75 0.497 0.044 2.15 3.906 2.61 0.0945
#4 RW 56 M 22.5 A R Ventolin 170 1.890 0.255 3.06 4.260 1.65 0.4658
#5 HT 63 F 29.8 A C 125 1.995 0.07 2.88 5.083 3.40 0.4062
#6 MF 77 F 22.8 A R Nitrazepam 50 0.112 0.031 0.92 1.935 1.49 0.0475
#7 DP 76 M 24.5 S A 20 0.065 0.023 0.42 0.701 0.44 0.0204
#8 VP 76 F 25.4 R 40 1.337 0.037 1.24 3.450 1.39 0.1776
#9 RW 63 F 20.7 C GTN,Aspirin 30 0.183 0.011 0.72 0.790 0.97 0.0207
#10 VP 79 M 24.1 A R Digoxin 30 0.794 0.064 0. 61 2.701 1.78 0.1986
#11 RM 66 F 20.7 A R 170 1.434 0.066 1.54 3.935 7.77 0.3706
#12 PL 86 F 16.3 A CA 60 0.833 0.034 1.05 4.064 1.89 0.0708
A adeno, S squamous, R Rectum, C Colon, A Anus, CA Caecum,
Appendix 8a -Urinary caffeine metabolites in




#1 AM 58 F 750 10.95 1.042
#2 KB 19 F 800 9.08 1.144
#3 DB 36 M 700 18.27 0.861
#4 GG 61 M 210 2.442 0.231
#5 PR 19 M 400 9.004 0.816
#6 TG 37 M + 350 7.679 0.885
#7 JM 33 F 250 8.155 0.63
#8 SB 23 M 250 4.495 0.722
#9 LA 19 F 210 1.862 0.371
#10 SB 29 F 450 13.75 0.418
#11 DR 52 M 600 19.23 0.798
#12 JB 20 M 260 4.295 0.639
#13 RF 45 M + 240 5.181 0.638
#14 AM 27 F + 625 7.687 0.268
#15 RT 41 M 575 9.2 0.638
#16 JK 56 F 800 13.44 0.768
#17 MB 41 M 200 3.356 0.68
#18 LM 21 F 275 7.108 1.009
#19 KS 29 F 200 2.008 1.138
#20 SP 30 F 190 4.240 0.703
#21 NC 42 M + 350 3.223 0.479
#22 SR 24 F 360 5.626 1.072
#23 WR 60 M + 500 12.7 1.25
#24 PMC 38 F 950 21.29 0.304
#25 DB 39 F 300 3.603 0.657
#26 GW 70 F 250 3.38 0.295
#27 PS 21 M 250 3.187 0.36
#28 RR 46 M 810 5.799 0.121
#29 MB 25 M 440 9.521 1.020
#30 AK 69 M 500 7.91 0.445
#31 MC 24 F 300 4.239 1.032
#32 RD 29 M 530 10.57 0.588
#33 MT 43 M 650 9.035 0.442
patients with FAP.
1U 1-MX 1-MU AAMU CAFF
18.50 42.57 69.06 3.66
26.45 68.23 168.1 1.888
62.51 92.96 39.78 2.268
26.48 68.63 25.94 19.75
23.31 53.70 55.29 0.268
36.62 89.38 26.47 0.199
23.88 34.72 28.76 0.615
19.92 50.49 44.72 0.582
15.77 27.55 13.25 0.422
26.17 34.91 22.38 3.114
19.93 55.72 24.91 1.416
22.09 29.93 19.07 0.696
30.88 76.24 66.31 0.319
33.15 66.03 19.15 0.468
8.630 16.45 22.03 1.817
15.86 39.07 11.22 1.568
55. 69 123.0 41.41 0.264
40.74 68.38 32.82 1.105
6.086 1.976 12.96 1.074
45.02 82.47 7.216 0.406
32.45 56.08 89.02 0.332
21.73 39.20 15.73 ND
23 56.48 32.93 1.26
19.30 14.08 53.46 2.983
13.92 22.34 14.30 0.702
4.42 14.67 3.477 0.29
13.74 24.94 20.47 0.407
4.787 8.602 6.326 0.356
11.19 24.93 16.19 1.161
15.1 29.93 21.37 0.365
18.06 53.43 73.40 ND
24.41 60.51 66.49 0.810
24.90 47.83 28.04 1.033
#34 FS 43 F 600 9.69 0.582 25.99 47.18 72.72 1.506
#35 JT 19 M 310 8.884 0.849 12.41 27.39 14.10 0.570
#36 MT 39 M 300 3.141 0.9 10.16 21.04 6.828 0.585
#37 DT 21 M 150 1.876 0.297 15.00 27.76 16.84 0.432
Appendix 8b -Urinary caffeine metabolites in relatives of patients with FAP.
Vol Age Sex Smoker Urine Amount excreted in urine
vol 17-DMX 17-DMU 1-MX 1-MU AAMU CAFF 
(ml) (mg)
#1 AL 26 M + 390 4.083 0.273 13.65 33.99 26.70 0.347
#2 DC 46 M + 600 9.582 0.432 12.48 44.04 19.10 0.33
#3 TK 20 F + 220 4.072 0.475 25.39 54.35 81.98 0.33
#4 ML 65 M 610 10.65 1.006 9.686 29.09 60.98 1.335
#5 GL 18 F + 650 6.545 1.014 30.97 48.00 48.63 1.124
#6 KP 23 F + 900 9.189 0.36 16.28 34.2 46.50 0.828
#7 MH 27 M 250 2.597 0.487 10.79 25.33 12.00 0.542
#8 MT 22 M 450 8.959 0.747 21.66 41.04 37.06 0.949
#9 AF 20 F 850 15.83 1.555 40.38 56.85 39.61 2.38
#10 HS 53 F + 650 9.737 0.773 24.02 56.93 36.22 1.859
#11 SC 15 M 225 2.938 0.465 23.29 36.35 31.49 0.247
#12 TT 18 F 220 2.171 0.239 5.599 7.893 9.385 0.338
#13 RC 24 M 350 8.522 0.626 29.12 58.45 76.50 0.577
#14 MP 53 F 650 13.96 0.364 6.63 11.30 41.17 4.049
#15 SP 19 M 300 1.707 0.048 1.887 3.456 3.489 0.255
#16 GG 51 M 325 2.083 0.159 2.827 7.683 10.47 0.536
Appendix 9.
Recovery and measurement precision of nonpolar caffeine 
metabolites in 95:5% chloroform: isopropanol.
Caffeine 1,7-EMX *EMMIQD 1,3-EMX 3,7-DMX
Extraction
Efficiency (%) 99.8 95.5 82 99 92
CV % (n= 5) 4.0 2.8 8.4 2.2 9.1
* Originally thought to be the caffeine metabolite 1,7-EMU.
Recovery and measurement precision of polar caffeine metabolites 
in chloroform: isopropanol.
































to 4.84 13.12 1.03 45.56 50.71 73.32
tl 4.86 12.90 1.03 47.04 52.21 72.83
t2 4.75 13.13 1.04 46.73 54.88 74.12
t3 4.80 13.39 1.02 47.02 53.29 71.08
% Change 0.83% 2.06% 0.99% 3.20% 5.09% 3.15%
The stability of caffeine and its metabolites at 24-C
Hours 
@ 24°C
TMX 1,7-EMX 1,7-DMU 
(ug/ml)
1-MX 1-MU AAMU
to 4.84 13.12 1.03 45.56 50.71 73.32
t8 5.02 13.20 1.04 46.22 53.38 73.44
tl6 4.86 13.14 1.02 46.46 52.79 71.89
t24 4.90 13.15 1.03 46.35 52.81 73.03
% Change 1.24% 0.23% 0% 1.73% 4.14% 0.4%
Appendix 10 contd.
The stability of caffeine and its metabolites at 37-C
Hours TMX 1,7-DMX 1,7-DMU 1-MX 1-MU AAMU
§ 37°C (ug/ml)
tO 4.84 13.12 1.03 45.56 50.71 73.32
t2 4.80 13.10 1.04 45.81 52.64 72.89
t4 4.93 13.28 1.00 45.23 52.39 72.89
tlO 4.78 13.30 1.06 46.57 52.41 72.97
% Change 1.26% 1.37% 2.91% 2.22% 3.35% 0.48%
